Dose	O
-	O
limiting	O
toxicities	B-Disease
in	O
six	O
of	O
nine	O
patients	O
at	O
200	O
mg	O
/	O
m2	O
/	O
d	O
included	O
hypercalcemia	B-Disease
(	O
n	O
=	O
3	O
)	O
,	O
rash	B-Disease
(	O
n	O
=	O
2	O
)	O
,	O
and	O
anemia	B-Disease
/	O
thrombocytopenia	B-Disease
/	O
emesis	B-Disease
/	O
rash	B-Disease
(	O
n	O
=	O
1	O
)	O
.	O

All	O
toxicities	B-Disease
resolved	O
after	O
cis	O
-	O
RA	O
was	O
discontinued	O
.	O

Three	O
complete	O
responses	O
were	O
observed	O
in	O
marrow	O
metastases	B-Disease
.	O

Serum	O
levels	O
of	O
7	O
.	O
4	O
+	O
/	O
-	O
3	O
.	O
0	O
mumol	O
/	O
L	O
(	O
peak	O
)	O
and	O
4	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
8	O
mumol	O
/	O
L	O
(	O
trough	O
)	O
at	O
the	O
MTD	O
were	O
maintained	O
during	O
14	O
days	O
of	O
therapy	O
.	O

The	O
DLT	O
correlated	O
with	O
serum	O
levels	O
>	O
or	O
=	O
10	O
mumol	O
/	O
L	O
.	O

CONCLUSION	O
:	O
The	O
MTD	O
of	O
cis	O
-	O
RA	O
given	O
on	O
this	O
intermittent	O
schedule	O
was	O
160	O
mg	O
/	O
m2	O
/	O
d	O
.	O

Serum	O
levels	O
known	O
to	O
be	O
effective	O
against	O
neuroblastoma	B-Disease
in	O
vitro	O
were	O
achieved	O
at	O
this	O
dose	O
.	O

The	O
DLT	O
included	O
hypercalcemia	B-Disease
,	O
and	O
may	O
be	O
predicted	O
by	O
serum	O
cis	O
-	O
RA	O
levels	O
.	O

Monitoring	O
of	O
serum	O
calcium	O
and	O
cis	O
-	O
RA	O
levels	O
is	O
indicated	O
in	O
future	O
trials	O
.	O

Time	O
dependence	O
of	O
plasma	O
malondialdehyde	O
,	O
oxypurines	O
,	O
and	O
nucleosides	O
during	O
incomplete	O
cerebral	B-Disease
ischemia	I-Disease
in	O
the	O
rat	O
.	O

Incomplete	O
cerebral	B-Disease
ischemia	I-Disease
(	O
30	O
min	O
)	O
was	O
induced	O
in	O
the	O
rat	O
by	O
bilaterally	O
clamping	O
the	O
common	O
carotid	O
arteries	O
.	O

Peripheral	O
venous	O
blood	O
samples	O
were	O
withdrawn	O
from	O
the	O
femoral	O
vein	O
four	O
times	O
(	O
once	O
every	O
5	O
min	O
)	O
before	O
ischemia	B-Disease
(	O
0	O
time	O
)	O
and	O
5	O
,	O
15	O
,	O
and	O
30	O
min	O
after	O
ischemia	B-Disease
.	O

Plasma	O
extracts	O
were	O
analyzed	O
by	O
a	O
highly	O
sensitive	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
method	O
for	O
the	O
direct	O
determination	O
of	O
malondialdehyde	O
,	O
oxypurines	O
,	O
and	O
nucleosides	O
.	O

During	O
ischemia	B-Disease
,	O
a	O
time	O
-	O
dependent	O
increase	O
of	O
plasma	O
oxypurines	O
and	O
nucleosides	O
was	O
observed	O
.	O

Plasma	O
malondialdehyde	O
,	O
which	O
was	O
present	O
in	O
minimal	O
amount	O
at	O
zero	O
time	O
(	O
0	O
.	O
058	O
mumol	O
/	O
liter	O
plasma	O
;	O
SD	O
0	O
.	O
015	O
)	O
,	O
increased	O
after	O
5	O
min	O
of	O
ischemia	B-Disease
,	O
resulting	O
in	O
a	O
fivefold	O
increase	O
after	O
30	O
min	O
of	O
carotid	O
occlusion	O
(	O
0	O
.	O
298	O
mumol	O
/	O
liter	O
plasma	O
;	O
SD	O
0	O
.	O
078	O
)	O
.	O

Increased	O
plasma	O
malondialdehyde	O
was	O
also	O
recorded	O
in	O
two	O
other	O
groups	O
of	O
animals	O
subjected	O
to	O
the	O
same	O
experimental	O
model	O
,	O
one	O
receiving	O
20	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
of	O
the	O
cyclooxygenase	O
inhibitor	O
acetylsalicylate	O
intravenously	O
immediately	O
before	O
ischemia	B-Disease
,	O
the	O
other	O
receiving	O
650	O
micrograms	O
/	O
kg	O
b	O
.	O
w	O
.	O
of	O
the	O
hypotensive	B-Disease
drug	O
nitroprusside	O
at	O
a	O
flow	O
rate	O
of	O
103	O
microliters	O
/	O
min	O
intravenously	O
during	O
ischemia	B-Disease
,	O
although	O
in	O
this	O
latter	O
group	O
malondialdehyde	O
was	O
significantly	O
higher	O
.	O

The	O
present	O
data	O
indicate	O
that	O
the	O
determination	O
of	O
malondialdehyde	O
,	O
oxypurines	O
,	O
and	O
nucleosides	O
in	O
peripheral	O
blood	O
,	O
may	O
be	O
used	O
to	O
monitor	O
the	O
metabolic	O
alterations	O
of	O
tissues	O
occurring	O
during	O
ischemic	B-Disease
phenomena	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Acute	O
renal	B-Disease
toxicity	I-Disease
of	O
doxorubicin	O
(	O
adriamycin	O
)	O
-	O
loaded	O
cyanoacrylate	O
nanoparticles	O
.	O

Acute	O
doxorubicin	O
-	O
loaded	O
nanoparticle	O
(	O
DXNP	O
)	O
renal	B-Disease
toxicity	I-Disease
was	O
explored	O
in	O
both	O
normal	O
rats	O
and	O
rats	O
with	O
experimental	O
glomerulonephritis	B-Disease
.	O

In	O
normal	O
rats	O
,	O
2	O
/	O
6	O
rats	O
given	O
free	O
doxorubicin	O
(	O
DX	O
)	O
(	O
5	O
mg	O
/	O
kg	O
)	O
died	O
within	O
one	O
week	O
,	O
whereas	O
all	O
control	O
animals	O
and	O
all	O
rats	O
having	O
received	O
free	O
NP	O
or	O
DXNP	O
survived	O
.	O

A	O
3	O
times	O
higher	O
proteinuria	B-Disease
appeared	O
in	O
animals	O
treated	O
with	O
DXNP	O
than	O
in	O
those	O
treated	O
with	O
DX	O
.	O

Free	O
NP	O
did	O
not	O
provoke	O
any	O
proteinuria	B-Disease
.	O

Two	O
hr	O
post	O
-	O
injection	O
,	O
DXNP	O
was	O
2	O
.	O
7	O
times	O
more	O
concentrated	O
in	O
kidneys	O
than	O
free	O
DX	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
.	O

In	O
rats	O
with	O
immune	O
experimental	O
glomerulonephritis	B-Disease
,	O
5	O
/	O
6	O
rats	O
given	O
DX	O
died	O
within	O
7	O
days	O
,	O
in	O
contrast	O
to	O
animals	O
treated	O
by	O
DXNP	O
,	O
NP	O
,	O
or	O
untreated	O
,	O
which	O
all	O
survived	O
.	O

Proteinuria	B-Disease
appeared	O
in	O
all	O
series	O
,	O
but	O
was	O
2	O
-	O
5	O
times	O
more	O
intense	O
(	O
p	O
>	O
0	O
.	O
001	O
)	O
and	O
prolonged	O
after	O
doxorubicin	O
treatment	O
(	O
400	O
-	O
700	O
mg	O
/	O
day	O
)	O
,	O
without	O
significant	O
difference	O
between	O
DXNP	O
and	O
DX	O
.	O

Rats	O
treated	O
by	O
unloaded	O
NP	O
behaved	O
as	O
controls	O
.	O

These	O
results	O
demonstrate	O
that	O
,	O
in	O
these	O
experimental	O
conditions	O
,	O
DXNP	O
killed	O
less	O
animals	O
than	O
free	O
DX	O
,	O
despite	O
of	O
an	O
enhanced	O
renal	B-Disease
toxicity	I-Disease
of	O
the	O
former	O
.	O

Both	O
effects	O
(	O
better	O
survival	O
and	O
nephrosis	B-Disease
)	O
are	O
most	O
probably	O
related	O
to	O
an	O
enhanced	O
capture	O
of	O
DXNP	O
by	O
cells	O
of	O
the	O
mononuclear	O
phagocyte	O
system	O
,	O
including	O
mesangial	O
cells	O
.	O

Prostaglandin	O
E2	O
-	O
induced	O
bladder	B-Disease
hyperactivity	I-Disease
in	O
normal	O
,	O
conscious	O
rats	O
:	O
involvement	O
of	O
tachykinins	O
?	O

In	O
normal	O
conscious	O
rats	O
investigated	O
by	O
continuous	O
cystometry	O
,	O
intravesically	O
instilled	O
prostaglandin	O
(	O
PG	O
)	O
E2	O
facilitated	O
micturition	O
and	O
increased	O
basal	O
intravesical	O
pressure	O
.	O

The	O
effect	O
was	O
attenuated	O
by	O
both	O
the	O
NK1	O
receptor	O
selective	O
antagonist	O
RP	O
67	O
,	O
580	O
and	O
the	O
NK2	O
receptor	O
selective	O
antagonist	O
SR	O
48	O
,	O
968	O
,	O
given	O
intra	O
-	O
arterially	O
,	O
suggesting	O
that	O
it	O
was	O
mediated	O
by	O
stimulation	O
of	O
both	O
NK1	O
and	O
NK2	O
receptors	O
.	O

Intra	O
-	O
arterially	O
given	O
PGE2	O
produced	O
a	O
distinct	O
increase	O
in	O
bladder	O
pressure	O
before	O
initiating	O
a	O
micturition	O
reflex	O
,	O
indicating	O
that	O
the	O
PG	O
had	O
a	O
direct	O
contractant	O
effect	O
on	O
the	O
detrusor	O
smooth	O
muscle	O
.	O

The	O
effect	O
of	O
intra	O
-	O
arterial	O
PGE2	O
could	O
not	O
be	O
blocked	O
by	O
intra	O
-	O
arterial	O
RP	O
67	O
,	O
580	O
or	O
SR	O
48	O
,	O
968	O
,	O
which	O
opens	O
the	O
possibility	O
that	O
the	O
micturition	O
reflex	O
elicited	O
by	O
intra	O
-	O
arterial	O
PGE2	O
was	O
mediated	O
by	O
pathways	O
other	O
than	O
the	O
reflex	O
initiated	O
when	O
the	O
PG	O
was	O
given	O
intravesically	O
.	O

The	O
present	O
results	O
thus	O
suggest	O
that	O
intra	O
-	O
arterial	O
PGE2	O
,	O
given	O
near	O
the	O
bladder	O
,	O
may	O
initiate	O
micturition	O
in	O
the	O
normal	O
rat	O
chiefly	O
by	O
directly	O
contracting	O
the	O
smooth	O
muscle	O
of	O
the	O
detrusor	O
.	O

However	O
,	O
when	O
given	O
intravesically	O
,	O
PGE2	O
may	O
stimulate	O
micturition	O
by	O
releasing	O
tachykinins	O
from	O
nerves	O
in	O
and	O
/	O
or	O
immediately	O
below	O
the	O
urothelium	O
.	O

These	O
tachykinins	O
,	O
in	O
turn	O
,	O
initiate	O
a	O
micturition	O
reflex	O
by	O
stimulating	O
NK1	O
and	O
NK2	O
receptors	O
.	O

Prostanoids	O
may	O
,	O
via	O
release	O
of	O
tachykinins	O
,	O
contribute	O
to	O
both	O
urge	O
and	O
bladder	B-Disease
hyperactivity	I-Disease
seen	O
in	O
inflammatory	O
conditions	O
of	O
the	O
lower	O
urinary	O
tract	O
.	O

Refractory	O
cardiogenic	B-Disease
shock	I-Disease
and	O
complete	O
heart	B-Disease
block	I-Disease
after	O
verapamil	O
SR	O
and	O
metoprolol	O
treatment	O
.	O

A	O
case	O
report	O
.	O

A	O
seventy	O
-	O
eight	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
complete	O
heart	B-Disease
block	I-Disease
and	O
refractory	O
hypotension	B-Disease
two	O
days	O
after	O
a	O
therapeutic	O
dose	O
of	O
sustained	O
-	O
release	O
verapamil	O
with	O
concomitant	O
use	O
of	O
metoprolol	O
.	O

The	O
patient	O
continued	O
to	O
remain	O
hypotensive	B-Disease
with	O
complete	O
heart	B-Disease
block	I-Disease
,	O
even	O
with	O
multiple	O
uses	O
of	O
intravenous	O
atropine	O
as	O
well	O
as	O
high	O
doses	O
of	O
pressor	O
agents	O
such	O
as	O
dopamine	O
and	O
dobutamine	O
.	O

However	O
,	O
shortly	O
after	O
the	O
use	O
of	O
intravenous	O
calcium	O
chloride	O
,	O
the	O
refractory	O
hypotension	B-Disease
and	O
complete	O
heart	B-Disease
block	I-Disease
resolved	O
.	O

Protective	O
effect	O
of	O
misoprostol	O
on	O
indomethacin	O
induced	O
renal	B-Disease
dysfunction	I-Disease
in	O
elderly	O
patients	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
possible	O
protective	O
effects	O
of	O
misoprostol	O
on	O
renal	O
function	O
in	O
hospitalized	O
elderly	O
patients	O
treated	O
with	O
indomethacin	O
.	O

METHODS	O
:	O
Forty	O
-	O
five	O
hospitalized	O
elderly	O
patients	O
(	O
>	O
65	O
years	O
old	O
)	O
who	O
required	O
therapy	O
with	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(	O
NSAID	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
indomethacin	O
,	O
150	O
mg	O
/	O
day	O
(	O
Group	O
A	O
)	O
,	O
or	O
indomethacin	O
150	O
mg	O
/	O
day	O
plus	O
misoprostol	O
at	O
0	O
.	O
6	O
mg	O
/	O
day	O
(	O
Group	O
B	O
)	O
.	O

Laboratory	O
variables	O
of	O
renal	O
function	O
[	O
serum	O
creatinine	O
,	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
and	O
electrolytes	O
]	O
were	O
evaluated	O
before	O
initiation	O
of	O
therapy	O
and	O
every	O
2	O
days	O
,	O
until	O
termination	O
of	O
the	O
study	O
(	O
a	O
period	O
of	O
at	O
least	O
6	O
days	O
)	O
.	O

Response	O
to	O
treatment	O
was	O
estimated	O
by	O
the	O
visual	O
analog	O
scale	O
for	O
severity	O
of	O
pain	B-Disease
.	O

RESULTS	O
:	O
Forty	O
-	O
two	O
patients	O
completed	O
the	O
study	O
,	O
22	O
in	O
Group	O
A	O
and	O
20	O
in	O
Group	O
B	O
.	O

BUN	O
and	O
creatinine	O
increased	O
by	O
>	O
50	O
%	O
of	O
baseline	O
levels	O
in	O
54	O
and	O
45	O
%	O
of	O
Group	O
A	O
patients	O
,	O
respectively	O
,	O
compared	O
to	O
only	O
20	O
and	O
10	O
%	O
of	O
Group	O
B	O
patients	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Potassium	O
(	O
K	O
)	O
increment	O
of	O
0	O
.	O
6	O
mEq	O
/	O
l	O
or	O
more	O
was	O
observed	O
in	O
50	O
%	O
of	O
Group	O
A	O
,	O
but	O
in	O
only	O
15	O
%	O
of	O
Group	O
B	O
patients	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
mean	O
increments	O
in	O
BUN	O
,	O
creatinine	O
,	O
and	O
K	O
were	O
reduced	O
by	O
63	O
,	O
80	O
,	O
and	O
42	O
%	O
,	O
respectively	O
,	O
in	O
Group	O
B	O
patients	O
compared	O
to	O
Group	O
A	O
.	O
Response	O
to	O
treatment	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSION	O
:	O
Hospitalized	O
elderly	O
patients	O
are	O
at	O
risk	O
for	O
developing	O
indomethacin	O
related	O
renal	B-Disease
dysfunction	I-Disease
.	O

Addition	O
of	O
misoprostol	O
can	O
minimize	O
this	O
renal	B-Disease
impairment	I-Disease
without	O
affecting	O
pain	B-Disease
control	O
.	O

Cognitive	B-Disease
deterioration	I-Disease
from	O
long	O
-	O
term	O
abuse	O
of	O
dextromethorphan	O
:	O
a	O
case	O
report	O
.	O

Dextromethorphan	O
(	O
DM	O
)	O
,	O
the	O
dextrorotatory	O
isomer	O
of	O
3	O
-	O
hydroxy	O
-	O
N	O
-	O
methylmorphinan	O
,	O
is	O
the	O
main	O
ingredient	O
in	O
a	O
number	O
of	O
widely	O
available	O
,	O
over	O
-	O
the	O
-	O
counter	O
antitussives	O
.	O

Initial	O
studies	O
(	O
Bornstein	O
1968	O
)	O
showed	O
that	O
it	O
possessed	O
no	O
respiratory	O
suppressant	O
effects	O
and	O
no	O
addiction	O
liability	O
.	O

Subsequently	O
,	O
however	O
,	O
several	O
articles	O
reporting	O
abuse	O
of	O
this	O
drug	O
have	O
appeared	O
in	O
the	O
literature	O
.	O

The	O
drug	O
is	O
known	O
to	O
cause	O
a	O
variety	O
of	O
acute	O
toxic	O
effects	O
,	O
ranging	O
from	O
nausea	B-Disease
,	O
restlessness	B-Disease
,	O
insomnia	B-Disease
,	O
ataxia	B-Disease
,	O
slurred	O
speech	O
and	O
nystagmus	B-Disease
to	O
mood	O
changes	O
,	O
perceptual	O
alterations	O
,	O
inattention	O
,	O
disorientation	O
and	O
aggressive	B-Disease
behavior	I-Disease
(	O
Rammer	O
et	O
al	O
1988	O
;	O
Katona	O
and	O
Watson	O
1986	O
;	O
Isbell	O
and	O
Fraser	O
1953	O
;	O
Devlin	O
et	O
al	O
1985	O
;	O
McCarthy	O
1971	O
;	O
Dodds	O
and	O
Revai	O
1967	O
;	O
Degkwitz	O
1964	O
;	O
Hildebrand	O
et	O
al	O
1989	O
)	O
.	O

There	O
have	O
also	O
been	O
two	O
reported	O
fatalities	O
from	O
DM	O
overdoses	O
(	O
Fleming	O
1986	O
)	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
describing	O
the	O
effects	O
of	O
chronic	O
abuse	O
.	O

This	O
report	O
describes	O
a	O
case	O
of	O
cognitive	B-Disease
deterioration	I-Disease
resulting	O
from	O
prolonged	O
use	O
of	O
DM	O
.	O

Effects	O
of	O
ouabain	O
on	O
myocardial	O
oxygen	O
supply	O
and	O
demand	O
in	O
patients	O
with	O
chronic	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O

A	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
study	O
in	O
patients	O
without	O
heart	B-Disease
failure	I-Disease
.	O

The	O
effects	O
of	O
digitalis	O
glycosides	O
on	O
myocardial	O
oxygen	O
supply	O
and	O
demand	O
are	O
of	O
particular	O
interest	O
in	O
the	O
presence	O
of	O
obstructive	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
but	O
have	O
not	O
been	O
measured	O
previously	O
in	O
man	O
.	O

We	O
assessed	O
the	O
effects	O
of	O
ouabain	O
(	O
0	O
.	O
015	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
parameters	O
in	O
11	O
patients	O
with	O
severe	O
chronic	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
without	O
clinical	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
.	O

Because	O
the	O
protocol	O
was	O
long	O
and	O
involved	O
interventions	O
which	O
might	O
affect	O
the	O
determinations	O
,	O
we	O
also	O
studied	O
in	O
nine	O
patients	O
using	O
an	O
identical	O
protocol	O
except	O
that	O
ouabain	O
administration	O
was	O
omitted	O
.	O

Left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
volume	O
fell	O
in	O
each	O
patient	O
given	O
ouabain	O
,	O
even	O
though	O
they	O
were	O
initially	O
elevated	O
in	O
only	O
two	O
patients	O
.	O

Left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
fell	O
from	O
11	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
4	O
(	O
mean	O
+	O
/	O
-	O
SE	O
)	O
to	O
5	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
9	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
volume	O
fell	O
from	O
100	O
+	O
/	O
-	O
17	O
to	O
82	O
+	O
/	O
-	O
12	O
ml	O
/	O
m2	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
1	O
h	O
after	O
ouabain	O
infusion	O
was	O
completed	O
.	O

The	O
maximum	O
velocity	O
of	O
contractile	O
element	O
shortening	O
increased	O
from	O
1	O
.	O
68	O
+	O
/	O
-	O
0	O
.	O
11	O
ml	O
/	O
s	O
to	O
2	O
.	O
18	O
+	O
/	O
-	O
0	O
.	O
21	O
muscle	O
-	O
lengths	O
/	O
s	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
is	O
consistent	O
with	O
an	O
increase	O
in	O
contractility	O
.	O

No	O
significant	O
change	O
in	O
these	O
parameters	O
occurred	O
in	O
the	O
control	O
patients	O
.	O

No	O
significant	O
change	O
in	O
myocardial	O
oxygen	O
consumption	O
occurred	O
after	O
ouabain	O
administration	O
but	O
this	O
may	O
be	O
related	O
to	O
a	O
greater	O
decrease	O
in	O
mean	O
arterial	O
pressure	O
in	O
the	O
ouabain	O
patients	O
than	O
in	O
the	O
control	O
patients	O
.	O

We	O
conclude	O
that	O
in	O
patients	O
with	O
chronic	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
who	O
are	O
not	O
in	O
clinical	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
left	B-Disease
ventricular	I-Disease
end	I-Disease
-	I-Disease
diastolic	I-Disease
volume	I-Disease
falls	I-Disease
after	O
ouabain	O
administration	O
even	O
when	O
it	O
is	O
initially	O
normal	O
.	O

Though	O
this	O
fall	O
would	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
wall	O
tension	O
,	O
and	O
,	O
therefore	O
,	O
of	O
myocardial	O
oxygen	O
consumption	O
,	O
it	O
may	O
not	O
be	O
of	O
sufficient	O
magnitude	O
to	O
prevent	O
a	O
net	O
increase	O
in	O
myocardial	O
oxygen	O
consumption	O
.	O

Nevertheless	O
,	O
compensatory	O
mechanisms	O
prevent	O
a	O
deterioration	O
of	O
resting	O
myocardial	O
metabolism	O
.	O

Dexamethasone	O
-	O
induced	O
ocular	B-Disease
hypertension	I-Disease
in	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
.	O

PURPOSE	O
:	O
Glucocorticoid	O
administration	O
can	O
lead	O
to	O
the	O
development	O
of	O
ocular	B-Disease
hypertension	I-Disease
and	O
corticosteroid	B-Disease
glaucoma	I-Disease
in	O
a	O
subset	O
of	O
the	O
population	O
through	O
a	O
decrease	O
in	O
the	O
aqueous	O
humor	O
outflow	O
facility	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
glucocorticoid	O
treatment	O
can	O
directly	O
affect	O
the	O
outflow	O
facility	O
of	O
isolated	O
,	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
.	O

METHODS	O
:	O
The	O
anterior	O
segments	O
of	O
human	O
donor	O
eyes	O
from	O
regional	O
eye	O
banks	O
were	O
placed	O
in	O
a	O
constant	O
flow	O
,	O
variable	O
pressure	O
perfusion	O
culture	O
system	O
.	O

Paired	O
eyes	O
were	O
perfused	O
in	O
serum	O
-	O
free	O
media	O
with	O
or	O
without	O
10	O
(	O
-	O
7	O
)	O
M	O
dexamethasone	O
for	O
12	O
days	O
.	O

Intraocular	O
pressure	O
was	O
monitored	O
daily	O
.	O

After	O
incubation	O
,	O
the	O
eyes	O
were	O
morphologically	O
characterized	O
by	O
light	O
microscopy	O
,	O
transmission	O
and	O
scanning	O
electron	O
microscopy	O
,	O
and	O
scanning	O
laser	O
confocal	O
microscopy	O
.	O

RESULTS	O
:	O
A	O
significant	O
increase	O
in	O
intraocular	O
pressure	O
developed	O
in	O
13	O
of	O
the	O
44	O
pairs	O
of	O
eyes	O
perfused	O
with	O
dexamethasone	O
with	O
an	O
average	O
pressure	O
rise	O
of	O
17	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
after	O
12	O
days	O
of	O
dexamethasone	O
exposure	O
.	O

The	O
contralateral	O
control	O
eyes	O
,	O
which	O
did	O
not	O
receive	O
dexamethasone	O
,	O
maintained	O
a	O
stable	O
intraocular	O
pressure	O
during	O
the	O
same	O
period	O
.	O

The	O
outflow	O
pathway	O
of	O
the	O
untreated	O
eyes	O
appeared	O
morphologically	O
normal	O
.	O

In	O
contrast	O
,	O
the	O
dexamethasone	O
-	O
treated	O
hypertensive	B-Disease
eyes	I-Disease
had	O
thickened	O
trabecular	O
beams	O
,	O
decreased	O
intertrabecular	O
spaces	O
,	O
thickened	O
juxtacanalicular	O
tissue	O
,	O
activated	O
trabecular	O
meshwork	O
cells	O
,	O
and	O
increased	O
amounts	O
of	O
amorphogranular	O
extracellular	O
material	O
,	O
especially	O
in	O
the	O
juxtacanalicular	O
tissue	O
and	O
beneath	O
the	O
endothelial	O
lining	O
of	O
the	O
canal	O
of	O
Schlemm	O
.	O

The	O
dexamethasone	O
-	O
treated	O
nonresponder	O
eyes	O
appeared	O
to	O
be	O
morphologically	O
similar	O
to	O
the	O
untreated	O
eyes	O
,	O
although	O
several	O
subtle	O
dexamethasone	O
-	O
induced	O
morphologic	O
changes	O
were	O
evident	O
.	O

CONCLUSION	O
:	O
Dexamethasone	O
treatment	O
of	O
isolated	O
,	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
led	O
to	O
the	O
generation	O
of	O
ocular	B-Disease
hypertension	I-Disease
in	O
approximately	O
30	O
%	O
of	O
the	O
dexamethasone	O
-	O
treated	O
eyes	O
.	O

Steroid	O
treatment	O
resulted	O
in	O
morphologic	O
changes	O
in	O
the	O
trabecular	O
meshwork	O
similar	O
to	O
those	O
reported	O
for	O
corticosteroid	B-Disease
glaucoma	I-Disease
and	O
open	B-Disease
angle	I-Disease
glaucoma	I-Disease
.	O

This	O
system	O
may	O
provide	O
an	O
acute	O
model	O
in	O
which	O
to	O
study	O
the	O
pathogenic	O
mechanisms	O
involved	O
in	O
steroid	B-Disease
glaucoma	I-Disease
and	O
primary	B-Disease
open	I-Disease
angle	I-Disease
glaucoma	I-Disease
.	O

Auditory	O
disturbance	O
associated	O
with	O
interscalene	O
brachial	O
plexus	O
block	O
.	O

We	O
performed	O
an	O
audiometric	O
study	O
in	O
20	O
patients	O
who	O
underwent	O
surgery	O
of	O
the	O
shoulder	O
region	O
under	O
an	O
interscalene	O
brachial	O
plexus	O
block	O
(	O
IBPB	O
)	O
.	O

Bupivacaine	O
0	O
.	O
75	O
%	O
with	O
adrenaline	O
was	O
given	O
followed	O
by	O
a	O
24	O
-	O
hr	O
continuous	O
infusion	O
of	O
0	O
.	O
25	O
%	O
bupivacaine	O
.	O

Three	O
audiometric	O
threshold	O
measurements	O
(	O
0	O
.	O
25	O
-	O
18	O
kHz	O
)	O
were	O
made	O
:	O
the	O
first	O
before	O
IBPB	O
,	O
the	O
second	O
2	O
-	O
6	O
h	O
after	O
surgery	O
and	O
the	O
third	O
on	O
the	O
first	O
day	O
after	O
operation	O
.	O

In	O
four	O
patients	O
hearing	B-Disease
impairment	I-Disease
on	O
the	O
side	O
of	O
the	O
block	O
was	O
demonstrated	O
after	O
operation	O
,	O
in	O
three	O
measurements	O
on	O
the	O
day	O
of	O
surgery	O
and	O
in	O
one	O
on	O
the	O
following	O
day	O
.	O

The	O
frequencies	O
at	O
which	O
the	O
impairment	O
occurred	O
varied	O
between	O
patients	O
;	O
in	O
one	O
only	O
low	O
frequencies	O
(	O
0	O
.	O
25	O
-	O
0	O
.	O
5	O
kHz	O
)	O
were	O
involved	O
.	O

The	O
maximum	O
change	O
in	O
threshold	O
was	O
35	O
dB	O
at	O
6	O
kHz	O
measured	O
at	O
the	O
end	O
of	O
the	O
continuous	O
infusion	O
of	O
bupivacaine	O
.	O

This	O
patient	O
had	O
hearing	O
threshold	O
changes	O
(	O
15	O
-	O
20	O
dB	O
)	O
at	O
6	O
-	O
10	O
kHz	O
on	O
the	O
opposite	O
side	O
also	O
.	O

IBPB	O
may	O
cause	O
transient	O
auditory	B-Disease
dysfunction	I-Disease
in	O
the	O
ipsilateral	O
ear	O
,	O
possibly	O
via	O
an	O
effect	O
on	O
sympathetic	O
innervation	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
combination	O
N	O
-	O
butyl	O
-	O
deoxynojirimycin	O
(	O
SC	O
-	O
48334	O
)	O
and	O
zidovudine	O
in	O
patients	O
with	O
HIV	B-Disease
-	I-Disease
1	I-Disease
infection	I-Disease
and	O
200	O
-	O
500	O
CD4	O
cells	O
/	O
mm3	O
.	O

We	O
conducted	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
phase	O
II	O
study	O
to	O
evaluate	O
the	O
safety	O
and	O
activity	O
of	O
combination	O
therapy	O
with	O
N	O
-	O
butyl	O
-	O
deoxynojirimycin	O
(	O
SC	O
-	O
48334	O
)	O
(	O
an	O
alpha	O
-	O
glucosidase	O
I	O
inhibitor	O
)	O
and	O
zidovudine	O
versus	O
zidovudine	O
alone	O
.	O

Patients	O
with	O
200	O
to	O
500	O
CD4	O
cells	O
/	O
mm3	O
who	O
tolerated	O
<	O
or	O
=	O
12	O
weeks	O
of	O
prior	O
zidovudine	O
therapy	O
received	O
SC	O
-	O
48334	O
(	O
1000	O
mg	O
every	O
8	O
h	O
)	O
and	O
zidovudine	O
(	O
100	O
mg	O
every	O
8	O
h	O
)	O
or	O
zidovudine	O
and	O
placebo	O
.	O

Sixty	O
patients	O
received	O
combination	O
therapy	O
and	O
58	O
,	O
zidovudine	O
and	O
placebo	O
.	O

Twenty	O
-	O
three	O
patients	O
(	O
38	O
%	O
)	O
and	O
15	O
(	O
26	O
%	O
)	O
,	O
in	O
the	O
combination	O
and	O
zidovudine	O
groups	O
,	O
respectively	O
,	O
discontinued	O
therapy	O
(	O
p	O
=	O
0	O
.	O
15	O
)	O
.	O

The	O
mean	O
SC	O
-	O
48334	O
steady	O
-	O
state	O
trough	O
level	O
(	O
4	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O
99	O
micrograms	O
/	O
ml	O
)	O
was	O
below	O
the	O
in	O
vitro	O
inhibitory	O
concentration	O
for	O
human	O
immunodeficiency	B-Disease
virus	O
(	O
HIV	O
)	O
.	O

The	O
mean	O
increase	O
in	O
CD4	O
cells	O
at	O
week	O
4	O
was	O
73	O
.	O
8	O
cells	O
/	O
mm3	O
and	O
52	O
.	O
4	O
cells	O
/	O
mm3	O
for	O
the	O
combination	O
and	O
zidovudine	O
groups	O
,	O
respectively	O
(	O
p	O
>	O
0	O
.	O
36	O
)	O
.	O

For	O
patients	O
with	O
prior	O
zidovudine	O
therapy	O
,	O
the	O
mean	O
change	O
in	O
CD4	O
cells	O
in	O
the	O
combination	O
and	O
zidovudine	O
groups	O
was	O
63	O
.	O
7	O
cells	O
/	O
mm3	O
and	O
4	O
.	O
9	O
cells	O
/	O
mm3	O
at	O
week	O
8	O
and	O
6	O
.	O
8	O
cells	O
/	O
mm3	O
and	O
-	O
45	O
.	O
1	O
cells	O
/	O
mm3	O
at	O
week	O
16	O
,	O
respectively	O
.	O

The	O
number	O
of	O
patients	O
with	O
suppression	O
of	O
HIV	O
p24	O
antigenemia	O
in	O
the	O
combination	O
and	O
zidovudine	O
groups	O
was	O
six	O
(	O
40	O
%	O
)	O
and	O
two	O
(	O
11	O
%	O
)	O
at	O
week	O
4	O
(	O
p	O
=	O
0	O
.	O
10	O
)	O
and	O
five	O
(	O
45	O
%	O
)	O
and	O
two	O
(	O
14	O
%	O
)	O
at	O
week	O
24	O
(	O
p	O
=	O
0	O
.	O
08	O
)	O
,	O
respectively	O
.	O

Diarrhea	B-Disease
,	O
flatulence	B-Disease
,	O
abdominal	B-Disease
pain	I-Disease
,	O
and	O
weight	B-Disease
loss	I-Disease
were	O
common	O
for	O
combination	O
recipients	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Prolonged	O
paralysis	B-Disease
due	O
to	O
nondepolarizing	O
neuromuscular	O
blocking	O
agents	O
and	O
corticosteroids	O
.	O

The	O
long	O
-	O
term	O
use	O
of	O
nondepolarizing	O
neuromuscular	O
blocking	O
agents	O
(	O
ND	O
-	O
NMBA	O
)	O
has	O
recently	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
prolonged	O
muscle	B-Disease
weakness	I-Disease
,	O
although	O
the	O
site	O
of	O
the	O
lesion	O
and	O
the	O
predisposing	O
factors	O
have	O
been	O
unclear	O
.	O

We	O
report	O
3	O
patients	O
(	O
age	O
37	O
-	O
52	O
years	O
)	O
with	O
acute	O
respiratory	B-Disease
insufficiency	I-Disease
who	O
developed	O
prolonged	O
weakness	B-Disease
following	O
the	O
discontinuation	O
of	O
ND	O
-	O
NMBAs	O
.	O

Two	O
patients	O
also	O
received	O
intravenous	O
corticosteroids	O
.	O

Renal	O
function	O
was	O
normal	O
but	O
hepatic	O
function	O
was	O
impaired	O
in	O
all	O
patients	O
,	O
and	O
all	O
had	O
acidosis	B-Disease
.	O

Electrophysiologic	O
studies	O
revealed	O
low	O
amplitude	O
compound	O
motor	O
action	O
potentials	O
,	O
normal	O
sensory	O
studies	O
,	O
and	O
fibrillations	O
.	O

Repetitive	O
stimulation	O
at	O
2	O
Hz	O
showed	O
a	O
decremental	O
response	O
in	O
2	O
patients	O
.	O

The	O
serum	O
vecuronium	O
level	O
measured	O
in	O
1	O
patient	O
14	O
days	O
after	O
the	O
drug	O
had	O
been	O
discontinued	O
was	O
172	O
ng	O
/	O
mL	O
.	O

A	O
muscle	O
biopsy	O
in	O
this	O
patient	O
showed	O
loss	B-Disease
of	I-Disease
thick	I-Disease
,	I-Disease
myosin	I-Disease
filaments	I-Disease
.	O

The	O
weakness	B-Disease
in	O
these	O
patients	O
is	O
due	O
to	O
pathology	B-Disease
at	I-Disease
both	I-Disease
the	I-Disease
neuromuscular	I-Disease
junction	I-Disease
(	O
most	O
likely	O
due	O
to	O
ND	O
-	O
NMBA	O
)	O
and	O
muscle	O
(	O
most	O
likely	O
due	O
to	O
corticosteroids	O
)	O
.	O

Hepatic	B-Disease
dysfunction	I-Disease
and	O
acidosis	B-Disease
are	O
contributing	O
risk	O
factors	O
.	O

Failure	O
of	O
ancrod	O
in	O
the	O
treatment	O
of	O
heparin	O
-	O
induced	O
arterial	O
thrombosis	B-Disease
.	O

The	O
morbidity	O
and	O
mortality	O
associated	O
with	O
heparin	O
-	O
induced	O
thrombosis	B-Disease
remain	O
high	O
despite	O
numerous	O
empirical	O
therapies	O
.	O

Ancrod	O
has	O
been	O
used	O
successfully	O
for	O
prophylaxis	O
against	O
development	O
of	O
thrombosis	B-Disease
in	O
patients	O
with	O
heparin	O
induced	O
platelet	B-Disease
aggregation	I-Disease
who	O
require	O
brief	O
reexposure	O
to	O
heparin	O
,	O
but	O
its	O
success	O
in	O
patients	O
who	O
have	O
developed	O
the	O
thrombosis	B-Disease
syndrome	O
is	O
not	O
well	O
defined	O
.	O

The	O
authors	O
present	O
a	O
case	O
of	O
failure	O
of	O
ancrod	O
treatment	O
in	O
a	O
patient	O
with	O
heparin	O
-	O
induced	O
thrombosis	B-Disease
.	O

Water	B-Disease
intoxication	I-Disease
associated	O
with	O
oxytocin	O
administration	O
during	O
saline	O
-	O
induced	O
abortion	B-Disease
.	O

Four	O
cases	O
of	O
water	B-Disease
intoxication	I-Disease
in	O
connection	O
with	O
oxytocin	O
administration	O
during	O
saline	O
-	O
induced	O
abortions	B-Disease
are	O
described	O
.	O

The	O
mechanism	O
of	O
water	B-Disease
intoxication	I-Disease
is	O
discussed	O
in	O
regard	O
to	O
these	O
cases	O
.	O

Oxytocin	O
administration	O
during	O
midtrimester	O
-	O
induced	O
abortions	B-Disease
is	O
advocated	O
only	O
if	O
it	O
can	O
be	O
carried	O
out	O
under	O
careful	O
observations	O
of	O
an	O
alert	O
nursing	O
staff	O
,	O
aware	O
of	O
the	O
symptoms	O
of	O
water	B-Disease
intoxication	I-Disease
and	O
instructed	O
to	O
watch	O
the	O
diuresis	O
and	O
report	O
such	O
early	O
signs	O
of	O
the	O
syndrome	O
as	O
asthenia	B-Disease
,	O
muscular	O
irritability	B-Disease
,	O
or	O
headaches	B-Disease
.	O

The	O
oxytocin	O
should	O
be	O
given	O
only	O
in	O
Ringers	O
lactate	O
or	O
,	O
alternately	O
,	O
in	O
Ringers	O
lactate	O
and	O
a	O
5	O
per	O
cent	O
dextrose	O
and	O
water	O
solutions	O
.	O

The	O
urinary	O
output	O
should	O
be	O
monitored	O
and	O
the	O
oxytocin	O
administration	O
discontinued	O
and	O
the	O
serum	O
electrolytes	O
checked	O
if	O
the	O
urinary	O
output	O
decreases	O
.	O

The	O
oxytocin	O
should	O
not	O
be	O
administered	O
in	O
excess	O
of	O
36	O
hours	O
.	O

If	O
the	O
patient	O
has	O
not	O
aborted	O
by	O
then	O
the	O
oxytocin	O
should	O
be	O
discontinued	O
for	O
10	O
to	O
12	O
hours	O
in	O
order	O
to	O
perform	O
electrolyte	O
determinations	O
and	O
correct	O
any	O
electrolyte	O
imbalance	O
.	O

Light	O
chain	O
proteinuria	B-Disease
and	O
cellular	O
mediated	O
immunity	O
in	O
rifampin	O
treated	O
patients	O
with	O
tuberculosis	B-Disease
.	O

Light	O
chain	O
proteinuria	B-Disease
was	O
found	O
in	O
9	O
of	O
17	O
tuberculosis	B-Disease
patients	O
treated	O
with	O
rifampin	O
.	O

Concomitant	O
assay	O
of	O
cellular	O
mediated	O
immunity	O
in	O
these	O
patients	O
using	O
skin	O
test	O
antigen	O
and	O
a	O
lymphokine	O
in	O
vitro	O
test	O
provided	O
results	O
that	O
were	O
different	O
.	O

Response	O
to	O
Varidase	O
skin	O
test	O
antigen	O
was	O
negative	O
for	O
all	O
eight	O
tuberculosis	B-Disease
patients	O
tested	O
,	O
but	O
there	O
occurred	O
a	O
hyper	O
-	O
responsiveness	O
of	O
the	O
lymphocytes	O
of	O
these	O
eight	O
patients	O
to	O
phytomitogen	O
(	O
PHA	O
-	O
P	O
)	O
.	O
as	O
well	O
as	O
of	O
those	O
of	O
seven	O
other	O
tuberculous	B-Disease
patients	O
.	O

This	O
last	O
finding	O
may	O
be	O
related	O
to	O
time	O
of	O
testing	O
and	O
/	O
or	O
endogenous	O
serum	O
binding	O
of	O
rifampin	O
which	O
could	O
have	O
inhibited	O
mitogen	O
activity	O
for	O
the	O
lymphocyte	O
.	O

KF17837	O
:	O
a	O
novel	O
selective	O
adenosine	O
A2A	O
receptor	O
antagonist	O
with	O
anticataleptic	O
activity	O
.	O

KF17837	O
is	O
a	O
novel	O
selective	O
adenosine	O
A2A	O
receptor	O
antagonist	O
.	O

Oral	O
administration	O
of	O
KF17837	O
(	O
2	O
.	O
5	O
,	O
10	O
.	O
0	O
and	O
30	O
.	O
0	O
mg	O
/	O
kg	O
)	O
significantly	O
ameliorated	O
the	O
cataleptic	B-Disease
responses	O
induced	O
by	O
intracerebroventricular	O
administration	O
of	O
an	O
adenosine	O
A2A	O
receptor	O
agonist	O
,	O
CGS	O
21680	O
(	O
10	O
micrograms	O
)	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

KF17837	O
also	O
reduced	O
the	O
catalepsy	B-Disease
induced	O
by	O
haloperidol	O
(	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
and	O
by	O
reserpine	O
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

These	O
anticataleptic	O
effects	O
were	O
exhibited	O
dose	O
dependently	O
at	O
doses	O
from	O
0	O
.	O
625	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
,	O
respectively	O
.	O

Moreover	O
,	O
KF17837	O
(	O
0	O
.	O
625	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
potentiated	O
the	O
anticataleptic	O
effects	O
of	O
a	O
subthreshold	O
dose	O
of	O
L	O
-	O
3	O
,	O
4	O
-	O
dihydroxyphenylalanine	O
(	O
L	O
-	O
DOPA	O
;	O
25	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
plus	O
benserazide	O
(	O
6	O
.	O
25	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

These	O
results	O
suggested	O
that	O
KF17837	O
is	O
a	O
centrally	O
active	O
adenosine	O
A2A	O
receptor	O
antagonist	O
and	O
that	O
the	O
dopaminergic	O
function	O
of	O
the	O
nigrostriatal	O
pathway	O
is	O
potentiated	O
by	O
adenosine	O
A2A	O
receptor	O
antagonists	O
.	O

Furthermore	O
,	O
KF17837	O
may	O
be	O
a	O
useful	O
drug	O
in	O
the	O
treatment	O
of	O
parkinsonism	B-Disease
.	O

Effect	O
of	O
nondopaminergic	O
drugs	O
on	O
L	O
-	O
dopa	O
-	O
induced	O
dyskinesias	B-Disease
in	O
MPTP	O
-	O
treated	O
monkeys	O
.	O

A	O
group	O
of	O
four	O
monkeys	O
was	O
rendered	O
parkinsonian	B-Disease
with	O
the	O
toxin	O
MPTP	O
.	O

They	O
were	O
then	O
treated	O
chronically	O
with	O
L	O
-	O
DOPA	O
/	O
benserazide	O
50	O
/	O
12	O
.	O
5	O
mg	O
/	O
kg	O
given	O
orally	O
daily	O
for	O
2	O
months	O
.	O

This	O
dose	O
produced	O
a	O
striking	O
antiparkinsonian	O
effect	O
,	O
but	O
all	O
animals	O
manifested	O
dyskinesia	B-Disease
.	O

A	O
series	O
of	O
agents	O
acting	O
primarily	O
on	O
neurotransmitters	O
other	O
than	O
dopamine	O
were	O
then	O
tested	O
in	O
combination	O
with	O
L	O
-	O
DOPA	O
to	O
see	O
if	O
the	O
dyskinetic	B-Disease
movements	O
would	O
be	O
modified	O
.	O

Several	O
drugs	O
,	O
including	O
clonidine	O
,	O
physostigmine	O
,	O
methysergide	O
,	O
5	O
-	O
MDOT	O
,	O
propranolol	O
,	O
and	O
MK	O
-	O
801	O
,	O
markedly	O
reduced	O
the	O
dyskinetic	B-Disease
movements	O
but	O
at	O
the	O
cost	O
of	O
a	O
return	O
of	O
parkinsonian	B-Disease
symptomatology	O
.	O

However	O
,	O
yohimbine	O
and	O
meperidine	O
reduced	O
predominantly	O
the	O
dyskinetic	B-Disease
movements	O
.	O

Baclofen	O
was	O
also	O
useful	O
in	O
one	O
monkey	O
against	O
a	O
more	O
dystonic	B-Disease
form	O
of	O
dyskinesia	B-Disease
.	O

Atropine	O
converted	O
the	O
dystonic	B-Disease
movements	O
into	O
chorea	B-Disease
.	O

Hallucinations	B-Disease
and	O
ifosfamide	O
-	O
induced	O
neurotoxicity	B-Disease
.	O

BACKGROUND	O
:	O
Hallucinations	B-Disease
as	O
a	O
symptom	O
of	O
central	O
neurotoxicity	B-Disease
are	O
a	O
known	O
but	O
poorly	O
described	O
side	O
effect	O
of	O
ifosfamide	O
.	O

Most	O
cases	O
of	O
ifosfamide	O
-	O
induced	O
hallucinations	B-Disease
have	O
been	O
reported	O
with	O
other	O
mental	O
status	O
changes	O
.	O

METHODS	O
:	O
The	O
authors	O
interviewed	O
six	O
persons	O
with	O
ifosfamide	O
-	O
induced	O
hallucinations	B-Disease
in	O
the	O
presence	O
of	O
a	O
clear	O
sensorium	O
.	O

All	O
patients	O
were	O
receiving	O
high	O
-	O
dose	O
ifosfamide	O
as	O
part	O
of	O
their	O
bone	O
marrow	O
transplant	O
procedure	O
.	O

RESULTS	O
:	O
Hallucinations	B-Disease
occurred	O
only	O
when	O
the	O
patient	O
'	O
s	O
eyes	O
were	O
closed	O
and	O
,	O
in	O
all	O
but	O
one	O
case	O
,	O
were	O
reported	O
as	O
disturbing	O
or	O
frightening	O
.	O

Underreporting	O
of	O
these	O
hallucinations	B-Disease
by	O
patients	O
is	O
likely	O
.	O

CONCLUSIONS	O
:	O
Hallucinations	B-Disease
may	O
be	O
the	O
sole	O
or	O
first	O
manifestation	O
of	O
neurotoxicity	B-Disease
.	O

The	O
incidence	O
may	O
be	O
dose	O
and	O
infusion	O
-	O
time	O
related	O
.	O

The	O
clinician	O
should	O
be	O
alerted	O
for	O
possible	O
ifosfamide	O
-	O
induced	O
hallucinations	B-Disease
,	O
which	O
may	O
occur	O
without	O
other	O
signs	O
of	O
neurotoxicity	B-Disease
.	O

"	O
Eyes	O
-	O
closed	O
"	O
hallucinatory	B-Disease
experiences	O
appear	O
to	O
be	O
an	O
unusual	O
feature	O
of	O
this	O
presentation	O
.	O

Patients	O
anxious	O
about	O
this	O
experience	O
respond	O
well	O
to	O
support	O
and	O
education	O
about	O
this	O
occurrence	O
.	O

Optimal	O
pharmacologic	O
management	O
of	O
disturbed	O
patients	O
is	O
unclear	O
.	O

If	O
agitation	B-Disease
becomes	O
marked	O
,	O
high	O
-	O
potency	O
neuroleptics	O
(	O
i	O
.	O
e	O
.	O
,	O
haloperidol	O
)	O
may	O
be	O
effective	O
.	O

Photodistributed	O
nifedipine	O
-	O
induced	O
facial	O
telangiectasia	B-Disease
.	O

Five	O
months	O
after	O
starting	O
nifedipine	O
(	O
Adalat	O
)	O
,	O
two	O
patients	O
developed	O
photodistributed	O
facial	O
telangiectasia	B-Disease
,	O
which	O
became	O
more	O
noticeable	O
with	O
time	O
.	O

Neither	O
patient	O
complained	O
of	O
photosensitivity	O
or	O
flushing	B-Disease
.	O

Both	O
patients	O
reported	O
a	O
significant	O
cosmetic	O
improvement	O
after	O
discontinuing	O
the	O
drug	O
.	O

One	O
commenced	O
the	O
closely	O
related	O
drug	O
amlodipine	O
3	O
years	O
later	O
,	O
with	O
recurrence	O
of	O
telangiectasia	B-Disease
.	O

The	O
photodistribution	O
of	O
the	O
telangiectasia	B-Disease
suggests	O
a	O
significant	O
drug	O
/	O
light	O
interaction	O
.	O

Penicillamine	O
-	O
induced	O
rapidly	O
progressive	O
glomerulonephritis	B-Disease
in	O
a	O
patient	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O

A	O
67	O
-	O
year	O
-	O
old	O
woman	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
presented	O
rapidly	O
progressive	O
glomerulonephritis	B-Disease
(	O
RPGN	B-Disease
)	O
after	O
5	O
months	O
of	O
D	O
-	O
penicillamine	O
(	O
250	O
mg	O
/	O
day	O
)	O
treatment	O
.	O

Light	O
microscopy	O
study	O
showed	O
severe	O
glomerulonephritis	B-Disease
with	O
crescent	O
formation	O
in	O
60	O
%	O
of	O
the	O
glomeruli	O
and	O
infiltration	O
of	O
inflammatory	O
cells	O
in	O
the	O
wall	O
of	O
an	O
arteriole	O
.	O

Immunofluorescence	O
revealed	O
scanty	O
granular	O
IgG	O
,	O
IgA	O
and	O
C3	O
deposits	O
along	O
the	O
capillary	O
walls	O
and	O
mesangium	O
.	O

The	O
patient	O
was	O
treated	O
with	O
steroid	O
pulse	O
,	O
plasmapheresis	O
,	O
cyclophosphamide	O
and	O
antiplatelet	O
agents	O
.	O

A	O
complete	O
recovery	O
of	O
renal	O
function	O
was	O
achieved	O
in	O
a	O
few	O
weeks	O
.	O

This	O
new	O
case	O
of	O
RPGN	B-Disease
in	O
the	O
course	O
of	O
D	O
-	O
penicillamine	O
treatment	O
emphasizes	O
the	O
need	O
for	O
frequent	O
monitoring	O
of	O
renal	O
function	O
and	O
evaluation	O
of	O
urinary	O
sediment	O
and	O
proteinuria	B-Disease
in	O
these	O
patients	O
.	O

The	O
prompt	O
discontinuation	O
of	O
D	O
-	O
penicillamine	O
and	O
vigorous	O
treatment	O
measures	O
could	O
allow	O
for	O
a	O
good	O
prognosis	O
as	O
in	O
this	O
case	O
.	O

A	O
case	O
of	O
polymyositis	B-Disease
in	O
a	O
patient	O
with	O
primary	B-Disease
biliary	I-Disease
cirrhosis	I-Disease
treated	O
with	O
D	O
-	O
penicillamine	O
.	O

Although	O
D	O
-	O
penicillamine	O
has	O
been	O
used	O
for	O
many	O
rheumatologic	B-Disease
diseases	I-Disease
,	O
toxicity	B-Disease
limits	O
its	O
usefulness	O
in	O
many	O
patients	O
.	O

Polymyositis	B-Disease
/	O
dermatomyositis	B-Disease
can	O
develop	O
as	O
one	O
of	O
the	O
autoimmune	O
complications	O
of	O
D	O
-	O
penicillamine	O
treatment	O
,	O
but	O
its	O
exact	O
pathogenesis	O
remains	O
unclear	O
.	O

We	O
report	O
a	O
patient	O
with	O
primary	B-Disease
biliary	I-Disease
cirrhosis	I-Disease
,	O
who	O
developed	O
polymyositis	B-Disease
while	O
receiving	O
D	O
-	O
penicillamine	O
therapy	O
.	O

We	O
described	O
the	O
special	O
clinical	O
course	O
of	O
the	O
patient	O
.	O

Patients	O
receiving	O
D	O
-	O
penicillamine	O
therapy	O
should	O
be	O
followed	O
carefully	O
for	O
the	O
development	O
of	O
autoimmune	O
complications	O
like	O
polymyositis	B-Disease
/	O
dermatomyositis	B-Disease
.	O

Hyperalgesia	B-Disease
and	O
myoclonus	B-Disease
in	O
terminal	O
cancer	B-Disease
patients	O
treated	O
with	O
continuous	O
intravenous	O
morphine	O
.	O

Eight	O
cancer	B-Disease
patients	O
in	O
the	O
terminal	O
stages	O
of	O
the	O
disease	O
treated	O
with	O
high	O
doses	O
of	O
intravenous	O
morphine	O
developed	O
hyperalgesia	B-Disease
.	O

All	O
cases	O
were	O
retrospectively	O
sampled	O
from	O
three	O
different	O
hospitals	O
in	O
Copenhagen	O
.	O

Five	O
patients	O
developed	O
universal	O
hyperalgesia	B-Disease
and	O
hyperesthesia	B-Disease
which	O
in	O
2	O
cases	O
were	O
accompanied	O
by	O
myoclonus	B-Disease
.	O

In	O
3	O
patients	O
a	O
pre	O
-	O
existing	O
neuralgia	B-Disease
increased	O
to	O
excruciating	O
intensity	O
and	O
in	O
2	O
of	O
these	O
cases	O
myoclonus	B-Disease
occurred	O
simultaneously	O
.	O

Although	O
only	O
few	O
clinical	O
descriptions	O
of	O
the	O
relationship	O
between	O
hyperalgesia	B-Disease
/	O
myoclonus	B-Disease
and	O
high	O
doses	O
of	O
morphine	O
are	O
available	O
,	O
experimental	O
support	O
from	O
animal	O
studies	O
indicates	O
that	O
morphine	O
,	O
or	O
its	O
metabolites	O
,	O
plays	O
a	O
causative	O
role	O
for	O
the	O
observed	O
behavioural	O
syndrome	O
.	O

The	O
possible	O
mechanisms	O
are	O
discussed	O
and	O
treatment	O
proposals	O
given	O
suggesting	O
the	O
use	O
of	O
more	O
efficacious	O
opioids	O
with	O
less	O
excitatory	O
potency	O
in	O
these	O
situations	O
.	O

Liposomal	O
daunorubicin	O
in	O
advanced	O
Kaposi	B-Disease
'	I-Disease
s	I-Disease
sarcoma	I-Disease
:	O
a	O
phase	O
II	O
study	O
.	O

We	O
report	O
a	O
non	O
-	O
randomized	O
Phase	O
II	O
clinical	O
trial	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
liposomal	O
daunorubicin	O
(	O
DaunoXome	O
)	O
in	O
the	O
treatment	O
of	O
AIDS	B-Disease
related	O
Kaposi	B-Disease
'	I-Disease
s	I-Disease
sarcoma	I-Disease
.	O

Eleven	O
homosexual	O
men	O
with	O
advanced	O
Kaposi	B-Disease
'	I-Disease
s	I-Disease
sarcoma	I-Disease
were	O
entered	O
in	O
the	O
trial	O
.	O

Changes	O
in	O
size	O
,	O
colour	O
and	O
associated	O
oedema	B-Disease
of	O
selected	O
'	O
target	O
'	O
lesions	O
were	O
measured	O
.	O

Clinical	O
,	O
biochemical	O
and	O
haematological	O
toxicities	B-Disease
were	O
assessed	O
.	O

Ten	O
subjects	O
were	O
evaluated	O
.	O

A	O
partial	O
response	O
was	O
achieved	O
in	O
four	O
,	O
of	O
whom	O
two	O
subsequently	O
relapsed	O
.	O

Stabilization	O
of	O
Kaposi	B-Disease
'	I-Disease
s	I-Disease
sarcoma	I-Disease
occurred	O
in	O
the	O
remaining	O
six	O
,	O
maintained	O
until	O
the	O
end	O
of	O
the	O
trial	O
period	O
in	O
four	O
.	O

The	O
drug	O
was	O
generally	O
well	O
tolerated	O
,	O
with	O
few	O
mild	O
symptoms	O
of	O
toxicity	B-Disease
.	O

The	O
main	O
problem	O
encountered	O
was	O
haematological	O
toxicity	B-Disease
,	O
with	O
three	O
subjects	O
experiencing	O
severe	O
neutropenia	B-Disease
(	O
neutrophil	O
count	O
<	O
0	O
.	O
5	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
)	O
.	O

There	O
was	O
no	O
evidence	O
of	O
cardiotoxicity	B-Disease
.	O

In	O
this	O
small	O
patient	O
sample	O
,	O
liposomal	O
daunorubicin	O
was	O
an	O
effective	O
and	O
well	O
tolerated	O
agent	O
in	O
the	O
treatment	O
of	O
Kaposi	B-Disease
'	I-Disease
s	I-Disease
sarcoma	I-Disease
.	O

Long	O
-	O
term	O
effects	O
of	O
vincristine	O
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

Forty	O
patients	O
with	O
Non	B-Disease
-	I-Disease
Hodgkin	I-Disease
'	I-Disease
s	I-Disease
Lymphoma	I-Disease
treated	O
with	O
vincristine	O
between	O
1984	O
and	O
1990	O
(	O
cumulative	O
dose	O
12	O
mg	O
in	O
18	O
-	O
24	O
weeks	O
)	O
were	O
investigated	O
in	O
order	O
to	O
evaluate	O
the	O
long	O
term	O
effects	O
of	O
vincristine	O
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

The	O
patients	O
were	O
interviewed	O
with	O
emphasis	O
on	O
neuropathic	B-Disease
symptoms	I-Disease
.	O

Physical	O
and	O
quantitative	O
sensory	O
examination	O
with	O
determination	O
of	O
vibratory	O
perception	O
and	O
thermal	O
discrimination	O
thresholds	O
were	O
performed	O
,	O
four	O
to	O
77	O
months	O
(	O
median	O
34	O
months	O
)	O
after	O
vincristine	O
treatment	O
.	O

Twenty	O
-	O
seven	O
patients	O
reported	O
neuropathic	B-Disease
symptoms	I-Disease
.	O

In	O
13	O
of	O
these	O
27	O
patients	O
symptoms	O
were	O
still	O
present	O
at	O
the	O
time	O
of	O
examination	O
.	O

In	O
these	O
patients	O
sensory	O
signs	O
and	O
symptoms	O
predominated	O
.	O

In	O
the	O
other	O
14	O
patients	O
symptoms	O
had	O
been	O
present	O
in	O
the	O
past	O
.	O

Symptoms	O
persisted	O
maximally	O
40	O
months	O
since	O
cessation	O
of	O
therapy	O
.	O

There	O
was	O
no	O
age	O
difference	O
between	O
patients	O
with	O
and	O
without	O
complaints	O
at	O
the	O
time	O
of	O
examination	O
.	O

Normal	O
reflexes	O
were	O
found	O
in	O
two	O
third	O
of	O
patients	O
.	O

Neuropathic	O
complaints	O
were	O
not	O
very	O
troublesome	O
on	O
the	O
long	O
term	O
.	O

It	O
is	O
concluded	O
that	O
with	O
the	O
above	O
mentioned	O
vincristine	O
dose	O
schedule	O
signs	O
and	O
symptoms	O
of	O
vincristine	O
neuropathy	B-Disease
are	O
reversible	O
for	O
a	O
great	O
deal	O
and	O
prognosis	O
is	O
fairly	O
good	O
.	O

Hepatic	O
adenomas	B-Disease
and	O
focal	B-Disease
nodular	I-Disease
hyperplasia	I-Disease
of	O
the	O
liver	O
in	O
young	O
women	O
on	O
oral	O
contraceptives	O
:	O
case	O
reports	O
.	O

Two	O
cases	O
of	O
hepatic	O
adenoma	B-Disease
and	O
one	O
of	O
focal	B-Disease
nodular	I-Disease
hyperplasia	I-Disease
presumably	O
associated	O
with	O
the	O
use	O
of	O
oral	O
contraceptives	O
,	O
are	O
reported	O
.	O

Special	O
reference	O
is	O
made	O
to	O
their	O
clinical	O
presentation	O
,	O
which	O
may	O
be	O
totally	O
asymptomatic	O
.	O

Liver	O
-	O
function	O
tests	O
are	O
of	O
little	O
diagnostic	O
value	O
,	O
but	O
valuable	O
information	O
may	O
be	O
obtained	O
from	O
both	O
liver	O
scanning	O
and	O
hepatic	O
angiography	O
.	O

Histologic	O
differences	O
and	O
clinical	O
similarities	O
between	O
hepatic	O
adenoma	B-Disease
and	O
focal	B-Disease
nodular	I-Disease
hyperplasia	I-Disease
of	O
the	O
liver	O
are	O
discussed	O
.	O

Loss	O
of	O
glutamate	O
decarboxylase	O
mRNA	O
-	O
containing	O
neurons	O
in	O
the	O
rat	O
dentate	O
gyrus	O
following	O
pilocarpine	O
-	O
induced	O
seizures	B-Disease
.	O

In	O
situ	O
hybridization	O
methods	O
were	O
used	O
to	O
determine	O
if	O
glutamic	O
acid	O
decarboxylase	O
(	O
GAD	O
)	O
mRNA	O
-	O
containing	O
neurons	O
within	O
the	O
hilus	O
of	O
the	O
dentate	O
gyrus	O
are	O
vulnerable	O
to	O
seizure	B-Disease
-	O
induced	O
damage	O
in	O
a	O
model	O
of	O
chronic	O
seizures	B-Disease
.	O

Sprague	O
-	O
Dawley	O
rats	O
were	O
injected	O
intraperitoneally	O
with	O
pilocarpine	O
,	O
and	O
the	O
hippocampal	O
formation	O
was	O
studied	O
histologically	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
8	O
week	O
intervals	O
after	O
pilocarpine	O
-	O
induced	O
seizures	B-Disease
.	O

In	O
situ	O
hybridization	O
histochemistry	O
,	O
using	O
a	O
digoxigenin	O
-	O
labeled	O
GAD	O
cRNA	O
probe	O
,	O
demonstrated	O
a	O
substantial	O
decrease	O
in	O
the	O
number	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
in	O
the	O
hilus	O
of	O
the	O
dentate	O
gyrus	O
in	O
the	O
pilocarpine	O
-	O
treated	O
rats	O
as	O
compared	O
to	O
controls	O
at	O
all	O
time	O
intervals	O
.	O

Additional	O
neuronanatomical	O
studies	O
,	O
including	O
cresyl	O
violet	O
staining	O
,	O
neuronal	B-Disease
degeneration	I-Disease
methods	O
,	O
and	O
histochemical	O
localization	O
of	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
suggested	O
that	O
the	O
decrease	O
in	O
the	O
number	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
was	O
related	O
to	O
neuronal	B-Disease
loss	I-Disease
rather	O
than	O
to	O
a	O
decrease	O
in	O
GAD	O
mRNA	O
levels	O
.	O

The	O
loss	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
in	O
the	O
hilus	O
contrasted	O
with	O
the	O
relative	O
preservation	O
of	O
labeled	O
putative	O
basket	O
cells	O
along	O
the	O
inner	O
margin	O
of	O
the	O
granule	O
cell	O
layer	O
.	O

Quantitative	O
analyses	O
of	O
labeled	O
neurons	O
in	O
three	O
regions	O
of	O
the	O
dentate	O
gyrus	O
in	O
the	O
1	O
and	O
2	O
week	O
groups	O
showed	O
statistically	O
significant	O
decreases	O
in	O
the	O
mean	O
number	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
in	O
the	O
hilus	O
of	O
both	O
groups	O
of	O
experimental	O
animals	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
the	O
molecular	O
layer	O
or	O
the	O
granule	O
cell	O
layer	O
,	O
which	O
included	O
labeled	O
neurons	O
along	O
the	O
lower	O
margin	O
of	O
the	O
granule	O
cell	O
layer	O
.	O

The	O
results	O
indicate	O
that	O
,	O
in	O
this	O
model	O
,	O
a	O
subpopulation	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
within	O
the	O
dentate	O
gyrus	O
is	O
selectively	O
vulnerable	O
to	O
seizure	B-Disease
-	O
induced	O
damage	O
.	O

Such	O
differential	O
vulnerability	O
appears	O
to	O
be	O
another	O
indication	O
of	O
the	O
heterogeneity	O
of	O
GABA	O
neurons	O
.	O

Effects	O
of	O
deliberate	O
hypotension	B-Disease
induced	O
by	O
labetalol	O
with	O
isoflurane	O
on	O
neuropsychological	O
function	O
.	O

The	O
effect	O
of	O
deliberate	O
hypotension	B-Disease
on	O
brain	O
function	O
measured	O
by	O
neuropsychological	O
tests	O
was	O
studied	O
in	O
41	O
adult	O
patients	O
.	O

Twenty	O
-	O
four	O
patients	O
were	O
anaesthetized	O
for	O
middle	O
-	O
ear	O
surgery	O
with	O
deliberate	O
hypotension	B-Disease
induced	O
by	O
labetalol	O
with	O
isoflurane	O
(	O
hypotensive	B-Disease
group	O
)	O
.	O

Seventeen	O
patients	O
without	O
hypotension	B-Disease
served	O
as	O
a	O
control	O
group	O
.	O

The	O
mean	O
arterial	O
pressure	O
was	O
77	O
+	O
/	O
-	O
2	O
mmHg	O
(	O
10	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
3	O
kPa	O
)	O
before	O
hypotension	B-Disease
and	O
50	O
+	O
/	O
-	O
0	O
mmHg	O
(	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
0	O
kPa	O
)	O
during	O
hypotension	B-Disease
in	O
the	O
hypotensive	B-Disease
group	O
,	O
and	O
86	O
+	O
/	O
-	O
2	O
mmHg	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
3	O
kPa	O
)	O
during	O
anaesthesia	O
in	O
the	O
control	O
group	O
.	O

The	O
following	O
psychological	O
tests	O
were	O
performed	O
:	O
four	O
subtests	O
of	O
the	O
Wechsler	O
Adult	O
Intelligence	O
Scale	O
(	O
similarities	O
,	O
digit	O
span	O
,	O
vocabulary	O
and	O
digit	O
symbol	O
)	O
,	O
Trail	O
-	O
Making	O
tests	O
A	O
and	O
B	O
,	O
Zung	O
tests	O
(	O
self	O
-	O
rating	O
anxiety	B-Disease
scale	O
and	O
self	O
-	O
rating	O
depression	B-Disease
scale	O
)	O
and	O
two	O
-	O
part	O
memory	O
test	O
battery	O
with	O
immediate	O
and	O
delayed	O
recall	O
.	O

The	O
tests	O
were	O
performed	O
preoperatively	O
and	O
2	O
days	O
postoperatively	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
in	O
any	O
of	O
the	O
tests	O
in	O
the	O
changes	O
from	O
preoperative	O
value	O
to	O
postoperative	O
value	O
.	O

The	O
results	O
indicate	O
that	O
hypotension	B-Disease
induced	O
by	O
labetalol	O
with	O
isoflurane	O
has	O
no	O
significant	O
harmful	O
effects	O
on	O
mental	O
functions	O
compared	O
to	O
normotensive	O
anaesthesia	O
.	O

Apparent	O
cure	O
of	O
rheumatoid	B-Disease
arthritis	I-Disease
by	O
bone	O
marrow	O
transplantation	O
.	O

We	O
describe	O
the	O
induction	O
of	O
sustained	O
remissions	O
and	O
possible	O
cure	O
of	O
severe	O
erosive	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
)	O
by	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
in	O
2	O
patients	O
.	O

BMT	O
was	O
used	O
to	O
treat	O
severe	O
aplastic	B-Disease
anemia	I-Disease
which	O
was	O
caused	O
by	O
gold	O
in	O
one	O
case	O
and	O
D	O
-	O
penicillamine	O
in	O
the	O
other	O
.	O

In	O
the	O
8	O
and	O
6	O
years	O
since	O
the	O
transplants	O
(	O
representing	O
8	O
and	O
4	O
years	O
since	O
cessation	O
of	O
all	O
immunosuppressive	O
therapy	O
,	O
respectively	O
)	O
,	O
the	O
RA	B-Disease
in	O
each	O
case	O
has	O
been	O
completely	O
quiescent	O
.	O

Although	O
short	O
term	O
remission	O
of	O
severe	O
RA	B-Disease
following	O
BMT	O
has	O
been	O
reported	O
,	O
these	O
are	O
the	O
first	O
cases	O
for	O
which	O
prolonged	O
followup	O
has	O
been	O
available	O
.	O

This	O
experience	O
raises	O
the	O
question	O
of	O
the	O
role	O
of	O
BMT	O
itself	O
as	O
a	O
therapeutic	O
option	O
for	O
patients	O
with	O
uncontrolled	O
destructive	O
synovitis	B-Disease
.	O

Seizures	B-Disease
induced	O
by	O
combined	O
levomepromazine	O
-	O
fluvoxamine	O
treatment	O
.	O

We	O
report	O
a	O
case	O
of	O
combined	O
levomepromazine	O
-	O
fluvoxamine	O
treatment	O
-	O
induced	O
seizures	B-Disease
.	O

It	O
seems	O
that	O
combined	O
treatment	O
of	O
fluvoxamine	O
with	O
phenothiazines	O
may	O
possess	O
proconvulsive	O
activity	O
.	O

Case	O
report	O
:	O
pentamidine	O
and	O
polymorphic	O
ventricular	B-Disease
tachycardia	I-Disease
revisited	O
.	O

Pentamidine	O
isethionate	O
has	O
been	O
associated	O
with	O
ventricular	B-Disease
tachyarrhythmias	I-Disease
,	O
including	O
torsade	B-Disease
de	I-Disease
pointes	I-Disease
.	O

This	O
article	O
reports	O
two	O
cases	O
of	O
this	O
complication	O
and	O
reviews	O
all	O
reported	O
cases	O
to	O
date	O
.	O

Pentamidine	O
-	O
induced	O
torsade	B-Disease
de	I-Disease
pointes	I-Disease
may	O
be	O
related	O
to	O
serum	O
magnesium	O
levels	O
and	O
hypomagnesemia	B-Disease
may	O
synergistically	O
induce	O
torsade	O
.	O

Torsade	B-Disease
de	I-Disease
pointes	I-Disease
occurred	O
after	O
an	O
average	O
of	O
10	O
days	O
of	O
treatment	O
with	O
pentamidine	O
.	O

In	O
these	O
patients	O
,	O
no	O
other	O
acute	O
side	O
effects	O
of	O
pentamidine	O
were	O
observed	O
.	O

Torsade	B-Disease
de	I-Disease
pointes	I-Disease
can	O
be	O
treated	O
when	O
recognized	O
early	O
,	O
possibly	O
without	O
discontinuation	O
of	O
pentamidine	O
.	O

When	O
QTc	B-Disease
interval	I-Disease
prolongation	I-Disease
is	O
observed	O
,	O
early	O
magnesium	O
supplementation	O
is	O
advocated	O
.	O

Efficacy	O
and	O
tolerability	O
of	O
lovastatin	O
in	O
3390	O
women	O
with	O
moderate	O
hypercholesterolemia	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
lovastatin	O
in	O
women	O
with	O
moderate	O
hypercholesterolemia	B-Disease
.	O

DESIGN	O
:	O
The	O
Expanded	O
Clinical	O
Evaluation	O
of	O
Lovastatin	O
(	O
EXCEL	O
)	O
Study	O
,	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
diet	O
-	O
and	O
placebo	O
-	O
controlled	O
trial	O
,	O
in	O
which	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	O
or	O
lovastatin	O
at	O
doses	O
of	O
20	O
or	O
40	O
mg	O
once	O
daily	O
,	O
or	O
20	O
or	O
40	O
mg	O
twice	O
daily	O
for	O
48	O
weeks	O
.	O

SETTING	O
:	O
Ambulatory	O
patients	O
recruited	O
by	O
362	O
participating	O
centers	O
throughout	O
the	O
United	O
States	O
.	O

PATIENTS	O
:	O
Women	O
(	O
n	O
=	O
3390	O
)	O
from	O
the	O
total	O
cohort	O
of	O
8245	O
volunteers	O
.	O

MEASUREMENTS	O
:	O
Plasma	O
total	O
,	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
,	O
and	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
,	O
and	O
triglycerides	O
;	O
and	O
laboratory	O
and	O
clinical	O
evidence	O
of	O
adverse	O
events	O
monitored	O
periodically	O
throughout	O
the	O
study	O
.	O

RESULTS	O
:	O
Among	O
women	O
,	O
lovastatin	O
(	O
20	O
to	O
80	O
mg	O
/	O
d	O
)	O
produced	O
sustained	O
(	O
12	O
-	O
to	O
48	O
-	O
week	O
)	O
,	O
dose	O
-	O
related	O
changes	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
:	O
decreases	O
in	O
LDL	O
cholesterol	O
(	O
24	O
%	O
to	O
40	O
%	O
)	O
and	O
triglycerides	O
(	O
9	O
%	O
to	O
18	O
%	O
)	O
,	O
and	O
increases	O
in	O
HDL	O
cholesterol	O
(	O
6	O
.	O
7	O
%	O
to	O
8	O
.	O
6	O
%	O
)	O
.	O

Depending	O
on	O
the	O
dose	O
,	O
from	O
82	O
%	O
to	O
95	O
%	O
of	O
lovastatin	O
-	O
treated	O
women	O
achieved	O
the	O
National	O
Cholesterol	O
Education	O
Program	O
goal	O
of	O
LDL	O
cholesterol	O
levels	O
less	O
than	O
4	O
.	O
14	O
mmol	O
/	O
L	O
(	O
160	O
mg	O
/	O
dL	O
)	O
,	O
and	O
40	O
%	O
to	O
87	O
%	O
achieved	O
the	O
goal	O
of	O
3	O
.	O
36	O
mmol	O
/	O
L	O
(	O
130	O
mg	O
/	O
dL	O
)	O
.	O

Successive	O
transaminase	O
elevations	O
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
0	O
.	O
1	O
%	O
of	O
women	O
and	O
were	O
dose	O
dependent	O
above	O
the	O
20	O
-	O
mg	O
dose	O
.	O

Myopathy	B-Disease
,	O
defined	O
as	O
muscle	O
symptoms	O
with	O
creatine	O
kinase	O
elevations	O
greater	O
than	O
10	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
was	O
rare	O
and	O
associated	O
with	O
the	O
highest	O
recommended	O
daily	O
dose	O
of	O
lovastatin	O
(	O
80	O
mg	O
)	O
.	O

Estrogen	O
-	O
replacement	O
therapy	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
either	O
the	O
efficacy	O
or	O
safety	O
profile	O
of	O
lovastatin	O
.	O

CONCLUSION	O
:	O
Lovastatin	O
is	O
highly	O
effective	O
and	O
generally	O
well	O
tolerated	O
as	O
therapy	O
for	O
primary	O
hypercholesterolemia	B-Disease
in	O
women	O
.	O

Tetany	B-Disease
and	O
rhabdomyolysis	B-Disease
due	O
to	O
surreptitious	O
furosemide	O
-	O
-	O
importance	O
of	O
magnesium	O
supplementation	O
.	O

Diuretics	O
may	O
induce	O
hypokalemia	B-Disease
,	O
hypocalcemia	B-Disease
and	O
hypomagnesemia	B-Disease
.	O

While	O
severe	O
hypokalemia	B-Disease
may	O
cause	O
muscle	B-Disease
weakness	I-Disease
,	O
severe	O
hypomagnesemia	B-Disease
is	O
associated	O
with	O
muscle	B-Disease
spasms	I-Disease
and	O
tetany	B-Disease
which	O
cannot	O
be	O
corrected	O
by	O
potassium	O
and	O
calcium	O
supplementation	O
alone	O
(	O
1	O
,	O
2	O
)	O
.	O

Surreptitious	O
diuretic	O
ingestion	O
has	O
been	O
described	O
,	O
mainly	O
in	O
women	O
who	O
are	O
concerned	O
that	O
they	O
are	O
obese	B-Disease
or	O
edematous	B-Disease
.	O

Symptomatic	O
hypokalemia	B-Disease
has	O
been	O
reported	O
in	O
such	O
patients	O
(	O
3	O
-	O
7	O
)	O
and	O
in	O
one	O
case	O
hypocalcemia	B-Disease
was	O
observed	O
(	O
8	O
)	O
,	O
but	O
the	O
effects	O
of	O
magnesium	O
depletion	O
were	O
not	O
noted	O
in	O
these	O
patients	O
.	O

Ciprofloxacin	O
-	O
induced	O
nephrotoxicity	B-Disease
in	O
patients	O
with	O
cancer	B-Disease
.	O

Nephrotoxicity	B-Disease
associated	O
with	O
ciprofloxacin	O
is	O
uncommon	O
.	O

Five	O
patients	O
with	O
cancer	B-Disease
who	O
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
that	O
followed	O
treatment	O
with	O
ciprofloxacin	O
are	O
described	O
and	O
an	O
additional	O
15	O
cases	O
reported	O
in	O
the	O
literature	O
are	O
reviewed	O
.	O

Other	O
than	O
elevation	O
of	O
serum	O
creatinine	O
levels	O
,	O
characteristic	O
clinical	O
manifestations	O
and	O
abnormal	O
laboratory	O
findings	O
are	O
not	O
frequently	O
present	O
.	O

Allergic	O
interstitial	B-Disease
nephritis	I-Disease
is	O
believed	O
to	O
be	O
the	O
underlying	O
pathological	O
-	O
process	O
.	O

Definitive	O
diagnosis	O
requires	O
performance	O
of	O
renal	O
biopsy	O
,	O
although	O
this	O
is	O
not	O
always	O
feasible	O
.	O

An	O
improvement	O
in	O
renal	O
function	O
that	O
followed	O
the	O
discontinuation	O
of	O
the	O
offending	O
antibiotic	O
supports	O
the	O
presumptive	O
diagnosis	O
of	O
ciprofloxacin	O
-	O
induced	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

Venous	B-Disease
complications	I-Disease
of	O
midazolam	O
versus	O
diazepam	O
.	O

Although	O
some	O
studies	O
have	O
suggested	O
fewer	O
venous	B-Disease
complications	I-Disease
are	O
associated	O
with	O
midazolam	O
than	O
with	O
diazepam	O
for	O
endoscopic	O
procedures	O
,	O
this	O
variable	O
has	O
not	O
been	O
well	O
documented	O
.	O

We	O
prospectively	O
evaluated	O
the	O
incidence	O
of	O
venous	B-Disease
complications	I-Disease
after	O
intravenous	O
injection	O
of	O
diazepam	O
or	O
midazolam	O
in	O
122	O
consecutive	O
patients	O
undergoing	O
colonoscopy	O
and	O
esophagogastroduodenoscopy	O
.	O

Overall	O
,	O
venous	B-Disease
complications	I-Disease
were	O
more	O
frequent	O
with	O
diazepam	O
(	O
22	O
of	O
62	O
patients	O
)	O
than	O
with	O
midazolam	O
(	O
4	O
of	O
60	O
patients	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

A	O
palpable	O
venous	O
cord	O
was	O
present	O
in	O
23	O
%	O
(	O
14	O
of	O
62	O
)	O
of	O
patients	O
in	O
the	O
diazepam	O
group	O
,	O
compared	O
with	O
2	O
%	O
(	O
1	O
of	O
60	O
patients	O
)	O
in	O
the	O
midazolam	O
group	O
(	O
p	O
<	O
0	O
.	O
002	O
)	O
.	O

Pain	B-Disease
at	O
the	O
injection	O
site	O
occurred	O
in	O
35	O
%	O
(	O
22	O
of	O
62	O
)	O
of	O
patients	O
in	O
the	O
diazepam	O
group	O
compared	O
with	O
7	O
%	O
(	O
4	O
of	O
60	O
patients	O
)	O
in	O
the	O
midazolam	O
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Swelling	B-Disease
and	O
warmth	O
at	O
the	O
injection	O
site	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Smoking	O
,	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
use	O
,	O
intravenous	O
catheter	O
site	O
,	O
dwell	O
time	O
of	O
the	O
needle	O
,	O
alcohol	O
use	O
,	O
and	O
pain	B-Disease
during	O
the	O
injection	O
had	O
no	O
effect	O
on	O
the	O
incidence	O
of	O
venous	B-Disease
complications	I-Disease
.	O

Clarithromycin	O
-	O
associated	O
visual	B-Disease
hallucinations	I-Disease
in	O
a	O
patient	O
with	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
.	O

Visual	B-Disease
hallucinations	I-Disease
are	O
a	O
rare	O
event	O
in	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
and	O
not	O
related	O
to	O
uremia	B-Disease
per	O
se	O
.	O

Unreported	O
in	O
the	O
literature	O
is	O
visual	B-Disease
hallucinations	I-Disease
occurring	O
in	O
association	O
with	O
the	O
new	O
macrolide	O
antibiotic	O
,	O
clarithromycin	O
.	O

We	O
describe	O
such	O
a	O
case	O
in	O
a	O
patient	O
with	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
maintained	O
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
.	O

The	O
combination	O
of	O
a	O
relatively	O
high	O
dose	O
of	O
clarithromycin	O
in	O
face	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
in	O
a	O
functionally	O
anephric	O
patient	O
,	O
with	O
underlying	O
aluminum	O
intoxication	O
,	O
may	O
have	O
facilitated	O
the	O
appearance	O
of	O
this	O
neurotoxic	B-Disease
side	O
effect	O
.	O

It	O
is	O
important	O
to	O
understand	O
the	O
pharmacokinetics	O
of	O
medications	O
in	O
face	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
,	O
the	O
possibility	O
of	O
drug	O
interactions	O
,	O
and	O
how	O
these	O
factors	O
should	O
help	O
guide	O
medication	O
therapy	O
in	O
the	O
ESRD	B-Disease
patient	O
.	O

Changes	O
in	O
peroxisomes	O
in	O
preneoplastic	O
liver	O
and	O
hepatoma	B-Disease
of	O
mice	O
induced	O
by	O
alpha	O
-	O
benzene	O
hexachloride	O
.	O

Peroxisomes	O
in	O
hepatomas	B-Disease
and	O
hyperplastic	O
preneoplastic	O
liver	B-Disease
lesions	I-Disease
induced	O
in	O
mice	O
by	O
500	O
ppm	O
alpha	O
-	O
benzene	O
hexachloride	O
were	O
examined	O
histochemically	O
and	O
electron	O
microscopically	O
.	O

Although	O
most	O
of	O
the	O
hepatomas	B-Disease
were	O
well	O
-	O
differentiated	O
tumors	B-Disease
and	O
contained	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
,	O
the	O
tumor	B-Disease
cells	O
did	O
not	O
respond	O
to	O
ethyl	O
-	O
alpha	O
-	O
p	O
-	O
chlorophenoxyisobutyrate	O
with	O
proliferation	O
of	O
peroxisomes	O
.	O

At	O
the	O
16th	O
week	O
of	O
carcinogen	O
feeding	O
,	O
hyperplastic	O
nodules	O
appeared	O
and	O
advanced	O
to	O
further	O
stages	O
.	O

A	O
majority	O
of	O
the	O
nodules	O
showed	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
and	O
the	O
inductive	O
proliferation	O
of	O
peroxisomes	O
.	O

Within	O
the	O
nodules	O
,	O
foci	O
of	O
proliferation	O
of	O
the	O
cells	O
that	O
showed	O
no	O
inducibility	O
of	O
proliferation	O
of	O
peroxisomes	O
appeared	O
.	O

These	O
cells	O
proliferated	O
further	O
,	O
replacing	O
the	O
most	O
part	O
of	O
the	O
nodules	O
,	O
and	O
with	O
this	O
process	O
hepatomas	B-Disease
appeared	O
to	O
have	O
been	O
formed	O
.	O

No	O
abnormal	O
matrical	O
inclusions	O
of	O
peroxisomes	O
were	O
formed	O
in	O
the	O
cells	O
of	O
hyperplastic	O
nodules	O
by	O
ethyl	O
-	O
alpha	O
-	O
p	O
-	O
chlorophenoxyisobutyrate	O
unlike	O
in	O
the	O
case	O
of	O
rats	O
.	O

Contribution	O
of	O
the	O
sympathetic	O
nervous	O
system	O
to	O
salt	O
-	O
sensitivity	O
in	O
lifetime	O
captopril	O
-	O
treated	O
spontaneously	O
hypertensive	B-Disease
rats	O
.	O

OBJECTIVE	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
,	O
in	O
lifetime	O
captopril	O
-	O
treated	O
spontaneously	O
hypertensive	B-Disease
rats	O
(	O
SHR	O
)	O
,	O
the	O
sympathetic	O
nervous	O
system	O
contributes	O
importantly	O
to	O
the	O
hypertensive	B-Disease
effect	O
of	O
dietary	O
sodium	O
chloride	O
supplementation	O
.	O

METHODS	O
:	O
Male	O
SHR	O
(	O
aged	O
6	O
weeks	O
)	O
that	O
had	O
been	O
treated	O
from	O
conception	O
onward	O
with	O
either	O
captopril	O
or	O
vehicle	O
remained	O
on	O
a	O
basal	O
sodium	O
chloride	O
diet	O
or	O
were	O
fed	O
a	O
high	O
sodium	O
chloride	O
diet	O
.	O

After	O
2	O
weeks	O
,	O
the	O
rats	O
were	O
subjected	O
to	O
ganglionic	O
blockade	O
and	O
2	O
days	O
later	O
,	O
an	O
infusion	O
of	O
clonidine	O
.	O

RESULTS	O
:	O
Lifetime	O
captopril	O
treatment	O
significantly	O
lowered	O
mean	O
arterial	O
pressure	O
in	O
both	O
groups	O
.	O

Intravenous	O
infusion	O
of	O
the	O
ganglionic	O
blocker	O
hexamethonium	O
resulted	O
in	O
a	O
rapid	O
decline	O
in	O
MAP	O
that	O
eliminated	O
the	O
dietary	O
sodium	O
chloride	O
-	O
induced	O
increase	B-Disease
in	I-Disease
MAP	I-Disease
in	O
both	O
groups	O
.	O

Infusion	O
of	O
the	O
central	O
nervous	O
system	O
alpha2	O
-	O
adrenergic	O
receptor	O
agonist	O
clonidine	O
also	O
resulted	O
in	O
a	O
greater	O
reduction	O
in	O
MAP	O
in	O
both	O
groups	O
of	O
SHR	O
that	O
were	O
fed	O
the	O
high	O
(	O
compared	O
with	O
the	O
basal	O
)	O
sodium	O
chloride	O
diet	O
.	O

CONCLUSIONS	O
:	O
In	O
both	O
lifetime	O
captopril	O
-	O
treated	O
and	O
control	O
SHR	O
,	O
the	O
sympathetic	O
nervous	O
system	O
contributes	O
to	O
the	O
pressor	O
effects	O
of	O
a	O
high	O
sodium	O
chloride	O
diet	O
.	O

Angioedema	B-Disease
associated	O
with	O
droperidol	O
administration	O
.	O

Angioedema	B-Disease
,	O
also	O
known	O
as	O
angioneurotic	B-Disease
edema	I-Disease
or	O
Quincke	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
is	O
a	O
well	O
-	O
demarcated	O
,	O
localized	O
edema	B-Disease
involving	O
the	O
subcutaneous	O
tissues	O
that	O
may	O
cause	O
upper	B-Disease
-	I-Disease
airway	I-Disease
obstruction	I-Disease
.	O

We	O
report	O
the	O
case	O
of	O
a	O
previously	O
healthy	O
19	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
known	O
drug	B-Disease
allergies	I-Disease
in	O
whom	O
angioedema	B-Disease
with	O
significant	O
tongue	B-Disease
swelling	I-Disease
and	O
protrusion	O
developed	O
within	O
10	O
minutes	O
of	O
the	O
administration	O
of	O
a	O
single	O
IV	O
dose	O
of	O
droperidol	O
.	O

Late	O
cardiotoxicity	B-Disease
after	O
treatment	O
for	O
a	O
malignant	O
bone	B-Disease
tumor	I-Disease
.	O

Cardiac	O
function	O
was	O
assessed	O
in	O
long	O
-	O
term	O
survivors	O
of	O
malignant	O
bone	B-Disease
tumors	I-Disease
who	O
were	O
treated	O
according	O
to	O
Rosen	O
'	O
s	O
T5	O
or	O
T10	O
protocol	O
,	O
both	O
including	O
doxorubicin	O
.	O

Thirty	O
-	O
one	O
patients	O
,	O
age	O
10	O
-	O
45	O
years	O
(	O
median	O
age	O
17	O
.	O
8	O
years	O
)	O
were	O
evaluated	O
2	O
.	O
3	O
-	O
14	O
.	O
1	O
years	O
(	O
median	O
8	O
.	O
9	O
years	O
)	O
following	O
completion	O
of	O
treatment	O
.	O

Cumulative	O
doses	O
of	O
doxorubicin	O
were	O
225	O
-	O
550	O
mg	O
/	O
m2	O
(	O
median	O
dose	O
360	O
)	O
.	O

The	O
evaluation	O
consisted	O
of	O
a	O
history	O
,	O
physical	O
examination	O
,	O
electrocardiogram	O
(	O
ECG	O
)	O
,	O
signal	O
averaged	O
ECG	O
,	O
24	O
-	O
hour	O
ambulatory	O
ECG	O
,	O
echocardiography	O
and	O
radionuclide	O
angiography	O
.	O

Eighteen	O
of	O
31	O
(	O
58	O
%	O
)	O
patients	O
showed	O
cardiac	B-Disease
toxicity	I-Disease
,	O
defined	O
as	O
having	O
one	O
or	O
more	O
of	O
the	O
following	O
abnormalities	O
:	O
late	O
potentials	O
,	O
complex	O
ventricular	B-Disease
arrhythmias	I-Disease
,	O
left	O
ventricular	B-Disease
dilation	I-Disease
,	O
decreased	O
shortening	O
fraction	O
,	O
or	O
decreased	O
ejection	O
fraction	O
.	O

The	O
incidence	O
of	O
cardiac	B-Disease
abnormalities	I-Disease
increased	O
with	O
length	O
of	O
follow	O
-	O
up	O
(	O
P	O
<	O
or	O
=	O
.	O
05	O
)	O
.	O

No	O
correlation	O
could	O
be	O
demonstrated	O
between	O
cumulative	O
dose	O
of	O
doxorubicin	O
and	O
cardiac	O
status	O
,	O
except	O
for	O
heart	O
rate	O
variability	O
.	O

When	O
adjusted	O
to	O
body	O
surface	O
area	O
,	O
the	O
left	O
ventricular	O
posterior	O
wall	O
thickness	O
(	O
LVPW	O
index	O
)	O
was	O
decreased	O
in	O
all	O
patients	O
.	O

The	O
incidence	O
of	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B-Disease
is	O
high	O
and	O
increases	O
with	O
follow	O
-	O
up	O
,	O
irrespective	O
of	O
cumulative	O
dose	O
.	O

Life	O
-	O
long	O
cardiac	O
follow	O
-	O
up	O
in	O
these	O
patients	O
is	O
warranted	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
heart	O
rate	O
variability	O
and	O
LVPW	O
index	O
could	O
be	O
sensitive	O
indicators	O
for	O
cardiotoxicity	B-Disease
.	O

Acute	O
blood	O
pressure	O
elevations	O
with	O
caffeine	O
in	O
men	O
with	O
borderline	O
systemic	O
hypertension	B-Disease
.	O

Whether	O
the	O
vasoconstrictive	O
actions	O
of	O
caffeine	O
are	O
enhanced	O
in	O
hypertensive	B-Disease
persons	O
has	O
not	O
been	O
demonstrated	O
.	O

Thus	O
,	O
caffeine	O
(	O
3	O
.	O
3	O
mg	O
/	O
kg	O
)	O
versus	O
placebo	O
was	O
tested	O
in	O
48	O
healthy	O
men	O
(	O
aged	O
20	O
to	O
35	O
years	O
)	O
selected	O
after	O
screening	O
on	O
2	O
separate	O
occasions	O
.	O

Borderline	O
hypertensive	B-Disease
men	O
(	O
n	O
=	O
24	O
)	O
were	O
selected	O
with	O
screening	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
of	O
140	O
to	O
160	O
mm	O
Hg	O
and	O
/	O
or	O
diastolic	O
BP	O
90	O
to	O
99	O
mm	O
Hg	O
.	O

Low	O
-	O
risk	O
controls	O
(	O
n	O
=	O
24	O
)	O
reported	O
no	O
parental	O
history	O
of	O
hypertension	B-Disease
and	O
had	O
screening	O
BP	O
<	O
130	O
/	O
85	O
mm	O
Hg	O
.	O

Participants	O
were	O
then	O
tested	O
on	O
2	O
occasions	O
after	O
12	O
-	O
hour	O
abstinence	O
from	O
caffeine	O
in	O
each	O
of	O
2	O
protocols	O
;	O
this	O
required	O
a	O
total	O
of	O
4	O
laboratory	O
visits	O
.	O

Caffeine	O
-	O
induced	O
changes	O
in	O
diastolic	O
BP	O
were	O
2	O
to	O
3	O
times	O
larger	O
in	O
borderline	O
subjects	O
than	O
in	O
controls	O
(	O
+	O
8	O
.	O
4	O
vs	O
+	O
3	O
.	O
8	O
mm	O
Hg	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
and	O
were	O
attributable	O
to	O
larger	O
changes	O
in	O
impedance	O
-	O
derived	O
measures	O
of	O
systemic	O
vascular	O
resistance	O
(	O
+	O
135	O
vs	O
+	O
45	O
dynes	O
.	O
s	O
.	O
cm	O
-	O
5	O
,	O
p	O
<	O
0	O
.	O
004	O
)	O
.	O

These	O
findings	O
were	O
consistent	O
and	O
reached	O
significance	O
in	O
both	O
protocols	O
.	O

The	O
percentage	O
of	O
borderline	O
subjects	O
in	O
whom	O
diastolic	O
BP	O
changes	O
exceeded	O
the	O
median	O
control	O
response	O
was	O
96	O
%	O
.	O

Consequently	O
,	O
whereas	O
all	O
participants	O
exhibited	O
normotensive	O
levels	O
during	O
the	O
resting	O
predrug	O
baseline	O
,	O
33	O
%	O
of	O
borderline	O
subjects	O
achieved	O
hypertensive	B-Disease
BP	O
levels	O
after	O
caffeine	O
ingestion	O
.	O

Thus	O
,	O
in	O
borderline	O
hypertensive	B-Disease
men	O
,	O
exaggerated	O
responses	O
to	O
caffeine	O
were	O
:	O
selective	O
for	O
diastolic	O
BP	O
,	O
consistent	O
with	O
greater	O
vasoconstriction	O
,	O
replicated	O
in	O
2	O
protocols	O
,	O
and	O
representative	O
of	O
nearly	O
all	O
borderline	O
hypertensives	B-Disease
.	O

We	O
suspect	O
that	O
the	O
potential	O
for	O
caffeine	O
to	O
stabilize	O
high	O
resistance	O
states	O
in	O
susceptible	O
persons	O
suggests	O
that	O
its	O
use	O
may	O
facilitate	O
their	O
disease	O
progression	O
,	O
as	O
well	O
as	O
hinder	O
accurate	O
diagnosis	O
and	O
treatment	O
.	O

Absence	O
of	O
effect	O
of	O
sertraline	O
on	O
time	O
-	O
based	O
sensitization	O
of	O
cognitive	B-Disease
impairment	I-Disease
with	O
haloperidol	O
.	O

This	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
evaluated	O
the	O
effects	O
of	O
haloperidol	O
alone	O
and	O
haloperidol	O
plus	O
sertraline	O
on	O
cognitive	O
and	O
psychomotor	O
function	O
in	O
24	O
healthy	O
male	O
subjects	O
.	O

METHOD	O
:	O
All	O
subjects	O
received	O
placebo	O
on	O
Day	O
1	O
and	O
haloperidol	O
2	O
mg	O
on	O
Days	O
2	O
and	O
25	O
.	O

From	O
Days	O
9	O
to	O
25	O
,	O
subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
sertraline	O
(	O
12	O
subjects	O
)	O
or	O
placebo	O
(	O
12	O
subjects	O
)	O
;	O
the	O
sertraline	O
dose	O
was	O
titrated	O
from	O
50	O
to	O
200	O
mg	O
/	O
day	O
from	O
Days	O
9	O
to	O
16	O
,	O
and	O
remained	O
at	O
200	O
mg	O
/	O
day	O
for	O
the	O
final	O
10	O
days	O
of	O
the	O
drug	O
administration	O
period	O
.	O

Cognitive	O
function	O
testing	O
was	O
performed	O
before	O
dosing	O
and	O
over	O
a	O
24	O
-	O
hour	O
period	O
after	O
dosing	O
on	O
Days	O
1	O
,	O
2	O
,	O
and	O
25	O
.	O

RESULTS	O
:	O
Impairment	B-Disease
of	I-Disease
cognitive	I-Disease
function	I-Disease
was	O
observed	O
6	O
to	O
8	O
hours	O
after	O
administration	O
of	O
haloperidol	O
on	O
Day	O
2	O
but	O
was	O
not	O
evident	O
23	O
hours	O
after	O
dosing	O
.	O

When	O
single	O
-	O
dose	O
haloperidol	O
was	O
given	O
again	O
25	O
days	O
later	O
,	O
greater	O
impairment	O
with	O
earlier	O
onset	O
was	O
noted	O
in	O
several	O
tests	O
in	O
both	O
treatment	O
groups	O
,	O
suggesting	O
enhancement	O
of	O
this	O
effect	O
.	O

There	O
was	O
no	O
indication	O
that	O
sertraline	O
exacerbated	O
the	O
impairment	O
produced	O
by	O
haloperidol	O
since	O
an	O
equivalent	O
effect	O
also	O
occurred	O
in	O
the	O
placebo	O
group	O
.	O

Three	O
subjects	O
(	O
2	O
on	O
sertraline	O
and	O
1	O
on	O
placebo	O
)	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
side	O
effects	O
.	O

Ten	O
subjects	O
in	O
each	O
group	O
reported	O
side	O
effects	O
related	O
to	O
treatment	O
.	O

The	O
side	O
effect	O
profiles	O
of	O
sertraline	O
and	O
of	O
placebo	O
were	O
similar	O
.	O

CONCLUSION	O
:	O
Haloperidol	O
produced	O
a	O
clear	O
profile	O
of	O
cognitive	B-Disease
impairment	I-Disease
that	O
was	O
not	O
worsened	O
by	O
concomitant	O
sertraline	O
administration	O
.	O

Coexistence	O
of	O
cerebral	B-Disease
venous	I-Disease
sinus	I-Disease
and	I-Disease
internal	I-Disease
carotid	I-Disease
artery	I-Disease
thrombosis	I-Disease
associated	O
with	O
exogenous	O
sex	O
hormones	O
.	O

A	O
case	O
report	O
.	O

A	O
forty	O
-	O
six	O
year	O
-	O
old	O
premenopausal	O
woman	O
developed	O
headache	B-Disease
,	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
left	O
hemiparesis	B-Disease
and	O
seizure	B-Disease
two	O
days	O
after	O
parenteral	O
use	O
of	O
progesterone	O
and	O
estradiol	O
.	O

Diabetes	B-Disease
mellitus	I-Disease
(	O
DM	B-Disease
)	O
was	O
found	O
during	O
admission	O
.	O

Computed	O
tomography	O
showed	O
a	O
hemorrhagic	B-Disease
infarct	I-Disease
in	O
the	O
right	O
frontal	O
lobe	O
and	O
increased	O
density	O
in	O
the	O
superior	O
sagittal	O
sinus	O
(	O
SSS	O
)	O
.	O

Left	O
carotid	O
angiography	O
found	O
occlusion	B-Disease
of	I-Disease
the	I-Disease
left	I-Disease
internal	I-Disease
carotid	I-Disease
artery	I-Disease
(	O
ICA	O
)	O
.	O

Right	O
carotid	O
angiograms	O
failed	O
to	O
show	O
the	O
SSS	O
and	O
inferior	O
sagittal	O
sinus	O
,	O
suggestive	O
of	O
venous	B-Disease
sinus	I-Disease
thrombosis	I-Disease
.	O

Coexistence	O
of	O
the	O
cerebral	B-Disease
artery	I-Disease
and	I-Disease
the	I-Disease
venous	I-Disease
sinus	I-Disease
occlusion	I-Disease
has	O
been	O
described	O
infrequently	O
.	O

In	O
this	O
case	O
,	O
the	O
authors	O
postulate	O
that	O
the	O
use	O
of	O
estradiol	O
and	O
progesterone	O
and	O
the	O
underlying	O
DM	B-Disease
increased	O
vascular	O
thrombogenicity	O
,	O
which	O
provided	O
a	O
common	O
denominator	O
for	O
thrombosis	B-Disease
of	I-Disease
both	I-Disease
the	I-Disease
ICA	I-Disease
and	I-Disease
the	I-Disease
venous	I-Disease
sinus	I-Disease
.	O

Chemotherapy	O
of	O
advanced	O
inoperable	O
non	B-Disease
-	I-Disease
small	I-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
with	O
paclitaxel	O
:	O
a	O
phase	O
II	O
trial	O
.	O

Paclitaxel	O
(	O
Taxol	O
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
has	O
demonstrated	O
significant	O
antineoplastic	O
activity	O
against	O
different	O
tumor	B-Disease
types	O
,	O
notably	O
ovarian	B-Disease
and	I-Disease
breast	I-Disease
carcinoma	I-Disease
.	O

Two	O
phase	O
II	O
trials	O
of	O
24	O
-	O
hour	O
paclitaxel	O
infusions	O
in	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
non	B-Disease
-	I-Disease
small	I-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
(	O
NSCLC	B-Disease
)	O
reported	O
response	O
rates	O
of	O
21	O
%	O
and	O
24	O
%	O
.	O

Leukopenia	B-Disease
was	O
dose	O
limiting	O
:	O
as	O
many	O
as	O
62	O
.	O
5	O
%	O
of	O
patients	O
experienced	O
grade	O
4	O
leukopenia	B-Disease
.	O

We	O
investigated	O
the	O
efficacy	O
and	O
toxicity	B-Disease
of	O
a	O
3	O
-	O
hour	O
paclitaxel	O
infusion	O
in	O
a	O
phase	O
II	O
trial	O
in	O
patients	O
with	O
inoperable	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	B-Disease
.	O

The	O
58	O
patients	O
treated	O
(	O
41	O
men	O
and	O
17	O
women	O
)	O
had	O
a	O
median	O
age	O
of	O
59	O
years	O
(	O
age	O
range	O
,	O
25	O
to	O
75	O
)	O
and	O
a	O
performance	O
status	O
of	O
0	O
through	O
2	O
.	O

Most	O
patients	O
(	O
72	O
.	O
4	O
%	O
)	O
had	O
stage	O
IV	O
NSCLC	B-Disease
.	O

Paclitaxel	O
225	O
mg	O
/	O
m2	O
was	O
infused	O
over	O
3	O
hours	O
every	O
3	O
weeks	O
with	O
standard	O
prophylactic	O
premedication	O
.	O

Of	O
50	O
patients	O
evaluable	O
for	O
response	O
,	O
12	O
(	O
24	O
%	O
)	O
had	O
partial	O
remission	O
,	O
26	O
(	O
52	O
%	O
)	O
had	O
no	O
change	O
,	O
and	O
12	O
had	O
disease	O
progression	O
(	O
24	O
%	O
)	O
.	O

Hematologic	O
toxicities	B-Disease
were	O
mild	O
:	O
only	O
one	O
patient	O
(	O
2	O
%	O
)	O
developed	O
grade	O
3	O
or	O
4	O
neutropenia	B-Disease
,	O
while	O
29	O
%	O
had	O
grade	O
1	O
or	O
2	O
.	O

Grade	O
1	O
or	O
2	O
polyneuropathy	B-Disease
affected	O
56	O
%	O
of	O
patients	O
while	O
only	O
one	O
(	O
2	O
%	O
)	O
experienced	O
severe	O
polyneuropathy	B-Disease
.	O

Similarly	O
,	O
grade	O
1	O
or	O
2	O
myalgia	B-Disease
/	O
arthralgia	B-Disease
was	O
observed	O
in	O
63	O
.	O
2	O
%	O
of	O
patients	O
,	O
but	O
only	O
14	O
.	O
3	O
%	O
experienced	O
grade	O
3	O
or	O
4	O
.	O

Nausea	B-Disease
and	O
vomiting	B-Disease
were	O
infrequent	O
,	O
with	O
14	O
%	O
of	O
patients	O
experiencing	O
grade	O
1	O
or	O
2	O
and	O
only	O
2	O
%	O
experiencing	O
grade	O
3	O
or	O
4	O
.	O

Paclitaxel	O
is	O
thus	O
an	O
active	O
single	O
agent	O
in	O
this	O
patient	O
population	O
,	O
with	O
a	O
3	O
-	O
hour	O
infusion	O
proving	O
comparably	O
effective	O
to	O
a	O
24	O
-	O
hour	O
infusion	O
and	O
superior	O
in	O
terms	O
of	O
the	O
incidence	O
of	O
hematologic	O
and	O
nonhematologic	O
toxicity	B-Disease
.	O

Further	O
phase	O
II	O
studies	O
with	O
paclitaxel	O
combined	O
with	O
other	O
drugs	O
active	O
against	O
NSCLC	B-Disease
are	O
indicated	O
,	O
and	O
phase	O
III	O
studies	O
comparing	O
paclitaxel	O
with	O
standard	O
chemotherapy	O
remain	O
to	O
be	O
completed	O
.	O

Paclitaxel	O
combined	O
with	O
carboplatin	O
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
ovarian	B-Disease
cancer	I-Disease
.	O

In	O
a	O
phase	O
I	O
study	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
paclitaxel	O
(	O
Taxol	O
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
given	O
as	O
a	O
3	O
-	O
hour	O
infusion	O
in	O
combination	O
with	O
carboplatin	O
administered	O
every	O
21	O
days	O
to	O
women	O
with	O
advanced	O
ovarian	B-Disease
cancer	I-Disease
,	O
paclitaxel	O
doses	O
were	O
escalated	O
as	O
follows	O
:	O
level	O
1	O
,	O
135	O
mg	O
/	O
m2	O
;	O
level	O
2	O
,	O
160	O
mg	O
/	O
m2	O
;	O
level	O
3	O
,	O
185	O
mg	O
/	O
m2	O
;	O
and	O
level	O
4	O
,	O
210	O
mg	O
/	O
m2	O
.	O

The	O
fixed	O
dose	O
of	O
carboplatin	O
at	O
levels	O
1	O
through	O
4	O
was	O
given	O
to	O
achieve	O
an	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
of	O
5	O
using	O
the	O
Calvert	O
formula	O
.	O

In	O
levels	O
5	O
and	O
6	O
the	O
carboplatin	O
dose	O
was	O
targeted	O
at	O
AUCs	O
of	O
6	O
and	O
7	O
.	O
5	O
,	O
respectively	O
,	O
combined	O
with	O
a	O
fixed	O
paclitaxel	O
dose	O
of	O
185	O
mg	O
/	O
m2	O
.	O

To	O
date	O
,	O
30	O
previously	O
untreated	O
patients	O
,	O
all	O
with	O
a	O
good	O
performance	O
status	O
(	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
0	O
to	O
2	O
)	O
have	O
been	O
entered	O
into	O
this	O
ongoing	O
study	O
.	O

The	O
dose	O
-	O
limiting	O
toxicity	B-Disease
of	O
the	O
combination	O
was	O
myelosuppression	B-Disease
(	O
leukopenia	B-Disease
,	O
granulocytopenia	B-Disease
,	O
and	O
thrombocytopenia	B-Disease
)	O
.	O

Neurotoxicity	B-Disease
was	O
largely	O
moderate	O
.	O

So	O
far	O
,	O
14	O
patients	O
are	O
evaluable	O
for	O
response	O
;	O
of	O
these	O
,	O
eight	O
(	O
57	O
%	O
)	O
showed	O
objective	O
(	O
complete	O
or	O
partial	O
)	O
response	O
and	O
disease	O
stabilized	O
in	O
six	O
patients	O
.	O

No	O
patient	O
had	O
disease	O
progression	O
.	O

We	O
conclude	O
that	O
the	O
combination	O
of	O
paclitaxel	O
185	O
mg	O
/	O
m2	O
administered	O
as	O
a	O
3	O
-	O
hour	O
infusion	O
followed	O
immediately	O
by	O
a	O
1	O
-	O
hour	O
infusion	O
of	O
carboplatin	O
at	O
an	O
AUC	O
of	O
6	O
can	O
be	O
administered	O
safely	O
in	O
a	O
21	O
-	O
day	O
schedule	O
in	O
the	O
outpatient	O
setting	O
.	O

The	O
recommended	O
dose	O
for	O
phase	O
III	O
studies	O
is	O
paclitaxel	O
185	O
mg	O
/	O
m2	O
and	O
carboplatin	O
AUC	O
6	O
.	O

Effects	O
of	O
acute	O
steroid	O
administration	O
on	O
ventilatory	O
and	O
peripheral	O
muscles	O
in	O
rats	O
.	O

Occasional	O
case	O
reports	O
have	O
shown	O
that	O
acute	O
myopathy	B-Disease
may	O
occur	O
in	O
patients	O
treated	O
with	O
massive	O
doses	O
of	O
corticosteroids	O
.	O

The	O
mechanism	O
of	O
this	O
myopathy	B-Disease
is	O
poorly	O
understood	O
.	O

Therefore	O
,	O
60	O
male	O
rats	O
were	O
randomly	O
assigned	O
to	O
receive	O
daily	O
injection	O
of	O
saline	O
(	O
C	O
)	O
,	O
methylprednisolone	O
(	O
M	O
)	O
,	O
or	O
triamcinolone	O
(	O
T	O
)	O
80	O
mg	O
/	O
kg	O
/	O
d	O
for	O
5	O
d	O
.	O

Nutritional	O
intake	O
,	O
measured	O
daily	O
in	O
15	O
animals	O
,	O
showed	O
a	O
significant	O
reduction	B-Disease
of	I-Disease
food	I-Disease
intake	I-Disease
in	O
the	O
steroid	O
-	O
treated	O
groups	O
(	O
-	O
50	O
and	O
-	O
79	O
%	O
in	O
M	O
and	O
T	O
,	O
respectively	O
)	O
.	O

This	O
was	O
associated	O
with	O
a	O
similar	O
loss	B-Disease
in	I-Disease
body	I-Disease
weight	I-Disease
.	O

In	O
the	O
45	O
remaining	O
animals	O
,	O
diaphragm	O
contractility	O
and	O
histopathologic	O
features	O
of	O
several	O
muscles	O
were	O
studied	O
.	O

Weights	O
of	O
respiratory	O
and	O
peripheral	O
muscles	O
were	O
similarly	O
decreased	O
after	O
steroid	O
treatment	O
.	O

Maximal	O
twitches	O
of	O
the	O
diaphragm	O
were	O
lower	O
in	O
the	O
C	O
group	O
(	O
653	O
+	O
/	O
-	O
174	O
g	O
/	O
cm	O
(	O
2	O
)	O
)	O
than	O
in	O
the	O
M	O
group	O
(	O
837	O
+	O
/	O
-	O
171	O
g	O
/	O
cm	O
(	O
2	O
)	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
T	O
group	O
(	O
765	O
+	O
/	O
-	O
145	O
g	O
/	O
cm	O
(	O
2	O
)	O
,	O
NS	O
)	O
.	O

Half	O
-	O
relaxation	O
time	O
was	O
prolonged	O
in	O
both	O
steroid	O
groups	O
,	O
and	O
time	O
to	O
peak	O
tension	O
was	O
longer	O
with	O
M	O
,	O
whereas	O
tetanic	B-Disease
tensions	O
were	O
similar	O
.	O

Steroid	O
treatment	O
also	O
induced	O
a	O
leftward	O
shift	O
of	O
the	O
force	O
-	O
frequency	O
curve	O
at	O
25	O
and	O
50	O
Hz	O
when	O
compared	O
with	O
saline	O
treatment	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

ATPase	O
staining	O
of	O
the	O
diaphragm	O
,	O
scalenus	O
medius	O
,	O
and	O
gastrocnemius	O
showed	O
type	O
IIb	O
fiber	O
atrophy	B-Disease
in	O
the	O
steroid	O
groups	O
and	O
also	O
diaphragmatic	O
type	O
IIa	O
atrophy	B-Disease
with	O
T	O
,	O
whereas	O
histologic	O
examinations	O
revealed	O
a	O
normal	O
muscular	O
pattern	O
with	O
absence	O
of	O
necrosis	B-Disease
.	O

Finally	O
,	O
a	O
pair	O
-	O
fed	O
(	O
PF	O
)	O
study	O
,	O
performed	O
in	O
18	O
rats	O
(	O
C	O
,	O
T	O
,	O
and	O
PF	O
)	O
,	O
showed	O
that	O
muscle	B-Disease
atrophy	I-Disease
was	O
considerably	O
less	O
pronounced	O
in	O
PF	O
animals	O
than	O
in	O
T	O
-	O
treated	O
animals	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
short	O
-	O
term	O
treatment	O
with	O
massive	O
doses	O
of	O
steroids	O
induced	O
severe	O
respiratory	O
and	O
limb	O
muscle	O
wasting	O
;	O
(	O
2	O
)	O
both	O
types	O
of	O
steroids	O
induced	O
predominantly	O
type	O
IIb	O
atrophy	B-Disease
,	O
resulting	O
in	O
the	O
expected	O
alterations	O
in	O
diaphragm	O
contractile	O
properties	O
;	O
(	O
3	O
)	O
neither	O
steroid	O
caused	O
muscle	O
necrosis	B-Disease
;	O
(	O
4	O
)	O
type	O
IIb	O
atrophy	B-Disease
was	O
not	O
caused	O
by	O
acute	O
nutritional	O
deprivation	O
alone	O
.	O

Continuous	O
subcutaneous	O
administration	O
of	O
mesna	O
to	O
prevent	O
ifosfamide	O
-	O
induced	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O

Hemorrhagic	B-Disease
cystitis	I-Disease
is	O
a	O
major	O
potential	O
toxicity	B-Disease
of	O
ifosfamide	O
that	O
can	O
be	O
prevented	O
by	O
administering	O
mesna	O
along	O
with	O
the	O
cytotoxic	O
agent	O
.	O

Mesna	O
is	O
generally	O
administered	O
by	O
the	O
intravenous	O
route	O
,	O
although	O
experience	O
with	O
oral	O
delivery	O
of	O
the	O
drug	O
has	O
increased	O
.	O

The	O
continuous	O
subcutaneous	O
administration	O
of	O
mesna	O
has	O
the	O
advantage	O
of	O
not	O
requiring	O
intravenous	O
access	O
.	O

In	O
addition	O
,	O
subcutaneous	O
delivery	O
of	O
the	O
neutralizing	O
agent	O
will	O
not	O
be	O
associated	O
with	O
the	O
risk	O
of	O
inadequate	O
urinary	O
mesna	O
concentrations	O
,	O
such	O
as	O
in	O
a	O
patient	O
taking	O
oral	O
mesna	O
who	O
experiences	O
severe	O
ifosfamide	O
-	O
induced	O
emesis	B-Disease
and	O
is	O
unable	O
to	O
absorb	O
the	O
drug	O
.	O

Limited	O
clinical	O
experience	O
with	O
continuous	O
subcutaneous	O
mesna	O
administration	O
suggests	O
it	O
is	O
a	O
safe	O
,	O
practical	O
,	O
and	O
economic	O
method	O
of	O
drug	O
delivery	O
that	O
permits	O
ifosfamide	O
to	O
be	O
administered	O
successfully	O
in	O
the	O
outpatient	O
setting	O
.	O

Leg	B-Disease
and	I-Disease
back	I-Disease
pain	I-Disease
after	O
spinal	O
anaesthesia	O
involving	O
hyperbaric	O
5	O
%	O
lignocaine	O
.	O

Fifty	O
-	O
four	O
patients	O
,	O
aged	O
27	O
-	O
90	O
years	O
,	O
who	O
were	O
given	O
lignocaine	O
5	O
%	O
in	O
6	O
.	O
8	O
%	O
glucose	O
solution	O
for	O
spinal	O
anaesthesia	O
were	O
studied	O
.	O

Thirteen	O
of	O
these	O
patients	O
experienced	O
pain	B-Disease
in	I-Disease
the	I-Disease
legs	I-Disease
and	I-Disease
/	I-Disease
or	I-Disease
back	I-Disease
after	O
recovery	O
from	O
anaesthesia	O
.	O

The	O
patients	O
affected	O
were	O
younger	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
site	O
of	O
the	O
dural	O
puncture	O
was	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
than	O
those	O
individuals	O
without	O
pain	B-Disease
.	O

Five	O
of	O
the	O
13	O
patients	O
(	O
38	O
%	O
)	O
with	O
pain	B-Disease
and	O
seven	O
of	O
the	O
41	O
patients	O
(	O
17	O
%	O
)	O
without	O
pain	B-Disease
admitted	O
to	O
a	O
high	O
alcohol	O
intake	O
,	O
which	O
might	O
be	O
a	O
contributing	O
factor	O
.	O

Leg	B-Disease
and	I-Disease
/	I-Disease
or	I-Disease
back	I-Disease
pain	I-Disease
is	O
associated	O
with	O
the	O
intrathecal	O
use	O
of	O
hyperbaric	O
5	O
%	O
lignocaine	O
.	O

The	O
use	O
of	O
serum	O
cholinesterase	O
in	O
succinylcholine	O
apnoea	B-Disease
.	O

Fifteen	O
patients	O
demonstrating	O
unexpected	O
prolonged	O
apnoea	B-Disease
lasting	O
several	O
hours	O
after	O
succinylcholine	O
have	O
been	O
treated	O
by	O
a	O
new	O
preparation	O
of	O
human	O
serum	O
cholinesterase	O
.	O

Adequate	O
spontaneous	O
respiration	O
was	O
re	O
-	O
established	O
in	O
an	O
average	O
period	O
of	O
ten	O
minutes	O
after	O
the	O
injection	O
.	O

In	O
12	O
patients	O
biochemical	O
genetic	O
examinations	O
confirmed	O
the	O
presence	O
of	O
an	O
atypical	O
serum	O
cholinesterase	O
.	O

In	O
three	O
patients	O
none	O
of	O
the	O
usual	O
variants	O
were	O
found	O
.	O

It	O
is	O
therefore	O
supposed	O
that	O
other	O
unknown	O
variants	O
of	O
serum	O
cholinesterase	O
exist	O
which	O
cannot	O
hydrolyze	O
succinylcholine	O
.	O

The	O
use	O
of	O
serum	O
cholinesterase	O
in	O
succinylcholine	O
apnoea	B-Disease
provided	O
considerable	O
relief	O
to	O
both	O
patient	O
and	O
anaesthetist	O
.	O

Increased	O
sulfation	O
and	O
decreased	O
7alpha	O
-	O
hydroxylation	O
of	O
deoxycholic	O
acid	O
in	O
ethinyl	O
estradiol	O
-	O
induced	O
cholestasis	B-Disease
in	O
rats	O
.	O

Deoxycholic	O
acid	O
conjugation	O
,	O
transport	O
capacity	O
,	O
and	O
metabolism	O
were	O
compared	O
in	O
control	O
and	O
ethinyl	O
estradiol	O
-	O
treated	O
rats	O
.	O

Control	O
rats	O
were	O
found	O
to	O
have	O
a	O
lower	O
capacity	O
to	O
transport	O
deoxycholic	O
acid	O
than	O
taurodeoxycholic	O
acid	O
,	O
and	O
both	O
were	O
decreased	O
by	O
ethinyl	O
estradiol	O
treatment	O
.	O

During	O
[	O
24	O
-	O
14C	O
]	O
sodium	O
deoxycholate	O
infusion	O
,	O
[	O
14C	O
]	O
biliary	O
bile	O
acid	O
secretion	O
increased	O
,	O
but	O
bile	O
flow	O
did	O
not	O
change	O
significantly	O
in	O
either	O
control	O
or	O
ethinyl	O
estradiol	O
-	O
treated	O
rats	O
.	O

Ethinyl	O
estradiol	O
-	O
treated	O
animals	O
excreted	O
significantly	O
less	O
14C	O
as	O
taurocholic	O
acid	O
than	O
did	O
control	O
animals	O
,	O
consistent	O
with	O
an	O
impairment	O
of	O
7alpha	O
-	O
hydroxylation	O
of	O
taurodeoxycholic	O
acid	O
.	O

Ethinyl	O
estradiol	O
treatment	O
did	O
not	O
impair	O
conjugation	O
of	O
deoxycholic	O
acid	O
,	O
but	O
did	O
result	O
in	O
an	O
increase	O
in	O
sulfation	O
of	O
taurodeoxycholic	O
acid	O
from	O
1	O
.	O
5	O
%	O
in	O
controls	O
to	O
nearly	O
4	O
.	O
0	O
%	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
rat	O
has	O
a	O
poorer	O
tolerance	O
for	O
deoxycholic	O
acid	O
than	O
do	O
certain	O
other	O
species	O
.	O

Furthermore	O
,	O
the	O
rat	O
converts	O
deoxycholic	O
acid	O
,	O
a	O
poor	O
choleretic	O
,	O
to	O
taurocholic	O
acid	O
,	O
a	O
good	O
choleretic	O
.	O

When	O
this	O
conversion	O
is	O
impaired	O
with	O
ethinyl	O
estradiol	O
treatment	O
,	O
sulfation	O
may	O
be	O
an	O
important	O
alternate	O
pathway	O
for	O
excretion	O
of	O
this	O
potentially	O
harmful	O
bile	O
acid	O
.	O

Influence	O
of	O
diet	O
free	O
of	O
NAD	O
-	O
precursors	O
on	O
acetaminophen	O
hepatotoxicity	B-Disease
in	O
mice	O
.	O

Recently	O
,	O
we	O
demonstrated	O
the	O
hepatoprotective	O
effects	O
of	O
nicotinic	O
acid	O
amide	O
,	O
a	O
selective	O
inhibitor	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
;	O
EC	O
2	O
.	O
4	O
.	O
2	O
.	O
30	O
)	O
on	O
mice	O
suffering	O
from	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
hepatitis	B-Disease
,	O
suggesting	O
that	O
the	O
AAP	O
-	O
induced	O
liver	B-Disease
injury	I-Disease
involves	O
a	O
step	O
which	O
depends	O
on	O
adenoribosylation	O
.	O

The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
a	O
diet	O
free	O
of	O
precursors	O
of	O
NAD	O
,	O
the	O
substrate	O
on	O
which	O
PARP	O
acts	O
,	O
in	O
female	O
NMRI	O
mice	O
with	O
AAP	O
hepatitis	B-Disease
and	O
evaluates	O
the	O
influence	O
of	O
simultaneous	O
ethanol	O
consumption	O
in	O
these	O
animals	O
.	O

Liver	B-Disease
injuries	I-Disease
were	O
quantified	O
as	O
serum	O
activities	O
of	O
glutamate	O
-	O
oxaloacetate	O
transaminase	O
(	O
GOT	O
)	O
and	O
glutamate	O
-	O
pyruvate	O
transaminase	O
(	O
GPT	O
)	O
.	O

While	O
AAP	O
caused	O
a	O
117	O
-	O
fold	O
elevation	O
of	O
serum	O
transaminase	O
activities	O
in	O
mice	O
kept	O
on	O
a	O
standard	O
laboratory	O
diet	O
,	O
which	O
was	O
significantly	O
exacerbated	O
by	O
ethanol	O
and	O
inhibited	O
by	O
nicotinic	O
acid	O
amide	O
(	O
NAA	O
)	O
,	O
adverse	O
effects	O
were	O
noted	O
in	O
animals	O
fed	O
a	O
diet	O
free	O
of	O
precursors	O
of	O
NAD	O
.	O

In	O
these	O
animals	O
,	O
only	O
minor	O
increases	O
of	O
serum	O
transaminase	O
activities	O
were	O
measured	O
in	O
the	O
presence	O
of	O
AAP	O
,	O
and	O
unlike	O
the	O
exacerbation	O
caused	O
by	O
ethanol	O
in	O
mice	O
on	O
a	O
standard	O
diet	O
,	O
the	O
liver	B-Disease
damage	I-Disease
was	O
inhibited	O
by	O
50	O
%	O
by	O
ethanol	O
.	O

A	O
further	O
64	O
%	O
reduction	O
of	O
hepatitis	B-Disease
was	O
observed	O
,	O
when	O
NAA	O
was	O
given	O
to	O
ethanol	O
/	O
AAP	O
-	O
mice	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
the	O
AAP	O
-	O
induced	O
hepatitis	B-Disease
and	O
its	O
exacerbation	O
by	O
ethanol	O
can	O
either	O
be	O
reduced	O
by	O
end	O
-	O
product	O
inhibition	O
of	O
PARP	O
by	O
NAA	O
or	O
by	O
dietary	O
depletion	O
of	O
the	O
enzyme	O
'	O
s	O
substrate	O
NAD	O
.	O

We	O
see	O
the	O
main	O
application	O
of	O
NAA	O
as	O
for	O
the	O
combinational	O
use	O
in	O
pharmaceutical	O
preparations	O
of	O
acetaminophen	O
in	O
order	O
to	O
avoid	O
hepatic	B-Disease
damage	I-Disease
in	O
patients	O
treated	O
with	O
this	O
widely	O
used	O
analgesic	O
.	O

Nightmares	O
and	O
hallucinations	B-Disease
after	O
long	O
-	O
term	O
intake	O
of	O
tramadol	O
combined	O
with	O
antidepressants	O
.	O

Tramadol	O
is	O
a	O
weak	O
opioid	O
with	O
effects	O
on	O
adrenergic	O
and	O
serotonergic	O
neurotransmission	O
that	O
is	O
used	O
to	O
treat	O
cancer	B-Disease
pain	B-Disease
and	O
chronic	O
non	O
malignant	O
pain	B-Disease
.	O

This	O
drug	O
was	O
initiated	O
in	O
association	O
with	O
paroxetine	O
and	O
dosulepine	O
hydrochloride	O
in	O
a	O
tetraparetic	B-Disease
patient	O
with	O
chronic	B-Disease
pain	I-Disease
.	O

Fifty	O
-	O
six	O
days	O
after	O
initiation	O
of	O
the	O
treatment	O
the	O
patient	O
presented	O
hallucinations	B-Disease
that	O
only	O
stopped	O
after	O
the	O
withdrawal	O
of	O
psycho	O
-	O
active	O
drugs	O
and	O
tramadol	O
.	O

The	O
case	O
report	O
questions	O
the	O
long	O
term	O
use	O
of	O
pain	B-Disease
killers	O
combined	O
with	O
psycho	O
-	O
active	O
drugs	O
in	O
chronic	O
non	O
malignant	O
pain	B-Disease
,	O
especially	O
if	O
pain	B-Disease
is	O
under	O
control	O
.	O

Effect	O
of	O
calcium	O
chloride	O
and	O
4	O
-	O
aminopyridine	O
therapy	O
on	O
desipramine	O
toxicity	B-Disease
in	O
rats	O
.	O

BACKGROUND	O
:	O
Hypotension	B-Disease
is	O
a	O
major	O
contributor	O
to	O
mortality	O
in	O
tricyclic	O
antidepressant	O
overdose	B-Disease
.	O

Recent	O
data	O
suggest	O
that	O
tricyclic	O
antidepressants	O
inhibit	O
calcium	O
influx	O
in	O
some	O
tissues	O
.	O

This	O
study	O
addressed	O
the	O
potential	O
role	O
of	O
calcium	O
channel	O
blockade	O
in	O
tricyclic	O
antidepressant	O
-	O
induced	O
hypotension	B-Disease
.	O

METHODS	O
:	O
Two	O
interventions	O
were	O
studied	O
that	O
have	O
been	O
shown	O
previously	O
to	O
improve	O
blood	O
pressure	O
with	O
calcium	O
channel	O
blocker	O
overdose	B-Disease
.	O

CaCl2	O
and	O
4	O
-	O
aminopyridine	O
.	O

Anesthetized	O
rats	O
received	O
the	O
tricyclic	O
antidepressant	O
desipramine	O
IP	O
to	O
produce	O
hypotension	B-Disease
,	O
QRS	O
prolongation	O
,	O
and	O
bradycardia	B-Disease
.	O

Fifteen	O
min	O
later	O
,	O
animals	O
received	O
CaCl2	O
,	O
NaHCO3	O
,	O
or	O
saline	O
.	O

In	O
a	O
second	O
experiment	O
,	O
rats	O
received	O
tricyclic	O
antidepressant	O
desipramine	O
IP	O
followed	O
in	O
15	O
min	O
by	O
4	O
-	O
aminopyridine	O
or	O
saline	O
.	O

RESULTS	O
:	O
NaHCO3	O
briefly	O
(	O
5	O
min	O
)	O
reversed	O
hypotension	B-Disease
and	O
QRS	O
prolongation	O
.	O

CaCl2	O
and	O
4	O
-	O
aminopyridine	O
failed	O
to	O
improve	O
blood	O
pressure	O
.	O

The	O
incidence	O
of	O
ventricular	B-Disease
arrhythmias	I-Disease
(	O
p	O
=	O
0	O
.	O
004	O
)	O
and	O
seizures	B-Disease
(	O
p	O
=	O
0	O
.	O
03	O
)	O
in	O
the	O
CaCl2	O
group	O
was	O
higher	O
than	O
the	O
other	O
groups	O
.	O

CONCLUSION	O
:	O
The	O
administration	O
of	O
CaCl2	O
or	O
4	O
-	O
aminopyridine	O
did	O
not	O
reverse	O
tricyclic	O
antidepressant	O
-	O
induced	O
hypotension	B-Disease
in	O
rats	O
.	O

CaCl2	O
therapy	O
may	O
possibly	O
worsen	O
both	O
cardiovascular	B-Disease
and	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
toxicity	I-Disease
.	O

These	O
findings	O
do	O
not	O
support	O
a	O
role	O
for	O
calcium	O
channel	O
inhibition	O
in	O
the	O
pathogenesis	O
of	O
tricyclic	O
antidepressant	O
-	O
induced	O
hypotension	B-Disease
.	O

Valsartan	O
,	O
a	O
new	O
angiotensin	O
II	O
antagonist	O
for	O
the	O
treatment	O
of	O
essential	O
hypertension	B-Disease
:	O
a	O
comparative	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
against	O
amlodipine	O
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
antihypertensive	O
efficacy	O
of	O
a	O
new	O
angiotensin	O
II	O
antagonist	O
,	O
valsartan	O
,	O
with	O
a	O
reference	O
therapy	O
,	O
amlodipine	O
.	O

METHODS	O
:	O
One	O
hundred	O
sixty	O
-	O
eight	O
adult	O
outpatients	O
with	O
mild	O
to	O
moderate	O
hypertension	B-Disease
were	O
randomly	O
allocated	O
in	O
double	O
-	O
blind	O
fashion	O
and	O
equal	O
number	O
to	O
receive	O
80	O
mg	O
valsartan	O
or	O
5	O
mg	O
amlodipine	O
for	O
12	O
weeks	O
.	O

After	O
8	O
weeks	O
of	O
therapy	O
,	O
in	O
patients	O
whose	O
blood	O
pressure	O
remained	O
uncontrolled	O
,	O
5	O
mg	O
amlodipine	O
was	O
added	O
to	O
the	O
initial	O
therapy	O
.	O

Patients	O
were	O
assessed	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

The	O
primary	O
efficacy	O
variable	O
was	O
change	O
from	O
baseline	O
in	O
mean	O
sitting	O
diastolic	O
blood	O
pressure	O
at	O
8	O
weeks	O
.	O

Secondary	O
variables	O
included	O
change	O
in	O
sitting	O
systolic	O
blood	O
pressure	O
and	O
responder	O
rates	O
.	O

RESULTS	O
:	O
Both	O
valsartan	O
and	O
amlodipine	O
were	O
effective	O
at	O
lowering	O
blood	O
pressure	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

Similar	O
decreases	O
were	O
observed	O
in	O
both	O
groups	O
,	O
with	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
for	O
any	O
variable	O
analyzed	O
.	O

For	O
the	O
primary	O
variable	O
the	O
difference	O
was	O
0	O
.	O
5	O
mm	O
Hg	O
in	O
favor	O
of	O
valsartan	O
(	O
p	O
=	O
0	O
.	O
68	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
2	O
.	O
7	O
to	O
1	O
.	O
7	O
)	O
.	O

Responder	O
rates	O
at	O
8	O
weeks	O
were	O
66	O
.	O
7	O
%	O
for	O
valsartan	O
and	O
60	O
.	O
2	O
%	O
for	O
amlodipine	O
(	O
p	O
=	O
0	O
.	O
39	O
)	O
.	O

Both	O
treatments	O
were	O
well	O
tolerated	O
.	O

The	O
incidence	O
of	O
drug	O
-	O
related	O
dependent	O
edema	B-Disease
was	O
somewhat	O
higher	O
in	O
the	O
amlodipine	O
group	O
,	O
particularly	O
at	O
a	O
dose	O
of	O
10	O
mg	O
per	O
day	O
(	O
2	O
.	O
4	O
%	O
for	O
80	O
mg	O
valsartan	O
;	O
3	O
.	O
6	O
%	O
for	O
5	O
mg	O
amlodipine	O
;	O
0	O
%	O
for	O
valsartan	O
plus	O
5	O
mg	O
amlodipine	O
;	O
14	O
.	O
3	O
%	O
for	O
10	O
mg	O
amlodipine	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
show	O
that	O
valsartan	O
is	O
at	O
least	O
as	O
effective	O
as	O
amlodipine	O
in	O
the	O
treatment	O
of	O
mild	O
to	O
moderate	O
hypertension	B-Disease
.	O

The	O
results	O
also	O
show	O
valsartan	O
to	O
be	O
well	O
tolerated	O
and	O
suggest	O
that	O
it	O
is	O
not	O
associated	O
with	O
side	O
effects	O
characteristic	O
of	O
this	O
comparator	O
class	O
,	O
dihydropyridine	O
calcium	O
antagonists	O
.	O

A	O
measure	O
of	O
pupillary	B-Disease
oscillation	I-Disease
as	O
a	O
marker	O
of	O
cocaine	O
-	O
induced	O
paranoia	B-Disease
.	O

Cocaine	O
-	O
induced	O
paranoia	B-Disease
(	O
CIP	B-Disease
)	O
remains	O
an	O
important	O
drug	O
-	O
induced	O
model	O
of	O
idiopathic	O
paranoia	B-Disease
for	O
which	O
no	O
psychophysiologic	O
marker	O
has	O
yet	O
emerged	O
.	O

Measures	O
of	O
pupillary	B-Disease
oscillation	I-Disease
were	O
able	O
to	O
significantly	O
distinguish	O
a	O
group	O
of	O
abstinent	O
crack	O
cocaine	O
abusers	O
endorsing	O
past	O
CIP	B-Disease
(	O
n	O
=	O
32	O
)	O
from	O
another	O
group	O
of	O
crack	O
addicts	O
who	O
denied	O
past	O
CIP	B-Disease
(	O
n	O
=	O
29	O
)	O
.	O

Serotonin	B-Disease
syndrome	I-Disease
from	O
venlafaxine	O
-	O
tranylcypromine	O
interaction	O
.	O

Excessive	O
stimulation	O
of	O
serotonin	O
5HT1A	O
receptors	O
causes	O
a	O
syndrome	O
of	O
serotonin	O
excess	O
that	O
consists	O
of	O
shivering	O
,	O
muscle	B-Disease
rigidity	I-Disease
,	O
salivation	B-Disease
,	O
confusion	B-Disease
,	O
agitation	B-Disease
and	O
hyperthermia	B-Disease
.	O

The	O
most	O
common	O
cause	O
of	O
this	O
syndrome	O
is	O
an	O
interaction	O
between	O
a	O
monoamine	O
oxidase	O
inhibitor	O
(	O
MAOI	O
)	O
and	O
a	O
specific	O
serotonin	O
reuptake	O
inhibitor	O
.	O

Venlafaxine	O
is	O
a	O
new	O
antidepressant	O
agent	O
that	O
inhibits	O
the	O
reuptake	O
of	O
serotonin	O
and	O
norepinephrine	O
.	O

We	O
report	O
a	O
venlafaxine	O
-	O
MAOI	O
interaction	O
that	O
resulted	O
in	O
the	O
serotonin	B-Disease
syndrome	I-Disease
in	O
a	O
23	O
-	O
y	O
-	O
old	O
male	O
who	O
was	O
taking	O
tranylcypromine	O
for	O
depression	B-Disease
.	O

He	O
had	O
been	O
well	O
until	O
the	O
morning	O
of	O
presentation	O
when	O
he	O
took	O
1	O
/	O
2	O
tab	O
of	O
venlafaxine	O
.	O

Within	O
2	O
h	O
he	O
became	O
confused	O
with	O
jerking	O
movements	O
of	O
his	O
extremities	O
,	O
tremors	B-Disease
and	O
rigidity	B-Disease
.	O

He	O
was	O
brought	O
directly	O
to	O
a	O
hospital	O
where	O
he	O
was	O
found	O
to	O
be	O
agitated	O
and	O
confused	O
with	O
shivering	O
,	O
myoclonic	B-Disease
jerks	I-Disease
,	O
rigidity	B-Disease
,	O
salivation	B-Disease
and	O
diaphoresis	O
.	O

His	O
pupils	O
were	O
7	O
mm	O
and	O
sluggishly	O
reactive	O
to	O
light	O
.	O

Vital	O
signs	O
were	O
:	O
blood	O
pressure	O
120	O
/	O
67	O
mm	O
Hg	O
,	O
heart	O
rate	O
127	O
/	O
min	O
,	O
respiratory	O
rate	O
28	O
/	O
min	O
,	O
and	O
temperature	O
97	O
F	O
.	O

After	O
180	O
mg	O
of	O
diazepam	O
i	O
.	O
v	O
.	O
he	O
remained	O
tremulous	O
with	O
muscle	B-Disease
rigidity	I-Disease
and	O
clenched	O
jaws	O
.	O

He	O
was	O
intubated	O
for	O
airway	O
protection	O
and	O
because	O
of	O
hypoventilation	B-Disease
,	O
and	O
was	O
paralyzed	B-Disease
to	O
control	O
muscle	B-Disease
rigidity	I-Disease
.	O

His	O
subsequent	O
course	O
was	O
remarkable	O
for	O
non	O
-	O
immune	O
thrombocytopenia	B-Disease
which	O
resolved	O
.	O

The	O
patient	O
'	O
s	O
maximal	O
temperature	O
was	O
101	O
.	O
2	O
F	O
and	O
his	O
CPK	O
remained	O
<	O
500	O
units	O
/	O
L	O
with	O
no	O
other	O
evidence	O
of	O
rhabdomyolysis	B-Disease
.	O

His	O
mental	O
status	O
normalized	O
and	O
he	O
was	O
transferred	O
to	O
a	O
psychiatry	O
ward	O
.	O

This	O
patient	O
survived	O
without	O
sequelae	O
due	O
to	O
the	O
aggressive	O
sedation	O
and	O
neuromuscular	O
paralysis	B-Disease
.	O

Cyclophosphamide	O
associated	O
bladder	B-Disease
cancer	I-Disease
-	O
-	O
a	O
highly	O
aggressive	O
disease	O
:	O
analysis	O
of	O
12	O
cases	O
.	O

PURPOSE	O
:	O
We	O
gained	O
knowledge	O
of	O
the	O
etiology	O
,	O
treatment	O
and	O
prevention	O
of	O
cyclophosphamide	O
associated	O
urothelial	B-Disease
cancer	I-Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
medical	O
records	O
of	O
6	O
men	O
and	O
6	O
women	O
(	O
mean	O
age	O
55	O
years	O
)	O
with	O
cyclophosphamide	O
associated	O
bladder	B-Disease
cancer	I-Disease
were	O
reviewed	O
.	O

RESULTS	O
:	O
All	O
tumors	B-Disease
were	O
grade	O
3	O
or	O
4	O
transitional	O
cell	O
carcinoma	B-Disease
.	O

Of	O
the	O
5	O
patients	O
initially	O
treated	O
with	O
endoscopic	O
resection	O
alone	O
only	O
1	O
is	O
alive	O
without	O
disease	O
.	O

Of	O
the	O
6	O
patients	O
who	O
underwent	O
early	O
cystectomy	O
4	O
were	O
alive	O
at	O
24	O
to	O
111	O
months	O
.	O

The	O
remaining	O
patient	O
with	O
extensive	O
cancer	B-Disease
underwent	O
partial	O
cystectomy	O
for	O
palliation	O
and	O
died	O
3	O
months	O
later	O
.	O

CONCLUSIONS	O
:	O
Cyclophosphamide	O
associated	O
bladder	B-Disease
tumor	I-Disease
is	O
an	O
aggressive	O
disease	O
.	O

However	O
,	O
long	O
-	O
term	O
survival	O
is	O
possible	O
when	O
radical	O
cystectomy	O
is	O
performed	O
for	O
bladder	B-Disease
tumors	I-Disease
with	O
any	O
sign	O
of	O
invasion	O
and	O
for	O
recurrent	O
high	O
grade	O
disease	O
,	O
even	O
when	O
noninvasive	O
.	O

A	O
phase	O
I	O
clinical	O
study	O
of	O
the	O
antipurine	O
antifolate	O
lometrexol	O
(	O
DDATHF	O
)	O
given	O
with	O
oral	O
folic	O
acid	O
.	O

Lometrexol	O
is	O
an	O
antifolate	O
which	O
inhibits	O
glycinamide	O
ribonucleotide	O
formyltransferase	O
(	O
GARFT	O
)	O
,	O
an	O
enzyme	O
essential	O
for	O
de	O
novo	O
purine	O
synthesis	O
.	O

Extensive	O
experimental	O
and	O
limited	O
clinical	O
data	O
have	O
shown	O
that	O
lometrexol	O
has	O
activity	O
against	O
tumours	B-Disease
which	O
are	O
refractory	O
to	O
other	O
drugs	O
,	O
notably	O
methotrexate	O
.	O

However	O
,	O
the	O
initial	O
clinical	O
development	O
of	O
lometrexol	O
was	O
curtailed	O
because	O
of	O
severe	O
and	O
cumulative	O
antiproliferative	O
toxicities	B-Disease
.	O

Preclinical	O
murine	O
studies	O
demonstrated	O
that	O
the	O
toxicity	B-Disease
of	O
lometrexol	O
can	O
be	O
prevented	O
by	O
low	O
dose	O
folic	O
acid	O
administration	O
,	O
i	O
.	O
e	O
.	O
for	O
7	O
days	O
prior	O
to	O
and	O
7	O
days	O
following	O
a	O
single	O
bolus	O
dose	O
.	O

This	O
observation	O
prompted	O
a	O
Phase	O
I	O
clinical	O
study	O
of	O
lometrexol	O
given	O
with	O
folic	O
acid	O
supplementation	O
which	O
has	O
confirmed	O
that	O
the	O
toxicity	B-Disease
of	O
lometrexol	O
can	O
be	O
markedly	O
reduced	O
by	O
folic	O
acid	O
supplementation	O
.	O

Thrombocytopenia	B-Disease
and	O
mucositis	B-Disease
were	O
the	O
major	O
toxicities	B-Disease
.	O

There	O
was	O
no	O
clear	O
relationship	O
between	O
clinical	O
toxicity	B-Disease
and	O
the	O
extent	O
of	O
plasma	O
folate	O
elevation	O
.	O

Associated	O
studies	O
demonstrated	O
that	O
lometrexol	O
plasma	O
pharmacokinetics	O
were	O
not	O
altered	O
by	O
folic	O
acid	O
administration	O
indicating	O
that	O
supplementation	O
is	O
unlikely	O
to	O
reduce	O
toxicity	B-Disease
by	O
enhancing	O
lometrexol	O
plasma	O
clearance	O
.	O

The	O
work	O
described	O
in	O
this	O
report	O
has	O
identified	O
for	O
the	O
first	O
time	O
a	O
clinically	O
acceptable	O
schedule	O
for	O
the	O
administration	O
of	O
a	O
GARFT	O
inhibitor	O
.	O

This	O
information	O
will	O
facilitate	O
the	O
future	O
evaluation	O
of	O
this	O
class	O
of	O
compounds	O
in	O
cancer	B-Disease
therapy	O
.	O

Fatal	O
excited	O
delirium	B-Disease
following	O
cocaine	O
use	O
:	O
epidemiologic	O
findings	O
provide	O
new	O
evidence	O
for	O
mechanisms	O
of	O
cocaine	O
toxicity	B-Disease
.	O

We	O
describe	O
an	O
outbreak	O
of	O
deaths	O
from	O
cocaine	O
-	O
induced	O
excited	O
delirium	B-Disease
(	O
EDDs	B-Disease
)	O
in	O
Dade	O
County	O
,	O
Florida	O
between	O
1979	O
and	O
1990	O
.	O

From	O
a	O
registry	O
of	O
all	O
cocaine	O
-	O
related	O
deaths	O
in	O
Dade	O
County	O
,	O
Florida	O
,	O
from	O
1969	O
-	O
1990	O
,	O
58	O
EDDs	B-Disease
were	O
compared	O
with	O
125	O
victims	O
of	O
accidental	O
cocaine	O
overdose	B-Disease
without	O
excited	O
delirium	B-Disease
.	O

Compared	O
with	O
controls	O
,	O
EDDs	B-Disease
were	O
more	O
frequently	O
black	O
,	O
male	O
,	O
and	O
younger	O
.	O

They	O
were	O
less	O
likely	O
to	O
have	O
a	O
low	O
body	O
mass	O
index	O
,	O
and	O
more	O
likely	O
to	O
have	O
died	O
in	O
police	O
custody	O
,	O
to	O
have	O
received	O
medical	O
treatment	O
immediately	O
before	O
death	O
,	O
to	O
have	O
survived	O
for	O
a	O
longer	O
period	O
,	O
to	O
have	O
developed	O
hyperthermia	B-Disease
,	O
and	O
to	O
have	O
died	O
in	O
summer	O
months	O
.	O

EDDs	B-Disease
had	O
concentrations	O
of	O
cocaine	O
and	O
benzoylecgonine	O
in	O
autopsy	O
blood	O
that	O
were	O
similar	O
to	O
those	O
for	O
controls	O
.	O

The	O
epidemiologic	O
findings	O
are	O
most	O
consistent	O
with	O
the	O
hypothesis	O
that	O
chronic	O
cocaine	O
use	O
disrupts	O
dopaminergic	O
function	O
and	O
,	O
when	O
coupled	O
with	O
recent	O
cocaine	O
use	O
,	O
may	O
precipitate	O
agitation	B-Disease
,	O
delirium	B-Disease
,	O
aberrant	O
thermoregulation	O
,	O
rhabdomyolysis	B-Disease
,	O
and	O
sudden	B-Disease
death	I-Disease
.	O

Pemoline	O
induced	O
acute	O
choreoathetosis	B-Disease
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

BACKGROUND	O
:	O
Pemoline	O
is	O
an	O
oxazolidine	O
derivative	O
that	O
is	O
structurally	O
different	O
from	O
amphetamines	O
and	O
used	O
in	O
the	O
treatment	O
of	O
attention	B-Disease
deficit	I-Disease
disorder	I-Disease
.	O

Pemoline	O
has	O
not	O
been	O
commonly	O
associated	O
in	O
the	O
literature	O
as	O
a	O
cause	O
of	O
acute	O
movement	B-Disease
disorders	I-Disease
.	O

The	O
following	O
case	O
describes	O
two	O
children	O
acutely	O
poisoned	O
with	O
pemoline	O
who	O
experienced	O
profound	O
choreoathetosis	B-Disease
.	O

CASE	O
REPORT	O
:	O
Two	O
,	O
3	O
-	O
year	O
-	O
old	O
male	O
,	O
identical	O
twin	O
siblings	O
presented	O
to	O
the	O
emergency	O
department	O
after	O
found	O
playing	O
with	O
a	O
an	O
empty	O
bottle	O
of	O
pemoline	O
originally	O
containing	O
59	O
tablets	O
.	O

The	O
children	O
had	O
a	O
medical	O
history	O
significant	O
for	O
attention	B-Disease
deficit	I-Disease
disorder	I-Disease
previously	O
treated	O
with	O
methylphenidate	O
without	O
success	O
.	O

This	O
was	O
their	O
first	O
day	O
of	O
pemoline	O
therapy	O
.	O

The	O
choreoathetoid	B-Disease
movements	O
began	O
45	O
min	O
to	O
1	O
h	O
after	O
ingestion	O
.	O

The	O
children	O
gave	O
no	O
history	O
of	O
prior	O
movement	B-Disease
disorders	I-Disease
and	O
there	O
was	O
no	O
family	O
history	O
of	O
movement	B-Disease
disorders	I-Disease
.	O

The	O
children	O
received	O
gastrointestinal	O
decontamination	O
and	O
high	O
doses	O
of	O
intravenous	O
benzodiazepines	O
in	O
an	O
attempt	O
to	O
control	O
the	O
choreoathetoid	B-Disease
movements	O
.	O

Despite	O
treatment	O
,	O
the	O
children	O
continued	O
to	O
have	O
choreoathetosis	B-Disease
for	O
approximately	O
24	O
hours	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
admission	O
,	O
the	O
children	O
appeared	O
to	O
be	O
at	O
their	O
baseline	O
and	O
were	O
discharged	O
home	O
.	O

CONCLUSION	O
:	O
Pemoline	O
associated	O
movement	B-Disease
disorder	I-Disease
has	O
been	O
rarely	O
reported	O
in	O
the	O
acute	O
toxicology	O
literature	O
.	O

The	O
possibility	O
of	O
choreoathetoid	B-Disease
movements	O
should	O
be	O
considered	O
in	O
patients	O
presenting	O
after	O
pemoline	O
overdose	B-Disease
.	O

Effect	O
of	O
myopic	O
excimer	O
laser	O
photorefractive	O
keratectomy	O
on	O
the	O
electrophysiologic	O
function	O
of	O
the	O
retina	O
and	O
optic	O
nerve	O
.	O

PURPOSE	O
:	O
To	O
assess	O
by	O
electrophysiologic	O
testing	O
the	O
effect	O
of	O
photorefractive	O
keratectomy	O
(	O
PRK	O
)	O
on	O
the	O
retina	O
and	O
optic	O
nerve	O
.	O

SETTING	O
:	O
Eye	O
Clinic	O
,	O
S	O
.	O

Salvatore	O
Hospital	O
,	O
L	O
'	O
Aquila	O
University	O
,	O
Italy	O
.	O

METHODS	O
:	O
Standard	O
pattern	O
electroretinograms	O
(	O
P	O
-	O
ERGs	O
)	O
and	O
standard	O
pattern	O
visual	O
evoked	O
potentials	O
(	O
P	O
-	O
VEPs	O
)	O
were	O
done	O
in	O
25	O
eyes	O
of	O
25	O
patients	O
who	O
had	O
myopic	O
PRK	O
for	O
an	O
attempted	O
correction	O
between	O
5	O
.	O
00	O
and	O
15	O
.	O
00	O
diopters	O
(	O
D	O
)	O
(	O
mean	O
8	O
.	O
00	O
D	O
)	O
.	O

Testing	O
was	O
done	O
preoperatively	O
and	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
months	O
postoperatively	O
.	O

The	O
contralateral	O
eyes	O
served	O
as	O
controls	O
.	O

During	O
the	O
follow	O
-	O
up	O
,	O
3	O
patients	O
(	O
12	O
%	O
)	O
developed	O
steroid	O
-	O
induced	O
elevated	B-Disease
intraocular	I-Disease
pressure	I-Disease
(	O
IOP	O
)	O
that	O
resolved	O
after	O
corticosteroid	O
therapy	O
was	O
discontinued	O
.	O

RESULTS	O
:	O
No	O
statistically	O
significant	O
differences	O
were	O
seen	O
between	O
treated	O
and	O
control	O
eyes	O
nor	O
between	O
treated	O
eyes	O
preoperatively	O
and	O
postoperatively	O
.	O

CONCLUSION	O
:	O
Myopic	O
excimer	O
laser	O
PRK	O
did	O
not	O
seem	O
to	O
affect	O
the	O
posterior	O
segment	O
.	O

The	O
transient	O
steroid	O
-	O
induced	O
IOP	B-Disease
rise	I-Disease
did	O
not	O
seem	O
to	O
cause	O
functional	O
impairment	O
.	O

Neutrophil	O
superoxide	O
and	O
hydrogen	O
peroxide	O
production	O
in	O
patients	O
with	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
.	O

Defects	O
in	O
superoxide	O
and	O
hydrogen	O
peroxide	O
production	O
may	O
be	O
implicated	O
in	O
the	O
high	O
incidence	O
of	O
bacterial	B-Disease
infections	I-Disease
in	O
patients	O
with	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
(	O
ALF	B-Disease
)	O
.	O

In	O
the	O
present	O
study	O
,	O
oxygen	O
radical	O
production	O
in	O
patients	O
with	O
ALF	B-Disease
due	O
to	O
paracetamol	O
overdose	B-Disease
was	O
compared	O
with	O
that	O
of	O
healthy	O
volunteers	O
.	O

Neutrophils	O
from	O
14	O
ALF	B-Disease
patients	O
were	O
stimulated	O
via	O
the	O
complement	O
receptors	O
using	O
zymosan	O
opsonized	O
with	O
ALF	B-Disease
or	O
control	O
serum	O
.	O

Superoxide	O
and	O
hydrogen	O
peroxide	O
production	O
by	O
ALF	B-Disease
neutrophils	O
stimulated	O
with	O
zymosan	O
opsonized	O
with	O
ALF	B-Disease
serum	O
was	O
significantly	O
reduced	O
compared	O
with	O
the	O
control	O
subjects	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

This	O
defect	O
persisted	O
when	O
zymosan	O
opsonized	O
by	O
control	O
serum	O
was	O
used	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Superoxide	O
and	O
hydrogen	O
peroxide	O
production	O
in	O
neutrophils	O
stimulated	O
with	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
(	O
fMLP	O
)	O
from	O
a	O
further	O
18	O
ALF	B-Disease
patients	O
was	O
unaffected	O
compared	O
with	O
control	O
neutrophils	O
.	O

Serum	O
C3	O
complement	O
levels	O
were	O
significantly	O
reduced	O
in	O
ALF	B-Disease
patients	O
compared	O
with	O
control	O
subjects	O
(	O
P	O
<	O
0	O
.	O
0005	O
)	O
.	O

These	O
results	O
demonstrate	O
a	O
neutrophil	O
defect	O
in	O
ALF	B-Disease
due	O
to	O
paracetamol	O
overdose	B-Disease
,	O
that	O
is	O
complement	O
dependent	O
but	O
independent	O
of	O
serum	O
complement	O
,	O
possibly	O
connected	O
to	O
the	O
complement	O
receptor	O
.	O

Cholesteryl	O
hemisuccinate	O
treatment	O
protects	O
rodents	O
from	O
the	O
toxic	O
effects	O
of	O
acetaminophen	O
,	O
adriamycin	O
,	O
carbon	O
tetrachloride	O
,	O
chloroform	O
and	O
galactosamine	O
.	O

In	O
addition	O
to	O
its	O
use	O
as	O
a	O
stabilizer	O
/	O
rigidifier	O
of	O
membranes	O
,	O
cholesteryl	O
hemisuccinate	O
,	O
tris	O
salt	O
(	O
CS	O
)	O
administration	O
has	O
also	O
been	O
shown	O
to	O
protect	O
rats	O
from	O
the	O
hepatotoxic	B-Disease
effects	O
of	O
carbon	O
tetrachloride	O
(	O
CCl4	O
)	O
.	O

To	O
further	O
our	O
understanding	O
of	O
the	O
mechanism	O
of	O
CS	O
cytoprotection	O
,	O
we	O
examined	O
in	O
rats	O
and	O
mice	O
the	O
protective	O
abilities	O
of	O
CS	O
and	O
the	O
non	O
-	O
hydrolyzable	O
ether	O
form	O
of	O
CS	O
,	O
gamma	O
-	O
cholesteryloxybutyric	O
acid	O
,	O
tris	O
salt	O
(	O
CSE	O
)	O
against	O
acetaminophen	O
-	O
,	O
adriamycin	O
-	O
,	O
carbon	O
tetrachloride	O
-	O
,	O
chloroform	O
-	O
and	O
galactosamine	O
-	O
induced	O
toxicity	B-Disease
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrated	O
that	O
CS	O
-	O
mediated	O
protection	O
is	O
not	O
selective	O
for	O
a	O
particular	O
species	O
,	O
organ	O
system	O
or	O
toxic	O
chemical	O
.	O

A	O
24	O
-	O
h	O
pretreatment	O
of	O
both	O
rats	O
and	O
mice	O
with	O
a	O
single	O
dose	O
of	O
CS	O
(	O
100mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
resulted	O
in	O
significant	O
protection	O
against	O
the	O
hepatotoxic	B-Disease
effects	O
of	O
CCl4	O
,	O
CHCl3	O
,	O
acetaminophen	O
and	O
galactosamine	O
and	O
against	O
the	O
lethal	O
(	O
and	O
presumably	O
cardiotoxic	B-Disease
)	O
effect	O
of	O
adriamycin	O
administration	O
.	O

Maximal	O
CS	O
-	O
mediated	O
protection	O
was	O
observed	O
in	O
experimental	O
animals	O
pretreated	O
24	O
h	O
prior	O
to	O
the	O
toxic	O
insult	O
.	O

These	O
data	O
suggest	O
that	O
CS	O
intervenes	O
in	O
a	O
critical	O
cellular	O
event	O
that	O
is	O
an	O
important	O
common	O
pathway	O
to	O
toxic	O
cell	O
death	O
.	O

The	O
mechanism	O
of	O
CS	O
protection	O
does	O
not	O
appear	O
to	O
be	O
dependent	O
on	O
the	O
inhibition	O
of	O
chemical	O
bioactivation	O
to	O
a	O
toxic	O
reactive	O
intermediate	O
(	O
in	O
light	O
of	O
the	O
protection	O
observed	O
against	O
galactosamine	O
hepatotoxicity	B-Disease
)	O
.	O

However	O
,	O
based	O
on	O
the	O
data	O
presented	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
CS	O
administration	O
inhibits	O
chemical	O
bioactivation	O
.	O

Our	O
findings	O
do	O
suggest	O
that	O
CS	O
-	O
mediated	O
protection	O
is	O
dependent	O
on	O
the	O
action	O
of	O
the	O
intact	O
anionic	O
CS	O
molecule	O
(	O
non	O
-	O
hydrolyzable	O
CSE	O
was	O
as	O
protective	O
as	O
CS	O
)	O
,	O
whose	O
mechanism	O
has	O
yet	O
to	O
be	O
defined	O
.	O

A	O
murine	O
model	O
of	O
adenomyosis	B-Disease
:	O
the	O
effects	O
of	O
hyperprolactinemia	B-Disease
induced	O
by	O
fluoxetine	O
hydrochloride	O
,	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
,	O
on	O
adenomyosis	B-Disease
induction	O
in	O
Wistar	O
albino	O
rats	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
fluoxetine	O
given	O
to	O
castrated	O
and	O
noncastrated	O
rats	O
caused	O
hyperprolactinemia	B-Disease
and	O
its	O
effects	O
with	O
respect	O
to	O
adenomyosis	B-Disease
.	O

DESIGN	O
:	O
Fluoxetine	O
,	O
a	O
serotonin	O
reuptake	O
inhibitor	O
,	O
was	O
given	O
to	O
Wistar	O
Albino	O
rats	O
for	O
98	O
days	O
to	O
produce	O
hyperprolactinemia	B-Disease
.	O

The	O
drug	O
was	O
given	O
to	O
two	O
groups	O
consisting	O
of	O
castrated	O
and	O
noncastrated	O
rats	O
and	O
compared	O
to	O
two	O
groups	O
of	O
castrated	O
and	O
noncastrated	O
controls	O
.	O

Prolactin	O
levels	O
were	O
measured	O
and	O
the	O
uteri	O
of	O
the	O
rats	O
were	O
removed	O
for	O
histopathological	O
analysis	O
at	O
the	O
end	O
of	O
98	O
days	O
.	O

SETTING	O
:	O
Marmara	O
University	O
School	O
of	O
Medicine	O
,	O
Department	O
of	O
Histology	O
and	O
Embryology	O
,	O
Zeynep	O
Kamil	O
Women	O
and	O
Children	O
'	O
s	O
Hospital	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Serum	O
prolactin	O
levels	O
,	O
uterine	O
histopathology	O
.	O

RESULTS	O
:	O
The	O
prolactin	O
levels	O
of	O
castrated	O
and	O
noncastrated	O
groups	O
treated	O
with	O
fluoxetine	O
were	O
statistically	O
significantly	O
higher	O
when	O
compared	O
to	O
their	O
respective	O
control	O
groups	O
.	O

Histological	O
studies	O
revealed	O
11	O
cases	O
of	O
adenomyosis	B-Disease
,	O
all	O
within	O
the	O
noncastrated	O
group	O
receiving	O
fluoxetine	O
.	O

CONCLUSION	O
:	O
It	O
was	O
suggested	O
that	O
high	O
serum	O
prolactin	O
levels	O
cause	O
degeneration	O
of	O
myometrial	O
cells	O
in	O
the	O
presence	O
of	O
ovarian	O
steroids	O
that	O
results	O
in	O
a	O
myometrial	O
invasion	O
by	O
endometrial	O
stroma	O
.	O

This	O
invasion	O
eventually	O
progresses	O
to	O
adenomyosis	B-Disease
.	O

Postinfarction	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
associated	O
with	O
long	O
-	O
term	O
steroid	O
therapy	O
.	O

Two	O
cases	O
of	O
postinfarction	O
ventricular	B-Disease
septal	I-Disease
rupture	I-Disease
in	O
patients	O
on	O
long	O
-	O
term	O
steroid	O
therapy	O
are	O
presented	O
and	O
the	O
favourable	O
outcome	O
in	O
both	O
cases	O
described	O
.	O

A	O
possible	O
association	O
between	O
steroid	O
therapy	O
and	O
subsequent	O
postinfarction	O
septal	B-Disease
rupture	I-Disease
is	O
discussed	O
.	O

Neuroactive	O
steroids	O
protect	O
against	O
pilocarpine	O
-	O
and	O
kainic	O
acid	O
-	O
induced	O
limbic	O
seizures	B-Disease
and	O
status	B-Disease
epilepticus	I-Disease
in	O
mice	O
.	O

Several	O
structurally	O
related	O
metabolites	O
of	O
progesterone	O
(	O
3	O
alpha	O
-	O
hydroxy	O
pregnane	O
-	O
20	O
-	O
ones	O
)	O
and	O
deoxycorticosterone	O
(	O
3	O
alpha	O
-	O
hydroxy	O
pregnane	O
-	O
21	O
-	O
diol	O
-	O
20	O
-	O
ones	O
)	O
and	O
their	O
3	O
beta	O
-	O
epimers	O
were	O
evaluated	O
for	O
protective	O
activity	O
against	O
pilocarpine	O
-	O
,	O
kainic	O
acid	O
-	O
and	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
-	O
induced	O
seizures	B-Disease
in	O
mice	O
.	O

Steroids	O
with	O
the	O
3	O
-	O
hydroxy	O
group	O
in	O
the	O
alpha	O
-	O
position	O
and	O
5	O
-	O
H	O
in	O
the	O
alpha	O
-	O
or	O
beta	O
-	O
configurations	O
were	O
highly	O
effective	O
in	O
protecting	O
against	O
pilocarpine	O
(	O
416	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
-	O
induced	O
limbic	O
motor	O
seizures	B-Disease
and	O
status	B-Disease
epilepticus	I-Disease
(	O
ED50	O
values	O
,	O
7	O
.	O
0	O
-	O
18	O
.	O
7	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

The	O
corresponding	O
epimers	O
with	O
the	O
3	O
-	O
hydroxy	O
group	O
in	O
the	O
beta	O
-	O
position	O
were	O
also	O
effective	O
but	O
less	O
potent	O
(	O
ED50	O
values	O
,	O
33	O
.	O
8	O
-	O
63	O
.	O
5	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

Although	O
the	O
neuroactive	O
steroids	O
were	O
considerably	O
less	O
potent	O
than	O
the	O
benzodiazepine	O
clonazepam	O
in	O
protecting	O
against	O
pilocarpine	O
seizures	B-Disease
,	O
steroids	O
with	O
the	O
5	O
alpha	O
,	O
3	O
alpha	O
-	O
configuration	O
had	O
comparable	O
or	O
higher	O
protective	O
index	O
values	O
(	O
TD50	O
for	O
motor	O
impairment	O
divided	O
by	O
ED50	O
for	O
seizure	B-Disease
protection	O
)	O
than	O
clonazepam	O
,	O
indicating	O
that	O
some	O
neuroactive	O
steroids	O
may	O
have	O
lower	O
relative	O
toxicity	B-Disease
.	O

Steroids	O
with	O
the	O
5	O
alpha	O
,	O
3	O
alpha	O
-	O
or	O
5	O
beta	O
,	O
3	O
alpha	O
-	O
configurations	O
also	O
produced	O
a	O
dose	O
-	O
dependent	O
delay	O
in	O
the	O
onset	O
of	O
limbic	O
seizures	B-Disease
induced	O
by	O
kainic	O
acid	O
(	O
32	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
,	O
but	O
did	O
not	O
completely	O
protect	O
against	O
the	O
seizures	B-Disease
.	O

However	O
,	O
when	O
a	O
second	O
dose	O
of	O
the	O
steroid	O
was	O
administered	O
1	O
hr	O
after	O
the	O
first	O
dose	O
,	O
complete	O
protection	O
from	O
the	O
kainic	O
acid	O
-	O
induced	O
limbic	O
seizures	B-Disease
and	O
status	B-Disease
epilepticus	I-Disease
was	O
obtained	O
.	O

The	O
steroids	O
also	O
caused	O
a	O
dose	O
-	O
dependent	O
delay	O
in	O
NMDA	O
(	O
257	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
-	O
induced	O
lethality	O
,	O
but	O
did	O
not	O
completely	O
protect	O
against	O
NMDA	O
seizures	B-Disease
or	O
lethality	O
.	O

We	O
conclude	O
that	O
neuroactive	O
steroids	O
are	O
highly	O
effective	O
in	O
protecting	O
against	O
pilocarpine	O
-	O
and	O
kainic	O
acid	O
-	O
induced	O
seizures	B-Disease
and	O
status	B-Disease
epilepticus	I-Disease
in	O
mice	O
,	O
and	O
may	O
be	O
of	O
utility	O
in	O
the	O
treatment	O
of	O
some	O
forms	O
of	O
status	B-Disease
epilepticus	I-Disease
in	O
humans	O
.	O

Hepatic	O
and	O
extrahepatic	O
angiotensinogen	O
gene	O
expression	O
in	O
rats	O
with	O
acute	O
nephrotic	B-Disease
syndrome	I-Disease
.	O

Plasma	O
concentration	O
and	O
urine	O
excretion	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
proteins	O
are	O
altered	O
in	O
rats	O
with	O
nephrotic	B-Disease
syndrome	I-Disease
(	O
NS	B-Disease
)	O
.	O

In	O
this	O
work	O
the	O
messenger	O
ribonucleic	O
acid	O
(	O
mRNA	O
)	O
levels	O
of	O
angiotensinogen	O
(	O
Ao	O
)	O
were	O
analyzed	O
with	O
the	O
slot	O
-	O
blot	O
hybridization	O
technique	O
in	O
liver	O
and	O
other	O
extrahepatic	O
tissues	O
:	O
kidney	O
,	O
heart	O
,	O
brain	O
,	O
and	O
adrenal	O
gland	O
from	O
control	O
,	O
nephrotic	B-Disease
,	O
and	O
pair	O
-	O
fed	O
(	O
PF	O
)	O
rats	O
.	O

NS	B-Disease
was	O
induced	O
by	O
a	O
single	O
injection	O
of	O
puromycin	O
amino	O
-	O
nucleoside	O
(	O
PAN	O
)	O
.	O

Although	O
a	O
great	O
urinary	O
excretion	O
and	O
half	O
-	O
normal	O
plasma	O
levels	O
of	O
Ao	O
were	O
observed	O
on	O
day	O
6	O
after	O
PAN	O
injection	O
,	O
when	O
NS	B-Disease
was	O
clearly	O
established	O
,	O
hepatic	O
Ao	O
mRNA	O
levels	O
did	O
not	O
change	O
.	O

Furthermore	O
,	O
the	O
Ao	O
mRNA	O
levels	O
did	O
not	O
change	O
in	O
any	O
of	O
the	O
extrahepatic	O
tissues	O
studied	O
on	O
day	O
6	O
,	O
nor	O
did	O
its	O
hepatic	O
levels	O
at	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
or	O
7	O
after	O
PAN	O
injection	O
.	O

These	O
data	O
suggest	O
that	O
the	O
hepatic	O
and	O
extrahepatic	O
Ao	O
mRNA	O
levels	O
are	O
unaltered	O
during	O
the	O
development	O
of	O
the	O
acute	O
NS	B-Disease
induced	O
by	O
PAN	O
.	O

Neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
with	O
risperidone	O
.	O

Neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
is	O
thought	O
to	O
be	O
a	O
result	O
of	O
dopamine	O
D2	O
receptor	O
blockade	O
in	O
the	O
striatum	O
of	O
the	O
basal	O
ganglia	O
.	O

Risperidone	O
,	O
a	O
benzisoxazole	O
derivative	O
antipsychotic	O
,	O
has	O
high	O
serotonin	O
5	O
-	O
HT2	O
receptor	O
blockade	O
and	O
dose	O
-	O
related	O
D2	O
receptor	O
blockade	O
.	O

The	O
high	O
ratio	O
is	O
believed	O
to	O
impart	O
the	O
low	O
frequency	O
of	O
extrapyramidal	B-Disease
symptoms	I-Disease
with	O
risperidone	O
at	O
low	O
dosages	O
.	O

With	O
this	O
low	O
frequency	O
of	O
extrapyramidal	B-Disease
symptoms	I-Disease
,	O
it	O
was	O
thought	O
the	O
frequency	O
of	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
might	O
also	O
be	O
lowered	O
.	O

A	O
73	O
-	O
year	O
-	O
old	O
woman	O
developed	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
after	O
monotherapy	O
with	O
risperidone	O
.	O

The	O
syndrome	O
reversed	O
after	O
discontinuing	O
risperidone	O
and	O
starting	O
treatment	O
with	O
dantrolene	O
and	O
bromocriptine	O
.	O

It	O
appears	O
that	O
the	O
protection	O
from	O
extrapyramidal	O
side	O
effects	O
observed	O
with	O
risperidone	O
does	O
not	O
ensure	O
protection	O
from	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
.	O

The	O
attenuating	O
effect	O
of	O
carteolol	O
hydrochloride	O
,	O
a	O
beta	O
-	O
adrenoceptor	O
antagonist	O
,	O
on	O
neuroleptic	O
-	O
induced	O
catalepsy	B-Disease
in	O
rats	O
.	O

It	O
is	O
known	O
that	O
beta	O
-	O
adrenoceptor	O
antagonists	O
are	O
effective	O
in	O
the	O
treatment	O
of	O
akathisia	B-Disease
,	O
one	O
of	O
the	O
extrapyramidal	O
side	O
effects	O
that	O
occur	O
during	O
neuroleptic	O
treatment	O
.	O

Neuroleptic	O
-	O
induced	O
catalepsy	B-Disease
,	O
a	O
model	O
of	O
neuroleptic	O
-	O
induced	O
extrapyramidal	O
side	O
effects	O
,	O
was	O
considered	O
suitable	O
as	O
a	O
model	O
for	O
predicting	O
neuroleptic	O
-	O
induced	O
akathisia	B-Disease
in	O
humans	O
,	O
although	O
neuroleptic	O
-	O
induced	O
catalepsy	B-Disease
was	O
not	O
considered	O
a	O
specific	O
test	O
for	O
neuroleptic	O
-	O
induced	O
akathisia	B-Disease
.	O

Therefore	O
,	O
the	O
effects	O
of	O
carteolol	O
,	O
a	O
beta	O
-	O
adrenoceptor	O
antagonist	O
,	O
on	O
haloperidol	O
-	O
induced	O
catalepsy	B-Disease
in	O
rats	O
were	O
behaviorally	O
studied	O
and	O
compared	O
with	O
those	O
of	O
propranolol	O
and	O
biperiden	O
,	O
a	O
muscarinic	O
receptor	O
antagonist	O
.	O

Carteolol	O
,	O
as	O
well	O
as	O
propranolol	O
and	O
biperiden	O
,	O
inhibited	O
the	O
haloperidol	O
-	O
induced	O
catalepsy	B-Disease
.	O

The	O
inhibitory	O
effect	O
of	O
carteolol	O
was	O
almost	O
comparable	O
to	O
that	O
of	O
propranolol	O
,	O
but	O
was	O
weaker	O
than	O
that	O
of	O
biperiden	O
.	O

Carteolol	O
did	O
not	O
evoke	O
postsynaptic	O
dopamine	O
receptor	O
-	O
stimulating	O
behavioral	O
signs	O
such	O
as	O
stereotypy	O
and	O
hyperlocomotion	B-Disease
in	O
rats	O
.	O

Carteolol	O
did	O
not	O
antagonize	O
the	O
inhibitory	O
effects	O
of	O
haloperidol	O
on	O
apomorphine	O
-	O
induced	O
stereotypy	O
and	O
locomotor	O
activity	O
in	O
rats	O
.	O

In	O
addition	O
,	O
carteolol	O
did	O
not	O
evoke	O
5	O
-	O
HT1A	O
receptor	O
-	O
stimulating	O
behavioral	O
signs	O
such	O
as	O
flat	O
body	O
posture	O
and	O
forepaw	O
treading	O
and	O
did	O
not	O
inhibit	O
5	O
-	O
hydroxytryptophan	O
-	O
induced	O
head	O
twitch	O
in	O
rats	O
.	O

Finally	O
,	O
carteolol	O
did	O
not	O
inhibit	O
physostigmine	O
-	O
induced	O
lethality	O
in	O
rats	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
carteolol	O
improves	O
haloperidol	O
-	O
induced	O
catalepsy	B-Disease
via	O
its	O
beta	O
-	O
adrenoceptor	O
antagonistic	O
activity	O
and	O
is	O
expected	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
akathisia	B-Disease
without	O
attenuating	O
neuroleptic	O
-	O
induced	O
antipsychotic	O
effects	O
due	O
to	O
its	O
postsynaptic	O
dopamine	O
receptor	O
antagonistic	O
activity	O
.	O

Granulosa	B-Disease
cell	I-Disease
tumor	I-Disease
of	I-Disease
the	I-Disease
ovary	I-Disease
associated	O
with	O
antecedent	O
tamoxifen	O
use	O
.	O

BACKGROUND	O
:	O
Increased	O
attention	O
has	O
been	O
focused	O
recently	O
on	O
the	O
estrogenic	O
effects	O
of	O
tamoxifen	O
.	O

Review	O
of	O
the	O
literature	O
reveals	O
an	O
association	O
between	O
tamoxifen	O
use	O
and	O
gynecologic	O
tumors	B-Disease
.	O

CASE	O
:	O
A	O
52	O
-	O
year	O
-	O
old	O
postmenopausal	O
woman	O
was	O
treated	O
with	O
tamoxifen	O
for	O
stage	O
II	O
estrogen	O
receptor	O
-	O
positive	O
breast	B-Disease
carcinoma	I-Disease
.	O

Her	O
aspartate	O
transaminase	O
and	O
alanine	O
transaminase	O
levels	O
increase	O
markedly	O
after	O
6	O
months	O
of	O
tamoxifen	O
use	O
.	O

After	O
an	O
additional	O
17	O
months	O
of	O
elevated	O
serum	O
transaminases	O
,	O
the	O
patient	O
was	O
found	O
to	O
have	O
a	O
stage	O
Ic	O
granulosa	B-Disease
cell	I-Disease
tumor	I-Disease
of	I-Disease
the	I-Disease
ovary	I-Disease
.	O

CONCLUSION	O
:	O
Patients	O
with	O
tamoxifen	O
-	O
induced	O
liver	B-Disease
dysfunction	I-Disease
may	O
be	O
at	O
increased	O
risk	O
for	O
granulosa	B-Disease
cell	I-Disease
tumors	I-Disease
because	O
of	O
alterations	O
in	O
tamoxifen	O
metabolism	O
.	O

Lifetime	O
treatment	O
of	O
mice	O
with	O
azidothymidine	O
(	O
AZT	O
)	O
produces	O
myelodysplasia	B-Disease
.	O

AZT	O
has	O
induced	O
a	O
macrocytic	B-Disease
anemia	I-Disease
in	O
AIDS	B-Disease
patients	O
on	O
long	O
term	O
AZT	O
therapy	O
.	O

It	O
is	O
generally	O
assumed	O
that	O
DNA	O
elongation	O
is	O
stopped	O
by	O
the	O
insertion	O
of	O
AZT	O
into	O
the	O
chain	O
in	O
place	O
of	O
thymidine	O
thus	O
preventing	O
the	O
phosphate	O
hydroxyl	O
linkages	O
and	O
therefore	O
suppresses	O
hemopoietic	O
progenitor	O
cell	O
proliferation	O
in	O
an	O
early	O
stage	O
of	O
differentiation	O
.	O

CBA	O
/	O
Ca	O
male	O
mice	O
started	O
on	O
AZT	O
0	O
.	O
75	O
mg	O
/	O
ml	O
H2O	O
at	O
84	O
days	O
of	O
age	O
and	O
kept	O
on	O
it	O
for	O
687	O
days	O
when	O
dosage	O
reduced	O
to	O
0	O
.	O
5	O
mg	O
/	O
ml	O
H2O	O
for	O
a	O
group	O
,	O
another	O
group	O
removed	O
from	O
AZT	O
to	O
see	O
recovery	O
,	O
and	O
third	O
group	O
remained	O
on	O
0	O
.	O
75	O
mg	O
.	O

At	O
687	O
days	O
mice	O
that	O
had	O
been	O
on	O
0	O
.	O
75	O
mg	O
had	O
average	O
platelet	O
counts	O
of	O
2	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
.	O

Histological	O
examination	O
on	O
9	O
of	O
10	O
mice	O
with	O
such	O
thrombocytopenia	B-Disease
showed	O
changes	O
compatible	O
with	O
myelodysplastic	B-Disease
syndrome	I-Disease
(	O
MDS	B-Disease
)	O
.	O

A	O
variety	O
of	O
histological	O
patterns	O
was	O
observed	O
.	O

There	O
were	O
two	O
cases	O
of	O
hypocellular	O
myelodysplasia	B-Disease
,	O
two	O
cases	O
of	O
hypersegmented	O
myelodysplastic	B-Disease
granulocytosis	O
,	O
two	O
cases	O
of	O
hypercellular	O
marrow	O
with	O
abnormal	O
megakaryocytes	O
with	O
bizarre	O
nuclei	O
,	O
one	O
case	O
of	O
megakaryocytic	O
myelosis	O
associated	O
with	O
a	O
hyperplastic	B-Disease
marrow	I-Disease
,	O
dysmyelopoiesis	B-Disease
and	O
a	O
hypocellular	B-Disease
marrow	I-Disease
and	O
two	O
cases	O
of	O
myelodysplasia	B-Disease
with	O
dyserythropoiesis	B-Disease
,	O
hemosiderosis	B-Disease
and	O
a	O
hypocellular	B-Disease
marrow	I-Disease
.	O

Above	O
mentioned	O
AZT	O
incorporation	O
may	O
have	O
induced	O
an	O
ineffective	O
hemopoiesis	O
in	O
the	O
primitive	O
hemopoietic	O
progenitor	O
cells	O
,	O
which	O
is	O
known	O
to	O
be	O
seen	O
commonly	O
in	O
the	O
myelodysplastic	B-Disease
syndrome	I-Disease
.	O

Biphasic	O
response	O
of	O
the	O
SA	O
node	O
of	O
the	O
dog	O
heart	O
in	O
vivo	O
to	O
selective	O
administration	O
of	O
ketamine	O
.	O

Effect	O
of	O
ketamine	O
on	O
the	O
SA	O
node	O
of	O
the	O
dog	O
heart	O
was	O
studied	O
in	O
vivo	O
using	O
a	O
selective	O
perfusion	O
technique	O
of	O
the	O
SA	O
node	O
artery	O
.	O

Injections	O
of	O
ketamine	O
in	O
doses	O
from	O
100	O
microgram	O
to	O
3	O
mg	O
into	O
the	O
artery	O
produced	O
a	O
depression	B-Disease
of	O
the	O
SA	O
nodal	O
activity	O
by	O
a	O
direct	O
action	O
.	O

This	O
depression	B-Disease
was	O
followed	O
by	O
the	O
sudden	O
appearance	O
of	O
a	O
stimulatory	O
phase	O
.	O

Bilateral	O
vagotomy	O
and	O
sympathectomy	O
or	O
prior	O
administration	O
of	O
a	O
ganglion	O
blocker	O
failed	O
to	O
inhibit	O
the	O
occurrence	O
of	O
the	O
ketamine	O
-	O
induced	O
tachycardia	B-Disease
,	O
while	O
it	O
was	O
completely	O
abolished	O
in	O
the	O
reserpinized	O
dogs	O
or	O
by	O
a	O
prior	O
injection	O
of	O
a	O
beta	O
-	O
blocking	O
agent	O
into	O
the	O
SA	O
node	O
artery	O
.	O

This	O
may	O
indicate	O
that	O
an	O
activation	O
of	O
the	O
peripheral	O
adrenergic	O
mechanism	O
plays	O
an	O
important	O
role	O
in	O
the	O
induction	O
of	O
the	O
excitatory	O
effect	O
of	O
ketamine	O
injected	O
in	O
the	O
SA	O
node	O
artery	O
.	O

Over	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
its	O
receptor	O
during	O
the	O
development	O
of	O
estrogen	O
-	O
induced	O
rat	O
pituitary	B-Disease
tumors	I-Disease
may	O
mediate	O
estrogen	O
-	O
initiated	O
tumor	B-Disease
angiogenesis	O
.	O

Estrogens	O
,	O
which	O
have	O
been	O
associated	O
with	O
several	O
types	O
of	O
human	O
and	O
animal	O
cancers	B-Disease
,	O
can	O
induce	O
tumor	B-Disease
angiogenesis	O
in	O
the	O
pituitary	O
of	O
Fischer	O
344	O
rats	O
.	O

The	O
mechanistic	O
details	O
of	O
tumor	B-Disease
angiogenesis	O
induction	O
,	O
during	O
estrogen	O
carcinogenesis	B-Disease
,	O
are	O
still	O
unknown	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
estrogen	O
in	O
the	O
regulation	O
of	O
tumor	B-Disease
angiogenesis	O
in	O
the	O
pituitary	O
of	O
female	O
rats	O
,	O
the	O
density	O
of	O
blood	O
vessels	O
was	O
analysed	O
using	O
factor	O
VIII	O
related	O
antigen	O
(	O
FVIIIRAg	O
)	O
immunohistochemistry	O
and	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
/	O
vascular	O
permeability	O
factor	O
(	O
VEGF	O
/	O
VPF	O
)	O
was	O
examined	O
by	O
Western	O
blot	O
and	O
immunohistochemical	O
analysis	O
.	O

The	O
expression	O
of	O
VEGF	O
receptor	O
(	O
VEGFR	O
-	O
2	O
/	O
Flk	O
-	O
1	O
/	O
KDR	O
)	O
was	O
also	O
examined	O
by	O
immunohistochemistry	O
.	O

The	O
results	O
demonstrated	O
that	O
17beta	O
-	O
estradiol	O
(	O
E2	O
)	O
induces	O
neovascularization	O
,	O
as	O
well	O
as	O
the	O
growth	O
and	O
enlargement	O
of	O
blood	O
vessels	O
after	O
7	O
days	O
of	O
exposure	O
.	O

The	O
high	O
tumor	B-Disease
angiogenic	O
potential	O
was	O
associated	O
with	O
an	O
elevated	O
VEGF	O
/	O
VPF	O
protein	O
expression	O
in	O
the	O
E2	O
exposed	O
pituitary	O
of	O
ovariectomized	O
(	O
OVEX	O
)	O
rats	O
.	O

VEGF	O
/	O
VPF	O
and	O
FVIIIRAg	O
immunohistochemistry	O
and	O
endothelial	O
specific	O
lectin	O
(	O
UEA1	O
)	O
binding	O
studies	O
,	O
indicate	O
that	O
the	O
elevation	O
of	O
VEGF	O
protein	O
expression	O
initially	O
occurred	O
in	O
both	O
blood	O
vessels	O
and	O
non	O
-	O
endothelial	O
cells	O
.	O

After	O
15	O
days	O
of	O
E2	O
exposure	O
,	O
VEGF	O
/	O
VPF	O
protein	O
expression	O
,	O
in	O
the	O
non	O
-	O
endothelial	O
cell	O
population	O
,	O
sharply	O
declined	O
and	O
was	O
restricted	O
to	O
the	O
blood	O
vessels	O
.	O

The	O
function	O
of	O
non	O
-	O
endothelial	O
-	O
derived	O
VEGF	O
is	O
not	O
clear	O
.	O

Furthermore	O
,	O
immunohistochemical	O
studies	O
demonstrated	O
that	O
VEGFR	O
-	O
2	O
(	O
flk	O
-	O
1	O
/	O
KDR	O
)	O
,	O
expression	O
was	O
elevated	O
significantly	O
in	O
the	O
endothelial	O
cells	O
of	O
microblood	O
vessels	O
after	O
7	O
days	O
of	O
E2	O
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
over	O
expression	O
of	O
VEGF	O
and	O
its	O
receptor	O
(	O
VEGFR	O
-	O
2	O
)	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
initial	O
step	O
of	O
the	O
regulation	O
of	O
estrogen	O
induced	O
tumor	B-Disease
angiogenesis	O
in	O
the	O
rat	O
pituitary	O
.	O

Persistent	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
following	O
lithium	O
therapy	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
severe	O
hypernatraemic	O
dehydration	B-Disease
following	O
a	O
head	B-Disease
injury	I-Disease
.	O

Ten	O
years	O
previously	O
he	O
had	O
been	O
diagnosed	O
to	O
have	O
lithium	O
-	O
induced	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
,	O
and	O
lithium	O
therapy	O
had	O
been	O
discontinued	O
.	O

He	O
remained	O
thirsty	O
and	O
polyuric	B-Disease
despite	O
cessation	O
of	O
lithium	O
and	O
investigations	O
on	O
admission	O
showed	O
him	O
to	O
have	O
normal	O
osmoregulated	O
thirst	O
and	O
vasopressin	O
secretion	O
,	O
with	O
clear	O
evidence	O
of	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
.	O

Lithium	O
induced	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
is	O
considered	O
to	O
be	O
reversible	O
on	O
cessation	O
of	O
therapy	O
but	O
polyuria	B-Disease
persisted	O
in	O
this	O
patient	O
for	O
ten	O
years	O
after	O
lithium	O
was	O
stopped	O
.	O

We	O
discuss	O
the	O
possible	O
renal	O
mechanisms	O
and	O
the	O
implications	O
for	O
management	O
of	O
patients	O
with	O
lithium	O
-	O
induced	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
.	O

Effects	O
of	O
NIK	O
-	O
247	O
on	O
cholinesterase	O
and	O
scopolamine	O
-	O
induced	O
amnesia	B-Disease
.	O

The	O
effects	O
of	O
NIK	O
-	O
247	O
on	O
cholinesterase	O
,	O
scopolamine	O
-	O
induced	O
amnesia	B-Disease
and	O
spontaneous	O
movement	O
were	O
examined	O
and	O
compared	O
with	O
those	O
of	O
the	O
well	O
-	O
known	O
cholinesterase	O
inhibitors	O
tacrine	O
and	O
E	O
-	O
2020	O
.	O

NIK	O
-	O
247	O
,	O
tacrine	O
and	O
E	O
-	O
2020	O
all	O
strongly	O
inhibited	O
acetylcholinesterase	O
(	O
AChE	O
)	O
in	O
human	O
red	O
blood	O
cells	O
(	O
IC50s	O
=	O
1	O
.	O
0	O
x	O
10	O
(	O
-	O
6	O
)	O
,	O
2	O
.	O
9	O
x	O
10	O
(	O
-	O
7	O
)	O
and	O
3	O
.	O
7	O
x	O
10	O
(	O
-	O
8	O
)	O
M	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
NIK	O
-	O
247	O
and	O
tacrine	O
,	O
but	O
not	O
E	O
-	O
2020	O
,	O
strongly	O
inhibited	O
butyrylcholinestrase	O
(	O
BuChE	O
)	O
in	O
human	O
serum	O
.	O

All	O
three	O
drugs	O
produced	O
mixed	O
inhibition	O
of	O
AChE	O
activity	O
.	O

Moreover	O
,	O
the	O
inhibitory	O
effect	O
of	O
NIK	O
-	O
247	O
on	O
AChE	O
was	O
reversible	O
.	O

All	O
compounds	O
at	O
0	O
.	O
1	O
-	O
1	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
significantly	O
improved	O
the	O
amnesia	B-Disease
induced	O
by	O
scopolamine	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
in	O
rats	O
performing	O
a	O
passive	O
avoidance	O
task	O
.	O

The	O
three	O
compounds	O
at	O
1	O
and	O
3	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
did	O
not	O
significantly	O
decrease	O
spontaneous	O
movement	O
by	O
rats	O
.	O

These	O
findings	O
suggest	O
that	O
NIK	O
-	O
247	O
at	O
a	O
low	O
dose	O
(	O
0	O
.	O
1	O
-	O
1	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
improves	O
scopolamine	O
-	O
induced	O
amnesia	B-Disease
but	O
does	O
not	O
affect	O
spontaneous	O
movement	O
.	O

The	O
findings	O
suggest	O
that	O
NIK	O
-	O
247	O
may	O
be	O
a	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

Potential	O
therapeutic	O
use	O
of	O
the	O
selective	O
dopamine	O
D1	O
receptor	O
agonist	O
,	O
A	O
-	O
86929	O
:	O
an	O
acute	O
study	O
in	O
parkinsonian	B-Disease
levodopa	O
-	O
primed	O
monkeys	O
.	O

The	O
clinical	O
utility	O
of	O
dopamine	O
(	O
DA	O
)	O
D1	O
receptor	O
agonists	O
in	O
the	O
treatment	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
is	O
still	O
unclear	O
.	O

The	O
therapeutic	O
use	O
of	O
selective	O
DA	O
D1	O
receptor	O
agonists	O
such	O
as	O
SKF	O
-	O
82958	O
(	O
6	O
-	O
chloro	O
-	O
7	O
,	O
8	O
-	O
dihydroxy	O
-	O
3	O
-	O
allyl	O
-	O
1	O
-	O
phenyl	O
-	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
tetrahydro	O
-	O
1H	O
-	O
3	O
-	O
benzaze	O
pine	O
hydrobromide	O
)	O
and	O
A	O
-	O
77636	O
(	O
[	O
1R	O
,	O
3S	O
]	O
3	O
-	O
[	O
1	O
'	O
-	O
admantyl	O
]	O
-	O
1	O
-	O
aminomethyl	O
-	O
3	O
,	O
4	O
-	O
dihydro	O
-	O
5	O
,	O
6	O
-	O
dihydroxy	O
-	O
1H	O
-	O
2	O
-	O
benzo	O
pyran	O
hydrochloride	O
)	O
seems	O
limited	O
because	O
of	O
their	O
duration	O
of	O
action	O
,	O
which	O
is	O
too	O
short	O
for	O
SKF	O
-	O
82958	O
(	O
<	O
1	O
hr	O
)	O
and	O
too	O
long	O
for	O
A	O
-	O
77636	O
(	O
>	O
20	O
hr	O
,	O
leading	O
to	O
behavioral	O
tolerance	O
)	O
.	O

We	O
therefore	O
conducted	O
the	O
present	O
acute	O
dose	O
-	O
response	O
study	O
in	O
four	O
1	O
-	O
methyl	O
-	O
4	O
-	O
phenyl	O
-	O
1	O
,	O
2	O
,	O
3	O
,	O
6	O
-	O
tetrahydropyridine	O
(	O
MPTP	O
)	O
-	O
exposed	O
cynomolgus	O
monkeys	O
primed	O
to	O
exhibit	O
levodopa	O
-	O
induced	O
dyskinesias	B-Disease
to	O
evaluate	O
the	O
locomotor	O
and	O
dyskinetic	B-Disease
effects	O
on	O
challenge	O
with	O
four	O
doses	O
(	O
from	O
0	O
.	O
03	O
to	O
1	O
.	O
0	O
mg	O
/	O
kg	O
)	O
of	O
A	O
-	O
86929	O
(	O
[	O
-	O
]	O
-	O
[	O
5aR	O
,	O
11bS	O
]	O
-	O
4	O
,	O
5	O
,	O
5a	O
,	O
6	O
,	O
7	O
,	O
11b	O
-	O
hexahydro	O
-	O
2	O
-	O
propyl	O
-	O
3	O
-	O
thia	O
-	O
5	O
-	O
+	O
+	O
+	O
azacyclopent	O
-	O
1	O
-	O
ena	O
[	O
c	O
]	O
phenathrene	O
-	O
9	O
-	O
10	O
-	O
diol	O
)	O
,	O
a	O
selective	O
and	O
full	O
DA	O
D1	O
-	O
like	O
receptor	O
agonist	O
with	O
an	O
intermediate	O
duration	O
of	O
action	O
.	O

Levodopa	O
and	O
the	O
DA	O
D2	O
-	O
like	O
receptor	O
agonist	O
,	O
LY	O
-	O
171555	O
(	O
[	O
4aR	O
-	O
trans	O
]	O
-	O
4	O
,	O
4a	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
8a	O
,	O
9	O
-	O
o	O
-	O
dihydro	O
-	O
5n	O
-	O
propyl	O
-	O
2H	O
-	O
pyrazo	O
lo	O
-	O
3	O
-	O
4	O
-	O
quinoline	O
hydrochloride	O
)	O
were	O
also	O
used	O
for	O
comparison	O
.	O

Acute	O
administration	O
of	O
A	O
-	O
86929	O
was	O
as	O
efficacious	O
in	O
alleviating	O
MPTP	O
-	O
induced	O
parkinsonism	B-Disease
as	O
levodopa	O
and	O
LY	O
-	O
171555	O
,	O
but	O
was	O
less	O
likely	O
to	O
reproduce	O
the	O
levodopa	O
-	O
induced	O
dyskinesias	B-Disease
in	O
these	O
animals	O
than	O
with	O
either	O
LY	O
-	O
171555	O
or	O
subsequent	O
challenge	O
of	O
levodopa	O
.	O

Selective	O
stimulation	O
of	O
the	O
DA	O
D1	O
receptor	O
may	O
provide	O
better	O
integration	O
of	O
neural	O
inputs	O
transmitted	O
to	O
the	O
internal	O
segment	O
of	O
the	O
globus	O
pallidus	O
(	O
referred	O
to	O
as	O
the	O
basal	O
ganglia	O
output	O
)	O
compared	O
with	O
levodopa	O
and	O
selective	O
DA	O
D2	O
receptor	O
agonist	O
.	O

Potent	O
DA	O
D1	O
receptor	O
agents	O
with	O
an	O
intermediate	O
duration	O
of	O
efficacy	O
such	O
as	O
A	O
-	O
86929	O
(	O
approximately	O
4	O
hr	O
at	O
higher	O
doses	O
tested	O
)	O
are	O
potential	O
therapeutic	O
tools	O
in	O
PD	B-Disease
and	O
merit	O
further	O
attention	O
.	O

Neuropeptide	O
-	O
Y	O
immunoreactivity	O
in	O
the	O
pilocarpine	O
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O

Neuropeptide	O
-	O
Y	O
(	O
NPY	O
)	O
is	O
expressed	O
by	O
granule	O
cells	O
and	O
mossy	O
fibres	O
of	O
the	O
hippocampal	O
dentate	O
gyrus	O
during	O
experimental	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
(	O
TLE	B-Disease
)	O
.	O

This	O
expression	O
may	O
represent	O
an	O
endogenous	O
damping	O
mechanism	O
since	O
NPY	O
has	O
been	O
shown	O
to	O
block	O
seizure	B-Disease
-	O
like	O
events	O
following	O
high	O
-	O
frequency	O
stimulation	O
in	O
hippocampal	O
slices	O
.	O

The	O
pilocarpine	O
(	O
PILO	O
)	O
model	O
of	O
epilepsy	B-Disease
is	O
characterized	O
by	O
an	O
acute	O
period	O
of	O
status	B-Disease
epilepticus	I-Disease
followed	O
by	O
spontaneous	O
recurrent	O
seizures	B-Disease
and	O
related	O
brain	B-Disease
damage	I-Disease
.	O

We	O
report	O
peroxidase	O
-	O
antiperoxidase	O
immunostaining	O
for	O
NPY	O
in	O
several	O
brain	O
regions	O
in	O
this	O
model	O
.	O

PILO	O
-	O
injected	O
animals	O
exhibited	O
NPY	O
immunoreactivity	O
in	O
the	O
region	O
of	O
the	O
mossy	O
fibre	O
terminals	O
,	O
in	O
the	O
dentate	O
gyrus	O
inner	O
molecular	O
layer	O
and	O
,	O
in	O
a	O
few	O
cases	O
,	O
within	O
presumed	O
granule	O
cells	O
.	O

NPY	O
immunoreactivity	O
was	O
also	O
dramatically	O
changed	O
in	O
the	O
entorhinal	O
cortex	O
,	O
amygdala	O
and	O
sensorimotor	O
areas	O
.	O

In	O
addition	O
,	O
PILO	O
injected	O
animals	O
exhibited	O
a	O
reduction	O
in	O
the	O
number	O
of	O
NPY	O
-	O
immunoreactive	O
interneurons	O
compared	O
with	O
controls	O
.	O

The	O
results	O
demonstrate	O
that	O
changes	O
in	O
NPY	O
expression	O
,	O
including	O
expression	O
in	O
the	O
granule	O
cells	O
and	O
mossy	O
fibres	O
and	O
the	O
loss	O
of	O
vulnerable	O
NPY	O
neurons	O
,	O
are	O
present	O
in	O
the	O
PILO	O
model	O
of	O
TLE	B-Disease
.	O

However	O
,	O
the	O
significance	O
of	O
this	O
changed	O
synthesis	O
of	O
NPY	O
remains	O
to	O
be	O
determined	O
.	O

Posteroventral	O
medial	O
pallidotomy	O
in	O
advanced	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O

BACKGROUND	O
:	O
Posteroventral	O
medial	O
pallidotomy	O
sometimes	O
produces	O
striking	O
improvement	O
in	O
patients	O
with	O
advanced	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
but	O
the	O
studies	O
to	O
date	O
have	O
involved	O
small	O
numbers	O
of	O
patients	O
and	O
short	O
-	O
term	O
follow	O
-	O
up	O
.	O

METHODS	O
:	O
Forty	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
underwent	O
serial	O
,	O
detailed	O
assessments	O
both	O
after	O
drug	O
withdrawal	O
(	O
"	O
off	O
"	O
period	O
)	O
and	O
while	O
taking	O
their	O
optimal	O
medical	O
regimens	O
(	O
"	O
on	O
"	O
period	O
)	O
.	O

All	O
patients	O
were	O
examined	O
preoperatively	O
and	O
39	O
were	O
examined	O
at	O
six	O
months	O
;	O
27	O
of	O
the	O
patients	O
were	O
also	O
examined	O
at	O
one	O
year	O
,	O
and	O
11	O
at	O
two	O
years	O
.	O

RESULTS	O
:	O
The	O
percent	O
improvements	O
at	O
six	O
months	O
were	O
as	O
follows	O
:	O
off	O
-	O
period	O
score	O
for	O
overall	O
motor	O
function	O
,	O
28	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
19	O
to	O
38	O
percent	O
)	O
,	O
with	O
most	O
of	O
the	O
improvement	O
in	O
the	O
contralateral	O
limbs	O
;	O
off	O
-	O
period	O
score	O
for	O
activities	O
of	O
daily	O
living	O
,	O
29	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
19	O
to	O
39	O
percent	O
)	O
;	O
on	O
-	O
period	O
score	O
for	O
contralateral	O
dyskinesias	B-Disease
,	O
82	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
72	O
to	O
91	O
percent	O
)	O
;	O
and	O
on	O
-	O
period	O
score	O
for	O
ipsilateral	O
dyskinesias	B-Disease
,	O
44	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
29	O
to	O
59	O
percent	O
)	O
.	O

The	O
improvements	O
in	O
dyskinesias	B-Disease
and	O
the	O
total	O
scores	O
for	O
off	O
-	O
period	O
parkinsonism	B-Disease
,	O
contralateral	O
bradykinesia	B-Disease
,	O
and	O
rigidity	B-Disease
were	O
sustained	O
in	O
the	O
11	O
patients	O
examined	O
at	O
two	O
years	O
.	O

The	O
improvement	O
in	O
ipsilateral	O
dyskinesias	B-Disease
was	O
lost	O
after	O
one	O
year	O
,	O
and	O
the	O
improvements	O
in	O
postural	O
stability	O
and	O
gait	O
lasted	O
only	O
three	O
to	O
six	O
months	O
.	O

Approximately	O
half	O
the	O
patients	O
who	O
had	O
been	O
dependent	O
on	O
assistance	O
in	O
activities	O
of	O
daily	O
living	O
in	O
the	O
off	O
period	O
before	O
surgery	O
became	O
independent	O
after	O
surgery	O
.	O

The	O
complications	O
of	O
surgery	O
were	O
generally	O
well	O
tolerated	O
,	O
and	O
there	O
were	O
no	O
significant	O
changes	O
in	O
the	O
use	O
of	O
medication	O
.	O

CONCLUSIONS	O
:	O
In	O
late	O
-	O
stage	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
pallidotomy	O
significantly	O
reduces	O
levodopa	O
-	O
induced	O
dyskinesias	B-Disease
and	O
off	O
-	O
period	O
disability	O
.	O

Much	O
of	O
the	O
benefit	O
is	O
sustained	O
at	O
two	O
years	O
,	O
although	O
some	O
improvements	O
,	O
such	O
as	O
those	O
on	O
the	O
ipsilateral	O
side	O
and	O
in	O
axial	O
symptoms	O
,	O
wane	O
within	O
the	O
first	O
year	O
.	O

The	O
on	O
-	O
period	O
symptoms	O
that	O
are	O
resistant	O
to	O
dopaminergic	O
therapy	O
do	O
not	O
respond	O
to	O
pallidotomy	O
.	O

Clarithromycin	O
-	O
induced	O
ventricular	B-Disease
tachycardia	I-Disease
.	O

Clarithromycin	O
is	O
a	O
relatively	O
new	O
macrolide	O
antibiotic	O
that	O
offers	O
twice	O
-	O
daily	O
dosing	O
.	O

It	O
differs	O
from	O
erythromycin	O
only	O
in	O
the	O
methylation	O
of	O
the	O
hydroxyl	O
group	O
at	O
position	O
6	O
.	O

Although	O
the	O
side	O
-	O
effect	O
profile	O
of	O
erythromycin	O
is	O
established	O
,	O
including	O
gastroenteritis	B-Disease
and	O
interactions	O
with	O
other	O
drugs	O
subject	O
to	O
hepatic	O
mixed	O
-	O
function	O
oxidase	O
metabolism	O
,	O
experience	O
with	O
the	O
newer	O
macrolides	O
is	O
still	O
being	O
recorded	O
.	O

Cardiotoxicity	B-Disease
has	O
been	O
demonstrated	O
after	O
both	O
intravenous	O
and	O
oral	O
administration	O
of	O
erythromycin	O
but	O
has	O
never	O
been	O
reported	O
with	O
the	O
newer	O
macrolides	O
.	O

We	O
report	O
a	O
case	O
of	O
ventricular	B-Disease
dysrhythmias	I-Disease
that	O
occurred	O
after	O
six	O
therapeutic	O
doses	O
of	O
clarithromycin	O
.	O

The	O
dysrhythmias	B-Disease
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Effect	O
of	O
glyceryl	O
trinitrate	O
on	O
the	O
sphincter	B-Disease
of	I-Disease
Oddi	I-Disease
spasm	I-Disease
evoked	O
by	O
prostigmine	O
-	O
morphine	O
administration	O
.	O

OBJECTIVE	O
:	O
In	O
this	O
study	O
the	O
effect	O
of	O
glyceryl	O
trinitrate	O
on	O
the	O
prostigmine	O
-	O
morphine	O
-	O
induced	O
sphincter	B-Disease
of	I-Disease
Oddi	I-Disease
spasm	I-Disease
was	O
evaluated	O
in	O
nine	O
female	O
patients	O
with	O
sphincter	B-Disease
of	I-Disease
Oddi	I-Disease
dyskinesia	I-Disease
.	O

METHOD	O
:	O
Sphincter	B-Disease
of	I-Disease
Oddi	I-Disease
spasm	I-Disease
was	O
induced	O
by	O
prostigmine	O
-	O
morphine	O
administration	O
(	O
0	O
.	O
5	O
mg	O
prostigmine	O
intramuscularly	O
and	O
10	O
mg	O
morphine	O
subcutaneously	O
)	O
and	O
visualized	O
by	O
quantitative	O
hepatobiliary	O
scintigraphy	O
.	O

The	O
entire	O
procedure	O
was	O
repeated	O
during	O
glyceryl	O
trinitrate	O
infusion	O
(	O
Nitrolingual	O
1	O
microg	O
/	O
kg	O
/	O
min	O
for	O
120	O
min	O
)	O
.	O

RESULTS	O
:	O
Prostigmine	O
-	O
morphine	O
provocation	O
caused	O
significant	O
increases	O
in	O
the	O
time	O
to	O
peak	O
activity	O
(	O
Tmax	O
)	O
over	O
the	O
hepatic	O
hilum	O
(	O
HH	O
:	O
34	O
.	O
33	O
+	O
/	O
-	O
5	O
.	O
05	O
vs	O
.	O
22	O
.	O
77	O
+	O
/	O
-	O
3	O
.	O
26	O
)	O
and	O
the	O
common	O
bile	O
duct	O
(	O
CBD	O
:	O
60	O
.	O
44	O
+	O
/	O
-	O
5	O
.	O
99	O
vs	O
.	O
40	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
88	O
)	O
and	O
in	O
the	O
half	O
-	O
time	O
of	O
excretion	O
(	O
T1	O
/	O
2	O
)	O
over	O
the	O
liver	O
parenchyma	O
(	O
LP	O
:	O
120	O
.	O
04	O
+	O
/	O
-	O
16	O
.	O
01	O
vs	O
.	O
27	O
.	O
37	O
+	O
/	O
-	O
2	O
.	O
19	O
)	O
,	O
HH	O
(	O
117	O
.	O
61	O
+	O
/	O
-	O
14	O
.	O
71	O
vs	O
.	O
31	O
.	O
85	O
+	O
/	O
-	O
3	O
.	O
99	O
)	O
and	O
CBD	O
(	O
158	O
.	O
11	O
+	O
/	O
-	O
9	O
.	O
18	O
vs	O
.	O
40	O
.	O
1	O
+	O
/	O
-	O
6	O
.	O
24	O
)	O
,	O
indicating	O
a	O
complete	O
spasm	B-Disease
at	O
the	O
level	O
of	O
the	O
sphincter	O
of	O
Oddi	O
.	O

Glyceryl	O
trinitrate	O
infusion	O
completely	O
normalized	O
the	O
prostigmine	O
-	O
morphine	O
-	O
induced	O
alterations	O
in	O
these	O
quantitative	O
parameters	O
(	O
TmaX	O
over	O
the	O
LP	O
:	O
11	O
.	O
33	O
+	O
/	O
-	O
1	O
.	O
13	O
;	O
over	O
the	O
HH	O
:	O
18	O
.	O
88	O
+	O
/	O
-	O
1	O
.	O
48	O
;	O
and	O
over	O
the	O
CBD	O
:	O
36	O
.	O
22	O
+	O
/	O
-	O
1	O
.	O
92	O
;	O
and	O
T1	O
/	O
2	O
over	O
the	O
LP	O
:	O
28	O
.	O
21	O
+	O
/	O
-	O
1	O
.	O
83	O
;	O
over	O
the	O
HH	O
:	O
33	O
.	O
42	O
+	O
/	O
-	O
3	O
.	O
10	O
;	O
and	O
over	O
the	O
CBD	O
:	O
41	O
.	O
66	O
+	O
/	O
-	O
6	O
.	O
33	O
)	O
,	O
suggesting	O
an	O
effective	O
sphincter	O
-	O
relaxing	O
effect	O
of	O
glyceryl	O
trinitrate	O
.	O

CONCLUSION	O
:	O
These	O
results	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
effectiveness	O
of	O
glyceryl	O
trinitrate	O
on	O
the	O
morphine	O
-	O
induced	O
sphincter	B-Disease
of	I-Disease
Oddi	I-Disease
spasm	I-Disease
in	O
humans	O
.	O

Since	O
glyceryl	O
trinitrate	O
is	O
able	O
to	O
overcome	O
even	O
the	O
drastic	O
effect	O
of	O
morphine	O
,	O
it	O
might	O
be	O
of	O
relevance	O
in	O
the	O
treatment	O
of	O
sphincter	B-Disease
of	I-Disease
Oddi	I-Disease
dyskinesia	I-Disease
.	O

Immunopathology	O
of	O
penicillamine	O
-	O
induced	O
glomerular	B-Disease
disease	I-Disease
.	O

Four	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
developed	O
heavy	O
proteinuria	B-Disease
after	O
five	O
to	O
12	O
months	O
of	O
treatment	O
with	O
D	O
-	O
penicillamine	O
.	O

Light	O
microscopy	O
of	O
renal	O
biopsy	O
samples	O
showed	O
minimal	O
glomerular	O
capillary	O
wall	O
thickening	O
and	O
mesangial	O
matrix	O
increase	O
,	O
or	O
no	O
departure	O
from	O
normal	O
.	O

Electron	O
microscopy	O
,	O
however	O
,	O
revealed	O
subepithelial	O
electron	O
-	O
dense	O
deposits	O
,	O
fusion	O
of	O
epithelial	O
cell	O
foot	O
processes	O
,	O
and	O
evidence	O
of	O
mesangial	O
cell	O
hyperactivity	O
.	O

Immunofluorescence	O
microscopy	O
demonstrated	O
granular	O
capillary	O
wall	O
deposits	O
of	O
IgG	O
and	O
C3	O
.	O

The	O
findings	O
were	O
similar	O
to	O
those	O
in	O
early	O
membranous	B-Disease
glomerulonephritis	I-Disease
,	O
differences	O
being	O
observed	O
however	O
in	O
the	O
results	O
of	O
staining	O
for	O
the	O
early	O
-	O
acting	O
complement	O
components	O
C1q	O
and	O
C4	O
.	O

It	O
is	O
tentatively	O
concluded	O
that	O
complement	O
was	O
activated	O
by	O
the	O
classical	O
pathway	O
.	O

Experimental	O
cranial	O
pain	B-Disease
elicited	O
by	O
capsaicin	O
:	O
a	O
PET	O
study	O
.	O

Using	O
a	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
it	O
was	O
shown	O
recently	O
that	O
in	O
migraine	B-Disease
without	O
aura	O
certain	O
areas	O
in	O
the	O
brain	O
stem	O
were	O
activated	O
during	O
the	O
headache	B-Disease
state	O
,	O
but	O
not	O
in	O
the	O
headache	B-Disease
free	O
interval	O
.	O

It	O
was	O
suggested	O
that	O
this	O
brain	O
stem	O
activation	O
is	O
inherent	O
to	O
the	O
migraine	B-Disease
attack	O
itself	O
and	O
represents	O
the	O
so	O
called	O
'	O
migraine	B-Disease
generator	O
'	O
.	O

To	O
test	O
this	O
hypothesis	O
we	O
performed	O
an	O
experimental	O
pain	B-Disease
study	O
in	O
seven	O
healthy	O
volunteers	O
,	O
using	O
the	O
same	O
positioning	O
in	O
the	O
PET	O
scanner	O
as	O
in	O
the	O
migraine	B-Disease
patients	O
.	O

A	O
small	O
amount	O
of	O
capsaicin	O
was	O
administered	O
subcutaneously	O
in	O
the	O
right	O
forehead	O
to	O
evoke	O
a	O
burning	O
painful	B-Disease
sensation	O
in	O
the	O
first	O
division	O
of	O
the	O
trigeminal	O
nerve	O
.	O

Increases	O
of	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
were	O
found	O
bilaterally	O
in	O
the	O
insula	O
,	O
in	O
the	O
anterior	O
cingulate	O
cortex	O
,	O
the	O
cavernous	O
sinus	O
and	O
the	O
cerebellum	O
.	O

Using	O
the	O
same	O
stereotactic	O
space	O
limits	O
as	O
in	O
the	O
above	O
mentioned	O
migraine	B-Disease
study	O
no	O
brain	O
stem	O
activation	O
was	O
found	O
in	O
the	O
acute	O
pain	B-Disease
state	O
compared	O
to	O
the	O
pain	B-Disease
free	O
state	O
.	O

The	O
increase	O
of	O
activation	O
in	O
the	O
region	O
of	O
the	O
cavernous	O
sinus	O
however	O
,	O
suggests	O
that	O
this	O
structure	O
is	O
more	O
likely	O
to	O
be	O
involved	O
in	O
trigeminal	O
transmitted	O
pain	B-Disease
as	O
such	O
,	O
rather	O
than	O
in	O
a	O
specific	O
type	O
of	O
headache	B-Disease
as	O
was	O
suggested	O
for	O
cluster	B-Disease
headache	I-Disease
.	O

Value	O
of	O
methylprednisolone	O
in	O
prevention	O
of	O
the	O
arthralgia	B-Disease
-	O
myalgia	B-Disease
syndrome	O
associated	O
with	O
the	O
total	O
dose	O
infusion	O
of	O
iron	O
dextran	O
:	O
a	O
double	O
blind	O
randomized	O
trial	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
total	O
dose	O
infusion	O
(	O
TDI	O
)	O
of	O
iron	O
dextran	O
has	O
been	O
well	O
documented	O
.	O

In	O
40	O
%	O
of	O
treated	O
patients	O
,	O
an	O
arthralgia	B-Disease
-	O
myalgia	B-Disease
syndrome	O
develops	O
.	O

The	O
purpose	O
of	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
prospective	O
study	O
was	O
to	O
investigate	O
whether	O
intravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
administration	O
of	O
methylprednisolone	O
(	O
MP	O
)	O
prevents	O
this	O
complication	O
.	O

Sixty	O
-	O
five	O
patients	O
,	O
34	O
women	O
and	O
31	O
men	O
,	O
ages	O
36	O
to	O
80	O
years	O
,	O
received	O
either	O
normal	O
saline	O
before	O
and	O
after	O
TDI	O
(	O
group	O
1	O
)	O
,	O
125	O
mg	O
i	O
.	O
v	O
.	O
MP	O
before	O
and	O
saline	O
after	O
TDI	O
(	O
group	O
2	O
)	O
,	O
or	O
125	O
mg	O
i	O
.	O
v	O
.	O
MP	O
before	O
and	O
after	O
TDI	O
(	O
group	O
3	O
)	O
.	O

Patients	O
were	O
observed	O
for	O
72	O
hours	O
and	O
reactions	O
were	O
recorded	O
and	O
graded	O
according	O
to	O
severity	O
.	O

Fifty	O
-	O
eight	O
percent	O
of	O
group	O
1	O
patients	O
,	O
33	O
%	O
of	O
group	O
2	O
,	O
and	O
26	O
%	O
of	O
group	O
3	O
had	O
reactions	O
to	O
TDI	O
.	O

The	O
severity	O
of	O
reactions	O
(	O
minimal	O
,	O
mild	O
,	O
and	O
moderate	O
,	O
respectively	O
)	O
was	O
as	O
follows	O
:	O
group	O
1	O
-	O
-	O
6	O
,	O
6	O
,	O
and	O
2	O
;	O
group	O
2	O
-	O
-	O
1	O
,	O
5	O
,	O
and	O
0	O
;	O
group	O
3	O
-	O
-	O
5	O
,	O
1	O
,	O
and	O
0	O
.	O

Data	O
were	O
analyzed	O
by	O
the	O
two	O
-	O
sided	O
Fisher	O
'	O
s	O
exact	O
test	O
using	O
95	O
%	O
confidence	O
intervals	O
with	O
the	O
approximation	O
of	O
Woolf	O
.	O

These	O
data	O
demonstrate	O
that	O
administration	O
of	O
MP	O
before	O
and	O
after	O
TDI	O
reduces	O
the	O
frequency	O
and	O
severity	O
of	O
the	O
arthralgia	B-Disease
-	O
myalgia	B-Disease
syndrome	O
.	O

We	O
conclude	O
that	O
125	O
mg	O
i	O
.	O
v	O
.	O
MP	O
should	O
be	O
given	O
routinely	O
before	O
and	O
after	O
TDI	O
of	O
iron	O
dextran	O
.	O

Prolongation	B-Disease
of	I-Disease
the	I-Disease
QT	I-Disease
interval	I-Disease
related	O
to	O
cisapride	O
-	O
diltiazem	O
interaction	O
.	O

Cisapride	O
,	O
a	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
substrate	O
,	O
is	O
widely	O
prescribed	O
for	O
the	O
treatment	O
of	O
gastrointestinal	B-Disease
motility	I-Disease
disorders	I-Disease
.	O

Prolongation	B-Disease
of	I-Disease
QT	I-Disease
interval	I-Disease
,	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
,	O
and	O
sudden	B-Disease
cardiac	I-Disease
death	I-Disease
have	O
been	O
reported	O
after	O
concomitant	O
administration	O
with	O
erythromycin	O
or	O
azole	O
antifungal	O
agents	O
,	O
but	O
not	O
with	O
other	O
CYP3A4	O
inhibitors	O
.	O

A	O
possible	O
drug	O
interaction	O
occurred	O
in	O
a	O
45	O
-	O
year	O
-	O
old	O
woman	O
who	O
was	O
taking	O
cisapride	O
for	O
gastroesophageal	B-Disease
reflux	I-Disease
disorder	I-Disease
and	O
diltiazem	O
,	O
an	O
agent	O
that	O
has	O
inhibitory	O
effect	O
on	O
CYP3A4	O
,	O
for	O
hypertension	B-Disease
.	O

The	O
patient	O
was	O
in	O
near	O
syncope	B-Disease
and	O
had	O
QT	B-Disease
-	I-Disease
interval	I-Disease
prolongation	I-Disease
.	O

After	O
discontinuing	O
cisapride	O
,	O
the	O
QT	O
interval	O
returned	O
to	O
normal	O
and	O
symptoms	O
did	O
not	O
recur	O
.	O

We	O
suggest	O
that	O
caution	O
be	O
taken	O
when	O
cisapride	O
is	O
prescribed	O
with	O
any	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
including	O
diltiazem	O
.	O

Cortical	O
motor	O
overactivation	O
in	O
parkinsonian	B-Disease
patients	O
with	O
L	O
-	O
dopa	O
-	O
induced	O
peak	O
-	O
dose	O
dyskinesia	B-Disease
.	O

We	O
have	O
studied	O
the	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
changes	O
induced	O
by	O
the	O
execution	O
of	O
a	O
finger	O
-	O
to	O
-	O
thumb	O
opposition	O
motor	O
task	O
in	O
the	O
supplementary	O
and	O
primary	O
motor	O
cortex	O
of	O
two	O
groups	O
of	O
parkinsonian	B-Disease
patients	O
on	O
L	O
-	O
dopa	O
medication	O
,	O
the	O
first	O
one	O
without	O
L	O
-	O
dopa	O
induced	O
dyskinesia	B-Disease
(	O
n	O
=	O
23	O
)	O
and	O
the	O
other	O
with	O
moderate	O
peak	O
-	O
dose	O
dyskinesia	B-Disease
(	O
n	O
=	O
15	O
)	O
,	O
and	O
of	O
a	O
group	O
of	O
14	O
normal	O
subjects	O
.	O

Single	O
photon	O
emission	O
tomography	O
with	O
i	O
.	O
v	O
.	O
133Xe	O
was	O
used	O
to	O
measure	O
the	O
rCBF	O
changes	O
.	O

The	O
dyskinetic	B-Disease
parkinsonian	B-Disease
patients	O
exhibited	O
a	O
pattern	O
of	O
response	O
which	O
was	O
markedly	O
different	O
from	O
those	O
of	O
the	O
normal	O
subjects	O
and	O
non	O
-	O
dyskinetic	B-Disease
parkinsonian	B-Disease
patients	O
,	O
with	O
a	O
significant	O
overactivation	O
in	O
the	O
supplementary	O
motor	O
area	O
and	O
the	O
ipsi	O
-	O
and	O
contralateral	O
primary	O
motor	O
areas	O
.	O

These	O
results	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
an	O
hyperkinetic	B-Disease
abnormal	B-Disease
involuntary	I-Disease
movement	I-Disease
,	O
like	O
L	O
-	O
dopa	O
-	O
induced	O
peak	O
dose	O
dyskinesia	B-Disease
,	O
is	O
due	O
to	O
a	O
disinhibition	O
of	O
the	O
primary	O
and	O
associated	O
motor	O
cortex	O
secondary	O
to	O
an	O
excessive	O
outflow	O
of	O
the	O
pallidothalamocortical	O
motor	O
loop	O
.	O

Open	O
-	O
label	O
assessment	O
of	O
levofloxacin	O
for	O
the	O
treatment	O
of	O
acute	O
bacterial	O
sinusitis	B-Disease
in	O
adults	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
levofloxacin	O
(	O
500	O
mg	O
orally	O
once	O
daily	O
for	O
10	O
to	O
14	O
days	O
)	O
in	O
treating	O
adult	O
outpatients	O
with	O
acute	O
bacterial	O
sinusitis	B-Disease
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
329	O
patients	O
enrolled	O
in	O
the	O
study	O
at	O
24	O
centers	O
.	O

All	O
patients	O
had	O
a	O
pre	O
-	O
therapy	O
Gram	O
'	O
s	O
stain	O
and	O
culture	O
of	O
sinus	O
exudate	O
obtained	O
by	O
antral	O
puncture	O
or	O
nasal	O
endoscopy	O
.	O

Clinical	O
response	O
was	O
assessed	O
on	O
the	O
basis	O
of	O
signs	O
and	O
symptoms	O
and	O
sinus	O
radiograph	O
or	O
computed	O
tomography	O
results	O
.	O

Microbiologic	O
cure	O
rates	O
were	O
determined	O
on	O
the	O
basis	O
of	O
presumed	O
plus	O
documented	O
eradication	O
of	O
the	O
pre	O
-	O
therapy	O
pathogen	O
(	O
s	O
)	O
.	O

RESULTS	O
:	O
The	O
most	O
common	O
pathogens	O
were	O
Haemophilus	O
influenzae	O
,	O
Streptococcus	O
pneumoniae	O
,	O
Staphylococcus	O
aureus	O
,	O
and	O
Moraxella	O
catarrhalis	O
.	O

Of	O
300	O
clinically	O
evaluable	O
patients	O
,	O
175	O
(	O
58	O
%	O
)	O
were	O
cured	O
and	O
90	O
(	O
30	O
%	O
)	O
were	O
improved	O
at	O
the	O
post	O
-	O
therapy	O
evaluation	O
,	O
resulting	O
in	O
a	O
clinical	O
success	O
rate	O
of	O
88	O
%	O
.	O

Thirty	O
-	O
five	O
patients	O
(	O
12	O
%	O
)	O
clinically	O
failed	O
treatment	O
.	O

The	O
microbiologic	O
eradication	O
rate	O
(	O
presumed	O
plus	O
documented	O
)	O
among	O
138	O
microbiologically	O
evaluable	O
patients	O
was	O
92	O
%	O
.	O

Microbiologic	O
eradication	O
rates	O
(	O
presumed	O
plus	O
documented	O
)	O
of	O
the	O
most	O
common	O
pathogens	O
ranged	O
from	O
93	O
%	O
(	O
M	O
.	O
catarrhalis	O
)	O
to	O
100	O
%	O
(	O
S	O
.	O
pneumoniae	O
)	O
at	O
the	O
post	O
-	O
therapy	O
visit	O
.	O

All	O
but	O
one	O
of	O
the	O
265	O
patients	O
who	O
were	O
cured	O
or	O
improved	O
at	O
post	O
-	O
therapy	O
returned	O
for	O
a	O
long	O
-	O
term	O
follow	O
-	O
up	O
visit	O
;	O
243	O
(	O
92	O
%	O
)	O
remained	O
well	O
4	O
to	O
6	O
weeks	O
after	O
therapy	O
;	O
and	O
21	O
(	O
8	O
%	O
)	O
had	O
a	O
relapse	O
of	O
symptoms	O
.	O

Adverse	O
events	O
considered	O
to	O
be	O
related	O
to	O
levofloxacin	O
administration	O
were	O
reported	O
by	O
29	O
patients	O
(	O
9	O
%	O
)	O
.	O

The	O
most	O
common	O
drug	O
-	O
related	O
adverse	O
events	O
were	O
diarrhea	B-Disease
,	O
flatulence	B-Disease
,	O
and	O
nausea	B-Disease
;	O
most	O
adverse	O
events	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
levofloxacin	O
500	O
mg	O
once	O
daily	O
is	O
an	O
effective	O
and	O
safe	O
treatment	O
for	O
acute	O
bacterial	O
sinusitis	B-Disease
.	O

Iatrogenic	O
risks	O
of	O
endometrial	B-Disease
carcinoma	I-Disease
after	O
treatment	O
for	O
breast	B-Disease
cancer	I-Disease
in	O
a	O
large	O
French	O
case	O
-	O
control	O
study	O
.	O

F	O
d	O
ration	O
Nationale	O
des	O
Centres	O
de	O
Lutte	O
Contre	O
le	O
Cancer	O
(	O
FNCLCC	O
)	O
.	O

Since	O
tamoxifen	O
is	O
widely	O
used	O
in	O
breast	B-Disease
cancer	I-Disease
treatment	O
and	O
has	O
been	O
proposed	O
for	O
the	O
prevention	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
its	O
endometrial	O
iatrogenic	O
effects	O
must	O
be	O
carefully	O
examined	O
.	O

We	O
have	O
investigated	O
the	O
association	O
between	O
endometrial	B-Disease
cancer	I-Disease
and	O
tamoxifen	O
use	O
or	O
other	O
treatments	O
in	O
women	O
treated	O
for	O
breast	B-Disease
cancer	I-Disease
in	O
a	O
case	O
-	O
control	O
study	O
.	O

Cases	O
of	O
endometrial	B-Disease
cancer	I-Disease
diagnosed	O
after	O
breast	B-Disease
cancer	I-Disease
(	O
n	O
=	O
135	O
)	O
and	O
467	O
controls	O
matched	O
for	O
age	O
,	O
year	O
of	O
diagnosis	O
of	O
breast	B-Disease
cancer	I-Disease
and	O
hospital	O
and	O
survival	O
time	O
with	O
an	O
intact	O
uterus	O
were	O
included	O
.	O

Women	O
who	O
had	O
received	O
tamoxifen	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
endometrial	B-Disease
cancer	I-Disease
diagnosed	O
than	O
those	O
who	O
had	O
not	O
(	O
crude	O
relative	O
risk	O
=	O
4	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

Univariate	O
and	O
adjusted	O
analyses	O
showed	O
that	O
the	O
risk	O
increased	O
with	O
the	O
length	O
of	O
treatment	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
or	O
the	O
cumulative	O
dose	O
of	O
tamoxifen	O
received	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
,	O
irrespective	O
of	O
the	O
daily	O
dose	O
.	O

Women	O
who	O
had	O
undergone	O
pelvic	O
radiotherapy	O
also	O
had	O
a	O
higher	O
risk	O
(	O
crude	O
relative	O
risk	O
=	O
7	O
.	O
8	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

After	O
adjusting	O
for	O
confounding	O
factors	O
,	O
the	O
risk	O
was	O
higher	O
for	O
tamoxifen	O
users	O
(	O
p	O
=	O
0	O
.	O
0012	O
)	O
,	O
treatment	O
for	O
more	O
than	O
3	O
years	O
(	O
all	O
p	O
<	O
0	O
.	O
03	O
)	O
and	O
pelvic	O
radiotherapy	O
(	O
p	O
=	O
0	O
.	O
012	O
)	O
.	O

Women	O
who	O
had	O
endometrial	B-Disease
cancer	I-Disease
and	O
had	O
received	O
tamoxifen	O
had	O
more	O
advanced	B-Disease
disease	I-Disease
and	O
poorer	O
prognosis	O
than	O
those	O
with	O
endometrial	B-Disease
cancer	I-Disease
who	O
had	O
not	O
received	O
this	O
treatment	O
.	O

Our	O
results	O
suggest	O
a	O
causal	O
role	O
of	O
tamoxifen	O
in	O
endometrial	B-Disease
cancer	I-Disease
,	O
particularly	O
when	O
used	O
as	O
currently	O
proposed	O
for	O
breast	B-Disease
cancer	I-Disease
prevention	O
.	O

Pelvic	O
radiotherapy	O
may	O
be	O
an	O
additional	O
iatrogenic	O
factor	O
for	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O

Endometrial	B-Disease
cancers	I-Disease
diagnosed	O
in	O
women	O
treated	O
with	O
tamoxifen	O
have	O
poorer	O
prognosis	O
.	O

Women	O
who	O
receive	O
tamoxifen	O
for	O
breast	B-Disease
cancer	I-Disease
should	O
be	O
offered	O
gynaecological	O
surveillance	O
during	O
and	O
after	O
treatment	O
.	O

A	O
long	O
-	O
term	O
evaluation	O
of	O
the	O
risk	O
-	O
benefit	O
ratio	O
of	O
tamoxifen	O
as	O
a	O
preventive	O
treatment	O
for	O
breast	B-Disease
cancer	I-Disease
is	O
clearly	O
warranted	O
.	O

Contribution	O
of	O
the	O
glycine	O
site	O
of	O
NMDA	O
receptors	O
in	O
rostral	O
and	O
intermediate	O
-	O
caudal	O
parts	O
of	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
in	O
rats	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
contribution	O
of	O
the	O
glycine	O
site	O
of	O
NMDA	O
receptors	O
in	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
.	O

Muscle	O
tone	O
was	O
examined	O
using	O
a	O
combined	O
mechanoand	O
electromyographic	O
method	O
,	O
which	O
measured	O
simultaneously	O
the	O
muscle	O
resistance	O
(	O
MMG	O
)	O
of	O
the	O
rat	O
'	O
s	O
hind	O
foot	O
to	O
passive	O
extension	O
and	O
flexion	O
in	O
the	O
ankle	O
joint	O
and	O
the	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
of	O
the	O
antagonistic	O
muscles	O
of	O
that	O
joint	O
:	O
gastrocnemius	O
and	O
tibialis	O
anterior	O
.	O

Muscle	B-Disease
rigidity	I-Disease
was	O
induced	O
by	O
haloperidol	O
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

5	O
,	O
7	O
-	O
dichlorokynurenic	O
acid	O
(	O
5	O
,	O
7	O
-	O
DCKA	O
)	O
,	O
a	O
selective	O
glycine	O
site	O
antagonist	O
,	O
injected	O
in	O
doses	O
of	O
2	O
.	O
5	O
and	O
4	O
.	O
5	O
microg	O
/	O
0	O
.	O
5	O
microl	O
bilaterally	O
,	O
into	O
the	O
rostral	O
region	O
of	O
the	O
striatum	O
,	O
decreased	O
both	O
the	O
haloperidol	O
-	O
induced	O
muscle	B-Disease
rigidity	I-Disease
(	O
MMG	O
)	O
and	O
the	O
enhanced	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
.	O

5	O
,	O
7	O
-	O
DCKA	O
injected	O
bilaterally	O
in	O
a	O
dose	O
of	O
4	O
.	O
5	O
microg	O
/	O
0	O
.	O
5	O
microl	O
into	O
the	O
intermediate	O
-	O
caudal	O
region	O
of	O
the	O
striatum	O
of	O
rats	O
not	O
pretreated	O
with	O
haloperidol	O
had	O
no	O
effect	O
on	O
the	O
muscle	O
tone	O
.	O

The	O
present	O
results	O
suggest	O
that	O
blockade	O
of	O
the	O
glycine	O
site	O
of	O
NMDA	O
receptors	O
in	O
the	O
rostral	O
part	O
of	O
the	O
striatum	O
may	O
be	O
mainly	O
responsible	O
for	O
the	O
antiparkinsonian	O
action	O
of	O
this	O
drug	O
.	O

Carboplatin	O
toxic	O
effects	O
on	O
the	O
peripheral	O
nervous	O
system	O
of	O
the	O
rat	O
.	O

BACKGROUND	O
:	O
The	O
most	O
striking	O
of	O
carboplatin	O
'	O
s	O
advantages	O
(	O
CBDCA	O
)	O
over	O
cisplatin	O
(	O
CDDP	O
)	O
is	O
its	O
markedly	O
reduced	O
rate	O
of	O
neurotoxic	B-Disease
effects	O
.	O

However	O
,	O
the	O
use	O
of	O
CBDCA	O
higher	O
-	O
intensity	O
schedules	O
and	O
the	O
association	O
with	O
other	O
neurotoxic	B-Disease
drugs	O
in	O
polychemotherapy	O
may	O
cause	O
some	O
concern	O
about	O
its	O
safety	O
with	O
respect	O
to	O
peripheral	B-Disease
nervous	I-Disease
system	I-Disease
damage	I-Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Two	O
different	O
schedules	O
of	O
CBDCA	O
administration	O
(	O
10	O
mg	O
/	O
kg	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
twice	O
a	O
week	O
for	O
nine	O
times	O
)	O
were	O
evaluated	O
in	O
Wistar	O
rats	O
.	O

Neurotoxicity	B-Disease
was	O
assessed	O
for	O
behavioral	O
(	O
tail	O
-	O
flick	O
test	O
)	O
,	O
neurophysiological	O
(	O
nerve	O
conduction	O
velocity	O
in	O
the	O
tail	O
nerve	O
)	O
,	O
morphological	O
,	O
morphometrical	O
and	O
analytical	O
effects	O
.	O

RESULTS	O
:	O
CBDCA	O
administration	O
induced	O
dose	O
-	O
dependent	O
peripheral	B-Disease
neurotoxicity	I-Disease
.	O

Pain	B-Disease
perception	O
and	O
nerve	O
conduction	O
velocity	O
in	O
the	O
tail	O
were	O
significantly	O
impaired	O
,	O
particularly	O
after	O
the	O
high	O
-	O
dose	O
treatment	O
.	O

The	O
dorsal	O
root	O
ganglia	O
sensory	O
neurons	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
satellite	O
cells	O
showed	O
the	O
same	O
changes	O
as	O
those	O
induced	O
by	O
CDDP	O
,	O
mainly	O
affecting	O
the	O
nucleus	O
and	O
nucleolus	O
of	O
ganglionic	O
sensory	O
neurons	O
.	O

Moreover	O
,	O
significant	O
amounts	O
of	O
platinum	O
were	O
detected	O
in	O
the	O
dorsal	O
root	O
ganglia	O
and	O
kidney	O
after	O
CBDCA	O
treatment	O
.	O

CONCLUSIONS	O
:	O
CBDCA	O
is	O
neurotoxic	B-Disease
in	O
our	O
model	O
,	O
and	O
the	O
type	O
of	O
pathological	O
changes	O
it	O
induces	O
are	O
so	O
closely	O
similar	O
to	O
those	O
caused	O
by	O
CDDP	O
that	O
it	O
is	O
probable	O
that	O
neurotoxicity	B-Disease
is	O
induced	O
in	O
the	O
two	O
drugs	O
by	O
the	O
same	O
mechanism	O
.	O

This	O
model	O
can	O
be	O
used	O
alone	O
or	O
in	O
combination	O
with	O
other	O
drugs	O
to	O
explore	O
the	O
effect	O
of	O
CBDCA	O
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

Effects	O
of	O
cisapride	O
on	O
symptoms	O
and	O
postcibal	O
small	O
-	O
bowel	O
motor	O
function	O
in	O
patients	O
with	O
irritable	B-Disease
bowel	I-Disease
syndrome	I-Disease
.	O

BACKGROUND	O
:	O
Irritable	B-Disease
bowel	I-Disease
syndrome	I-Disease
is	O
a	O
common	O
cause	O
of	O
abdominal	B-Disease
pain	I-Disease
and	O
discomfort	O
and	O
may	O
be	O
related	O
to	O
disordered	B-Disease
gastrointestinal	I-Disease
motility	I-Disease
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
effects	O
of	O
long	O
-	O
term	O
treatment	O
with	O
a	O
prokinetic	O
agent	O
,	O
cisapride	O
,	O
on	O
postprandial	O
jejunal	O
motility	O
and	O
symptoms	O
in	O
the	O
irritable	B-Disease
bowel	I-Disease
syndrome	I-Disease
(	O
IBS	B-Disease
)	O
.	O

METHODS	O
:	O
Thirty	O
-	O
eight	O
patients	O
with	O
IBS	B-Disease
(	O
constipation	B-Disease
-	O
predominant	O
,	O
n	O
=	O
17	O
;	O
diarrhoea	B-Disease
-	O
predominant	O
,	O
n	O
=	O
21	O
)	O
underwent	O
24	O
-	O
h	O
ambulatory	O
jejunal	O
manometry	O
before	O
and	O
after	O
12	O
week	O
'	O
s	O
treatment	O
[	O
cisapride	O
,	O
5	O
mg	O
three	O
times	O
daily	O
(	O
n	O
=	O
19	O
)	O
or	O
placebo	O
(	O
n	O
=	O
19	O
)	O
]	O
.	O

RESULTS	O
:	O
In	O
diarrhoea	B-Disease
-	O
predominant	O
patients	O
significant	O
differences	O
in	O
contraction	O
characteristics	O
were	O
observed	O
between	O
the	O
cisapride	O
and	O
placebo	O
groups	O
.	O

In	O
cisapride	O
-	O
treated	O
diarrhoea	B-Disease
-	O
predominant	O
patients	O
the	O
mean	O
contraction	O
amplitude	O
was	O
higher	O
(	O
29	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
2	O
versus	O
24	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
6	O
mm	O
Hg	O
,	O
cisapride	O
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
;	O
pretreatment	O
,	O
25	O
.	O
7	O
+	O
/	O
-	O
6	O
.	O
0	O
mm	O
Hg	O
)	O
,	O
the	O
mean	O
contraction	O
duration	O
longer	O
(	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
2	O
versus	O
3	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
sec	O
,	O
cisapride	O
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
;	O
pretreatment	O
,	O
3	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
5	O
sec	O
)	O
,	O
and	O
the	O
mean	O
contraction	O
frequency	O
lower	O
(	O
2	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
versus	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
4	O
cont	O
.	O
/	O
min	O
,	O
cisapride	O
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
;	O
pretreatment	O
,	O
2	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
1	O
cont	O
.	O
/	O
min	O
]	O
than	O
patients	O
treated	O
with	O
placebo	O
.	O

No	O
significant	O
differences	O
in	O
jejunal	O
motility	O
were	O
found	O
in	O
the	O
constipation	B-Disease
-	O
predominant	O
IBS	B-Disease
group	O
.	O

Symptoms	O
were	O
assessed	O
by	O
using	O
a	O
visual	O
analogue	O
scale	O
before	O
and	O
after	O
treatment	O
.	O

Symptom	O
scores	O
relating	O
to	O
the	O
severity	O
of	O
constipation	B-Disease
were	O
lower	O
in	O
cisapride	O
-	O
treated	O
constipation	B-Disease
-	O
predominant	O
IBS	B-Disease
patients	O
[	O
score	O
,	O
54	O
+	O
/	O
-	O
5	O
versus	O
67	O
+	O
/	O
-	O
14	O
mm	O
,	O
cisapride	O
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
pretreatment	O
,	O
62	O
+	O
/	O
-	O
19	O
mm	O
]	O
.	O

Diarrhoea	B-Disease
-	O
predominant	O
IBS	B-Disease
patients	O
had	O
a	O
higher	O
pain	B-Disease
score	O
after	O
cisapride	O
therapy	O
[	O
score	O
,	O
55	O
+	O
/	O
-	O
15	O
versus	O
34	O
+	O
/	O
-	O
12	O
mm	O
,	O
cisapride	O
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
pretreatment	O
,	O
67	O
+	O
/	O
-	O
19	O
mm	O
]	O
.	O

CONCLUSION	O
:	O
Cisapride	O
affects	O
jejunal	O
contraction	O
characteristics	O
and	O
some	O
symptoms	O
in	O
IBS	B-Disease
.	O

Prevention	O
of	O
breast	B-Disease
cancer	I-Disease
with	O
tamoxifen	O
:	O
preliminary	O
findings	O
from	O
the	O
Italian	O
randomised	O
trial	O
among	O
hysterectomised	O
women	O
.	O

Italian	O
Tamoxifen	O
Prevention	O
Study	O
.	O

BACKGROUND	O
:	O
Tamoxifen	O
is	O
a	O
candidate	O
chemopreventive	O
agent	O
in	O
breast	B-Disease
cancer	I-Disease
,	O
although	O
the	O
drug	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
endometrial	B-Disease
cancer	I-Disease
.	O

Therefore	O
we	O
did	O
a	O
trial	O
in	O
hysterectomised	O
women	O
of	O
tamoxifen	O
as	O
a	O
chemopreventive	O
.	O

METHODS	O
:	O
In	O
October	O
,	O
1992	O
,	O
we	O
started	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
,	O
randomised	O
trial	O
of	O
tamoxifen	O
in	O
women	O
(	O
mainly	O
in	O
Italy	O
)	O
who	O
did	O
not	O
have	O
breast	B-Disease
cancer	I-Disease
and	O
who	O
had	O
had	O
a	O
hysterectomy	O
.	O

Women	O
were	O
randomised	O
to	O
receive	O
tamoxifen	O
20	O
mg	O
per	O
day	O
or	O
placebo	O
,	O
both	O
orally	O
for	O
5	O
years	O
.	O

The	O
original	O
plan	O
was	O
to	O
follow	O
the	O
intervention	O
phase	O
by	O
5	O
years	O
'	O
follow	O
-	O
up	O
.	O

In	O
June	O
,	O
1997	O
,	O
the	O
trialists	O
and	O
the	O
data	O
-	O
monitoring	O
committee	O
decided	O
to	O
end	O
recruitment	O
primarily	O
because	O
of	O
the	O
number	O
of	O
women	O
dropping	O
out	O
of	O
the	O
study	O
.	O

Recruitment	O
ended	O
on	O
July	O
11	O
,	O
1997	O
,	O
and	O
the	O
study	O
will	O
continue	O
as	O
planned	O
.	O

The	O
primary	O
endpoints	O
are	O
the	O
occurrence	O
of	O
and	O
deaths	O
from	O
breast	B-Disease
cancer	I-Disease
.	O

This	O
preliminary	O
interim	O
analysis	O
is	O
based	O
on	O
intention	O
-	O
to	O
-	O
treat	O
.	O

FINDINGS	O
:	O
5408	O
women	O
were	O
randomised	O
;	O
participating	O
women	O
have	O
a	O
median	O
follow	O
-	O
up	O
of	O
46	O
months	O
for	O
major	O
endpoints	O
.	O

41	O
cases	O
of	O
breast	B-Disease
cancer	I-Disease
occurred	O
so	O
far	O
;	O
there	O
have	O
been	O
no	O
deaths	O
from	O
breast	B-Disease
cancer	I-Disease
.	O

There	O
is	O
no	O
difference	O
in	O
breast	B-Disease
-	I-Disease
cancer	I-Disease
frequency	O
between	O
the	O
placebo	O
(	O
22	O
cases	O
)	O
and	O
tamoxifen	O
(	O
19	O
)	O
arms	O
.	O

There	O
is	O
a	O
statistically	O
significant	O
reduction	O
of	O
breast	B-Disease
cancer	I-Disease
among	O
women	O
receiving	O
tamoxifen	O
who	O
also	O
used	O
hormone	O
-	O
replacement	O
therapy	O
during	O
the	O
trial	O
:	O
among	O
390	O
women	O
on	O
such	O
therapy	O
and	O
allocated	O
to	O
placebo	O
,	O
we	O
found	O
eight	O
cases	O
of	O
breast	B-Disease
cancer	I-Disease
compared	O
with	O
one	O
case	O
among	O
362	O
women	O
allocated	O
to	O
tamoxifen	O
.	O

Compared	O
with	O
the	O
placebo	O
group	O
,	O
there	O
was	O
a	O
significantly	O
increased	O
risk	O
of	O
vascular	B-Disease
events	I-Disease
and	O
hypertriglyceridaemia	B-Disease
among	O
women	O
on	O
tamoxifen	O
.	O

INTERPRETATION	O
:	O
Although	O
this	O
preliminary	O
analysis	O
has	O
low	O
power	O
,	O
in	O
this	O
cohort	O
of	O
women	O
at	O
low	O
-	O
to	O
-	O
normal	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
,	O
the	O
postulated	O
protective	O
effects	O
of	O
tamoxifen	O
are	O
not	O
yet	O
apparent	O
.	O

Women	O
using	O
hormone	O
-	O
replacement	O
therapy	O
appear	O
to	O
have	O
benefited	O
from	O
use	O
of	O
tamoxifen	O
.	O

There	O
were	O
no	O
deaths	O
from	O
breast	B-Disease
cancer	I-Disease
recorded	O
in	O
women	O
in	O
the	O
study	O
.	O

It	O
is	O
essential	O
to	O
continue	O
follow	O
-	O
up	O
to	O
quantify	O
the	O
long	O
-	O
term	O
risks	O
and	O
benefits	O
of	O
tamoxifen	O
therapy	O
.	O

Epileptogenic	O
activity	O
of	O
folic	O
acid	O
after	O
drug	O
induces	O
SLE	B-Disease
(	O
folic	O
acid	O
and	O
epilepsy	B-Disease
)	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
effect	O
of	O
folic	O
acid	O
-	O
containing	O
multivitamin	O
supplementation	O
in	O
epileptic	B-Disease
women	O
before	O
and	O
during	O
pregnancy	O
in	O
order	O
to	O
determine	O
the	O
rate	O
of	O
structural	O
birth	B-Disease
defects	I-Disease
and	O
epilepsy	B-Disease
-	O
related	O
side	O
effects	O
.	O

STUDY	O
DESIGN	O
:	O
First	O
a	O
randomised	O
trial	O
,	O
later	O
periconception	O
care	O
including	O
in	O
total	O
12225	O
females	O
.	O

RESULTS	O
:	O
Of	O
60	O
epileptic	B-Disease
women	O
with	O
periconceptional	O
folic	O
acid	O
(	O
0	O
.	O
8	O
mg	O
)	O
-	O
containing	O
multivitamin	O
supplementation	O
,	O
no	O
one	O
developed	O
epilepsy	B-Disease
-	O
related	O
side	O
effects	O
during	O
the	O
periconception	O
period	O
.	O

One	O
epileptic	B-Disease
woman	O
delivered	O
a	O
newborn	O
with	O
cleft	B-Disease
lip	I-Disease
and	I-Disease
palate	I-Disease
.	O

Another	O
patient	O
exhibited	O
with	O
a	O
cluster	O
of	O
seizures	B-Disease
after	O
the	O
periconception	O
period	O
using	O
another	O
multivitamin	O
.	O

This	O
22	O
-	O
year	O
-	O
old	O
epileptic	B-Disease
woman	O
was	O
treated	O
continuously	O
by	O
carbamazepine	O
and	O
a	O
folic	O
acid	O
(	O
1	O
mg	O
)	O
-	O
containing	O
multivitamin	O
from	O
the	O
20th	O
week	O
of	O
gestation	O
.	O

She	O
developed	O
status	B-Disease
epilepticus	I-Disease
and	O
later	O
symptoms	O
of	O
systemic	B-Disease
lupus	I-Disease
erythematodes	I-Disease
.	O

Her	O
pregnancy	O
ended	O
with	O
stillbirth	B-Disease
.	O

CONCLUSIONS	O
:	O
The	O
epileptic	B-Disease
pregnant	O
patient	O
'	O
s	O
autoimmune	B-Disease
disease	I-Disease
(	O
probably	O
drug	O
-	O
induced	O
lupus	B-Disease
)	O
could	O
damage	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
therefore	O
the	O
therapeutic	O
dose	O
(	O
>	O
or	O
=	O
1	O
mg	O
)	O
of	O
folic	O
acid	O
triggered	O
a	O
cluster	O
of	O
seizures	B-Disease
.	O

Physiological	O
dose	O
(	O
<	O
1	O
mg	O
)	O
of	O
folic	O
acid	O
both	O
in	O
healthy	O
and	O
60	O
epileptic	B-Disease
women	O
,	O
all	O
without	O
any	O
autoimmune	B-Disease
disease	I-Disease
,	O
did	O
not	O
increase	O
the	O
risk	O
for	O
epileptic	B-Disease
seizures	I-Disease
.	O

Stroke	B-Disease
and	O
cocaine	O
or	O
amphetamine	O
use	O
.	O

The	O
association	O
of	O
cocaine	O
and	O
amphetamine	O
use	O
with	O
hemorrhagic	O
and	O
ischemic	B-Disease
stroke	B-Disease
is	O
based	O
almost	O
solely	O
on	O
data	O
from	O
case	O
series	O
.	O

The	O
limited	O
number	O
of	O
epidemiologic	O
studies	O
of	O
stroke	B-Disease
and	O
use	O
of	O
cocaine	O
and	O
/	O
or	O
amphetamine	O
have	O
been	O
done	O
in	O
settings	O
that	O
serve	O
mostly	O
the	O
poor	O
and	O
/	O
or	O
minorities	O
.	O

This	O
case	O
-	O
control	O
study	O
was	O
conducted	O
in	O
the	O
defined	O
population	O
comprising	O
members	O
of	O
Kaiser	O
Permanente	O
of	O
Northern	O
and	O
Southern	O
California	O
.	O

We	O
attempted	O
to	O
identify	O
all	O
incident	O
strokes	B-Disease
in	O
women	O
ages	O
15	O
-	O
44	O
years	O
during	O
a	O
3	O
-	O
year	O
period	O
using	O
hospital	O
admission	O
and	O
discharge	O
records	O
,	O
emergency	O
department	O
logs	O
,	O
and	O
payment	O
requests	O
for	O
out	O
-	O
of	O
-	O
plan	O
hospitalizations	O
.	O

We	O
selected	O
controls	O
,	O
matched	O
on	O
age	O
and	O
facility	O
of	O
usual	O
care	O
,	O
at	O
random	O
from	O
healthy	O
members	O
of	O
the	O
health	O
plan	O
.	O

We	O
obtained	O
information	O
in	O
face	O
-	O
to	O
-	O
face	O
interviews	O
.	O

There	O
were	O
347	O
confirmed	O
stroke	B-Disease
cases	O
and	O
1	O
,	O
021	O
controls	O
.	O

The	O
univariate	O
matched	O
odds	O
ratio	O
for	O
stroke	B-Disease
in	O
women	O
who	O
admitted	O
to	O
using	O
cocaine	O
and	O
/	O
or	O
amphetamine	O
was	O
8	O
.	O
5	O
(	O
95	O
%	O
confidence	O
interval	O
=	O
3	O
.	O
6	O
-	O
20	O
.	O
0	O
)	O
.	O

After	O
further	O
adjustment	O
for	O
potential	O
confounders	O
,	O
the	O
odds	O
ratio	O
in	O
women	O
who	O
reported	O
using	O
cocaine	O
and	O
/	O
or	O
amphetamine	O
was	O
7	O
.	O
0	O
(	O
95	O
%	O
confidence	O
interval	O
=	O
2	O
.	O
8	O
-	O
17	O
.	O
9	O
)	O
.	O

The	O
use	O
of	O
cocaine	O
and	O
/	O
or	O
amphetamine	O
is	O
a	O
strong	O
risk	O
factor	O
for	O
stroke	B-Disease
in	O
this	O
socioeconomically	O
heterogeneous	O
,	O
insured	O
urban	O
population	O
.	O

Acute	B-Disease
renal	I-Disease
failure	I-Disease
subsequent	O
to	O
the	O
administration	O
of	O
rifampicin	O
.	O

A	O
follow	O
-	O
up	O
study	O
of	O
cases	O
reported	O
earlier	O
.	O

A	O
clinical	O
presentation	O
is	O
made	O
of	O
a	O
2	O
-	O
3	O
year	O
follow	O
-	O
up	O
of	O
six	O
cases	O
of	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
that	O
have	O
been	O
reported	O
earlier	O
.	O

The	O
patients	O
had	O
developed	O
transient	O
renal	B-Disease
failure	I-Disease
after	O
the	O
intermittent	O
administration	O
of	O
rifampicin	O
.	O

The	O
stage	O
of	O
olig	O
-	O
anuria	B-Disease
lasted	O
for	O
1	O
-	O
3	O
weeks	O
,	O
and	O
five	O
of	O
the	O
patients	O
were	O
treated	O
by	O
hemodialysis	O
.	O

Two	O
of	O
the	O
patients	O
died	O
due	O
to	O
unrelated	O
causes	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

The	O
four	O
patients	O
re	O
-	O
examined	O
were	O
clinically	O
cured	O
.	O

Pathologic	O
findings	O
by	O
light	O
microscopy	O
and	O
immunofluorescence	O
at	O
biopsy	O
were	O
scarce	O
.	O

Nothing	O
abnormal	O
was	O
seen	O
by	O
electron	O
microscopy	O
in	O
two	O
of	O
the	O
cases	O
studied	O
.	O

Renal	O
function	O
was	O
normal	O
.	O

In	O
three	O
cases	O
the	O
excretion	O
at	O
131I	O
-	O
hippuran	O
renography	O
was	O
slightly	O
slowed	O
.	O

Although	O
in	O
the	O
acute	O
stage	O
the	O
renal	B-Disease
lesions	I-Disease
histologically	O
appeared	O
toxic	O
,	O
evidence	O
suggestive	O
of	O
an	O
immunological	O
mechanism	O
cannot	O
be	O
excluded	O
.	O

Chronic	O
effects	O
of	O
a	O
novel	O
synthetic	O
anthracycline	O
derivative	O
(	O
SM	O
-	O
5887	O
)	O
on	O
normal	O
heart	O
and	O
doxorubicin	O
-	O
induced	O
cardiomyopathy	B-Disease
in	O
beagle	O
dogs	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
chronic	O
cardiotoxic	B-Disease
potential	O
of	O
SM	O
-	O
5887	O
and	O
a	O
possible	O
deteriorating	O
effect	O
of	O
SM	O
-	O
5887	O
on	O
low	O
-	O
grade	O
cardiotoxicity	B-Disease
pre	O
-	O
induced	O
by	O
doxorubicin	O
in	O
beagle	O
dogs	O
.	O

In	O
the	O
chronic	O
treatment	O
,	O
beagle	O
dogs	O
of	O
each	O
sex	O
were	O
given	O
intravenously	O
once	O
every	O
3	O
weeks	O
,	O
either	O
a	O
sublethal	O
dose	O
of	O
doxorubicin	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
or	O
SM	O
-	O
5887	O
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

The	O
experiment	O
was	O
terminated	O
3	O
weeks	O
after	O
the	O
ninth	O
dosing	O
.	O

Animals	O
which	O
received	O
over	O
six	O
courses	O
of	O
doxorubicin	O
demonstrated	O
the	O
electrocardiogram	O
(	O
ECG	O
)	O
changes	O
,	O
decrease	O
of	O
blood	O
pressure	O
and	O
high	O
-	O
grade	O
histopathological	O
cardiomyopathy	B-Disease
,	O
while	O
animals	O
which	O
were	O
terminally	O
sacrificed	O
after	O
the	O
SM	O
-	O
5887	O
administration	O
did	O
not	O
show	O
any	O
changes	O
in	O
ECG	O
,	O
blood	O
pressure	O
and	O
histopathological	O
examinations	O
.	O

To	O
examine	O
a	O
possibly	O
deteriorating	O
cardiotoxic	B-Disease
effect	O
of	O
SM	O
-	O
5887	O
,	O
low	O
-	O
grade	O
cardiomyopathy	B-Disease
was	O
induced	O
in	O
dogs	O
by	O
four	O
courses	O
of	O
doxorubicin	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Nine	O
weeks	O
after	O
pre	O
-	O
treatment	O
,	O
dogs	O
were	O
given	O
four	O
courses	O
of	O
either	O
doxorubicin	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
or	O
SM	O
-	O
5887	O
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
)	O
once	O
every	O
3	O
weeks	O
.	O

The	O
low	O
-	O
grade	O
cardiotoxic	B-Disease
changes	O
were	O
enhanced	O
by	O
the	O
additional	O
doxorubicin	O
treatment	O
.	O

On	O
the	O
contrary	O
,	O
the	O
SM	O
-	O
5887	O
treatment	O
did	O
not	O
progress	O
the	O
grade	O
of	O
cardiomyopathy	B-Disease
.	O

In	O
conclusion	O
,	O
SM	O
-	O
5887	O
does	O
not	O
have	O
any	O
potential	O
of	O
chronic	O
cardiotoxicity	B-Disease
and	O
deteriorating	O
effect	O
on	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	B-Disease
in	O
dogs	O
.	O

Risk	O
for	O
valvular	B-Disease
heart	I-Disease
disease	I-Disease
among	O
users	O
of	O
fenfluramine	O
and	O
dexfenfluramine	O
who	O
underwent	O
echocardiography	O
before	O
use	O
of	O
medication	O
.	O

BACKGROUND	O
:	O
Because	O
uncontrolled	O
echocardiographic	O
surveys	O
suggested	O
that	O
up	O
to	O
30	O
%	O
to	O
38	O
%	O
of	O
users	O
of	O
fenfluramine	O
and	O
dexfenfluramine	O
had	O
valvular	B-Disease
disease	I-Disease
,	O
these	O
drugs	O
were	O
withdrawn	O
from	O
the	O
market	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
risk	O
for	O
new	O
or	O
worsening	O
valvular	B-Disease
abnormalities	I-Disease
among	O
users	O
of	O
fenfluramine	O
or	O
dexfenfluramine	O
who	O
underwent	O
echocardiography	O
before	O
they	O
began	O
to	O
take	O
these	O
medications	O
.	O

DESIGN	O
:	O
Cohort	O
study	O
.	O

SETTING	O
:	O
Academic	O
primary	O
care	O
practices	O
.	O

PATIENTS	O
:	O
46	O
patients	O
who	O
used	O
fenfluramine	O
or	O
dexfenfluramine	O
for	O
14	O
days	O
or	O
more	O
and	O
had	O
echocardiograms	O
obtained	O
before	O
therapy	O
.	O

MEASUREMENTS	O
:	O
Follow	O
-	O
up	O
echocardiography	O
.	O

The	O
primary	O
outcome	O
was	O
new	O
or	O
worsening	O
valvulopathy	B-Disease
,	O
defined	O
as	O
progression	O
of	O
either	O
aortic	B-Disease
or	I-Disease
mitral	I-Disease
regurgitation	I-Disease
by	O
at	O
least	O
one	O
degree	O
of	O
severity	O
and	O
disease	O
that	O
met	O
U	O
.	O
S	O
.	O

Food	O
and	O
Drug	O
Administration	O
criteria	O
(	O
at	O
least	O
mild	O
aortic	B-Disease
regurgitation	I-Disease
or	O
moderate	O
mitral	B-Disease
regurgitation	I-Disease
)	O
.	O

RESULTS	O
:	O
Two	O
patients	O
(	O
4	O
.	O
3	O
%	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
6	O
%	O
to	O
14	O
.	O
8	O
%	O
]	O
)	O
receiving	O
fenfluramine	O
-	O
phentermine	O
developed	O
valvular	B-Disease
heart	I-Disease
disease	I-Disease
.	O

One	O
had	O
baseline	O
bicuspid	B-Disease
aortic	I-Disease
valve	I-Disease
and	O
mild	O
aortic	B-Disease
regurgitation	I-Disease
that	O
progressed	O
to	O
moderate	O
regurgitation	O
.	O

The	O
second	O
patient	O
developed	O
new	O
moderate	O
aortic	B-Disease
insufficiency	I-Disease
.	O

CONCLUSION	O
:	O
Users	O
of	O
diet	O
medications	O
are	O
at	O
risk	O
for	O
valvular	B-Disease
heart	I-Disease
disease	I-Disease
.	O

However	O
,	O
the	O
incidence	O
may	O
be	O
lower	O
than	O
that	O
reported	O
previously	O
.	O

Therapeutic	O
drug	O
monitoring	O
of	O
tobramycin	O
:	O
once	O
-	O
daily	O
versus	O
twice	O
-	O
daily	O
dosage	O
schedules	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
dosage	O
regimen	O
(	O
once	O
-	O
daily	O
vs	O
.	O
twice	O
-	O
daily	O
)	O
of	O
tobramicyn	O
on	O
steady	O
-	O
state	O
serum	O
concentrations	O
and	O
toxicity	B-Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Patients	O
undergoing	O
treatment	O
with	O
i	O
.	O
v	O
.	O
tobramycin	O
(	O
4	O
mg	O
/	O
kg	O
/	O
day	O
)	O
were	O
randomised	O
to	O
two	O
groups	O
.	O

Group	O
OD	O
(	O
n	O
=	O
22	O
)	O
received	O
a	O
once	O
-	O
daily	O
dose	O
of	O
tobramycin	O
and	O
group	O
TD	O
(	O
n	O
=	O
21	O
)	O
received	O
the	O
same	O
dose	O
divided	O
into	O
two	O
doses	O
daily	O
.	O

Tobramycin	O
serum	O
concentrations	O
(	O
peak	O
and	O
trough	O
)	O
were	O
measured	O
by	O
enzyme	O
multiplied	O
immunoassay	O
.	O

The	O
renal	O
and	O
auditory	O
functions	O
of	O
the	O
patients	O
were	O
monitored	O
before	O
,	O
during	O
and	O
immediately	O
after	O
treatment	O
.	O

RESULTS	O
:	O
The	O
two	O
groups	O
were	O
comparable	O
with	O
respect	O
to	O
sex	O
,	O
age	O
,	O
body	O
weight	O
and	O
renal	O
function	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
in	O
mean	O
daily	O
dose	O
,	O
duration	O
of	O
treatment	O
,	O
or	O
cumulative	O
dose	O
.	O

Trough	O
concentrations	O
were	O
<	O
2	O
g	O
/	O
ml	O
in	O
the	O
two	O
groups	O
(	O
100	O
%	O
)	O
.	O

Peak	O
concentrations	O
were	O
>	O
6	O
microg	O
/	O
ml	O
in	O
100	O
%	O
of	O
the	O
OD	O
group	O
and	O
in	O
67	O
%	O
of	O
the	O
TD	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Mean	O
peak	O
concentrations	O
were	O
markedly	O
different	O
:	O
11	O
.	O
00	O
+	O
/	O
-	O
2	O
.	O
89	O
microg	O
/	O
ml	O
in	O
OD	O
vs	O
.	O
6	O
.	O
53	O
+	O
/	O
-	O
1	O
.	O
45	O
microg	O
/	O
ml	O
in	O
TD	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
pharmacokinetics	O
parameters	O
were	O
:	O
Ke	O
,	O
(	O
0	O
.	O
15	O
+	O
/	O
-	O
0	O
.	O
03	O
/	O
h	O
in	O
OD	O
vs	O
.	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
06	O
/	O
h	O
in	O
TD	O
)	O
,	O
t1	O
/	O
2	O
,	O
(	O
4	O
.	O
95	O
+	O
/	O
-	O
1	O
.	O
41	O
h	O
in	O
OD	O
vs	O
.	O
3	O
.	O
07	O
+	O
/	O
-	O
0	O
.	O
71	O
h	O
in	O
TD	O
)	O
,	O
Vd	O
(	O
0	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
11	O
l	O
/	O
kg	O
in	O
OD	O
vs	O
.	O
0	O
.	O
33	O
+	O
/	O
-	O
0	O
.	O
09	O
l	O
/	O
kg	O
in	O
TD	O
)	O
,	O
Cl	O
(	O
0	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
29	O
ml	O
/	O
min	O
/	O
kg	O
in	O
OD	O
vs	O
.	O
1	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
33	O
ml	O
/	O
min	O
/	O
kg	O
in	O
TD	O
)	O
.	O

Increased	O
serum	O
creatinine	O
was	O
observed	O
in	O
73	O
%	O
of	O
patients	O
in	O
OD	O
versus	O
57	O
%	O
of	O
patients	O
in	O
TD	O
,	O
without	O
evidence	O
of	O
nephrotoxicity	B-Disease
.	O

In	O
TD	O
group	O
,	O
three	O
patients	O
developed	O
decreased	B-Disease
auditory	I-Disease
function	I-Disease
,	O
of	O
which	O
one	O
presented	O
with	O
an	O
auditory	B-Disease
loss	I-Disease
of	O
-	O
30	O
dB	O
,	O
whereas	O
in	O
the	O
OD	O
group	O
only	O
one	O
patient	O
presented	O
decreased	B-Disease
auditory	I-Disease
function	I-Disease
.	O

CONCLUSION	O
:	O
This	O
small	O
study	O
suggests	O
that	O
a	O
once	O
-	O
daily	O
dosing	O
regimen	O
of	O
tobramycin	O
is	O
at	O
least	O
as	O
effective	O
as	O
and	O
is	O
no	O
more	O
and	O
possibly	O
less	O
toxic	O
than	O
the	O
twice	O
-	O
daily	O
regimen	O
.	O

Using	O
a	O
single	O
-	O
dose	O
therapy	O
,	O
peak	O
concentration	O
determination	O
is	O
not	O
necessary	O
,	O
only	O
trough	O
samples	O
should	O
be	O
monitored	O
to	O
ensure	O
levels	O
below	O
2	O
microg	O
/	O
ml	O
.	O

Enhanced	O
bradycardia	B-Disease
induced	O
by	O
beta	O
-	O
adrenoceptor	O
antagonists	O
in	O
rats	O
pretreated	O
with	O
isoniazid	O
.	O

High	O
doses	O
of	O
isoniazid	O
increase	O
hypotension	B-Disease
induced	O
by	O
vasodilators	O
and	O
change	O
the	O
accompanying	O
reflex	O
tachycardia	B-Disease
to	O
bradycardia	B-Disease
,	O
an	O
interaction	O
attributed	O
to	O
decreased	O
synthesis	O
of	O
brain	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
possible	O
enhancement	O
by	O
isoniazid	O
of	O
bradycardia	B-Disease
induced	O
by	O
beta	O
-	O
adrenoceptor	O
antagonists	O
was	O
determined	O
in	O
rats	O
anaesthetised	O
with	O
chloralose	O
-	O
urethane	O
.	O

Isoniazid	O
significantly	O
increased	O
bradycardia	B-Disease
after	O
propranolol	O
,	O
pindolol	O
,	O
labetalol	O
and	O
atenolol	O
,	O
as	O
well	O
as	O
after	O
clonidine	O
,	O
but	O
not	O
after	O
hexamethonium	O
or	O
carbachol	O
.	O

Enhancement	O
was	O
not	O
observed	O
in	O
rats	O
pretreated	O
with	O
methylatropine	O
or	O
previously	O
vagotomised	O
.	O

These	O
results	O
are	O
compatible	O
with	O
interference	O
by	O
isoniazid	O
with	O
GABAergic	O
inhibition	O
of	O
cardiac	O
parasympathetic	O
tone	O
.	O

Such	O
interference	O
could	O
be	O
exerted	O
centrally	O
,	O
possibly	O
at	O
the	O
nucleus	O
ambiguus	O
,	O
or	O
peripherally	O
at	O
the	O
sinus	O
node	O
.	O

Structural	B-Disease
and	I-Disease
functional	I-Disease
impairment	I-Disease
of	I-Disease
mitochondria	I-Disease
in	O
adriamycin	O
-	O
induced	O
cardiomyopathy	B-Disease
in	O
mice	O
:	O
suppression	O
of	O
cytochrome	O
c	O
oxidase	O
II	O
gene	O
expression	O
.	O

The	O
use	O
of	O
adriamycin	O
(	O
ADR	O
)	O
in	O
cancer	B-Disease
chemotherapy	O
has	O
been	O
limited	O
due	O
to	O
its	O
cumulative	O
cardiovascular	B-Disease
toxicity	I-Disease
.	O

Earlier	O
observations	O
that	O
ADR	O
interacts	O
with	O
mitochondrial	O
cytochrome	O
c	O
oxidase	O
(	O
COX	O
)	O
and	O
suppresses	O
its	O
enzyme	O
activity	O
led	O
us	O
to	O
investigate	O
ADR	O
'	O
s	O
action	O
on	O
the	O
cardiovascular	O
functions	O
and	O
heart	O
mitochondrial	O
morphology	O
in	O
Balb	O
-	O
c	O
mice	O
i	O
.	O
p	O
.	O
treated	O
with	O
ADR	O
for	O
several	O
weeks	O
.	O

At	O
various	O
times	O
during	O
treatment	O
,	O
the	O
animals	O
were	O
assessed	O
for	O
cardiovascular	O
functions	O
by	O
electrocardiography	O
and	O
for	O
heart	O
tissue	O
damage	O
by	O
electron	O
microscopy	O
.	O

In	O
parallel	O
,	O
total	O
RNA	O
was	O
extracted	O
from	O
samples	O
of	O
dissected	O
heart	O
and	O
analyzed	O
by	O
Northern	O
blot	O
hybridization	O
to	O
determine	O
the	O
steady	O
-	O
state	O
level	O
of	O
three	O
RNA	O
transcripts	O
encoded	O
by	O
the	O
COXII	O
,	O
COXIII	O
,	O
and	O
COXIV	O
genes	O
.	O

Similarly	O
,	O
samples	O
obtained	O
from	O
the	O
liver	O
of	O
the	O
same	O
animals	O
were	O
analyzed	O
for	O
comparative	O
studies	O
.	O

Our	O
results	O
indicated	O
that	O
1	O
)	O
treatment	O
of	O
mice	O
with	O
ADR	O
caused	O
cardiovascular	B-Disease
arrhythmias	I-Disease
characterized	O
by	O
bradycardia	B-Disease
,	O
extension	O
of	O
ventricular	O
depolarization	O
time	O
(	O
tQRS	O
)	O
,	O
and	O
failure	O
of	O
QRS	O
at	O
high	O
concentrations	O
(	O
10	O
-	O
14	O
mg	O
/	O
kg	O
body	O
weight	O
cumulative	O
dose	O
)	O
;	O
2	O
)	O
the	O
heart	O
mitochondria	O
underwent	O
swelling	B-Disease
,	O
fusion	O
,	O
dissolution	O
,	O
and	O
/	O
or	O
disruption	O
of	O
mitochondrial	O
cristae	O
after	O
several	O
weeks	O
of	O
treatment	O
.	O

Such	O
abnormalities	O
were	O
not	O
observed	O
in	O
the	O
mitochondria	O
of	O
liver	O
tissue	O
;	O
and	O
3	O
)	O
among	O
the	O
three	O
genes	O
of	O
COX	O
enzyme	O
examined	O
,	O
only	O
COXII	O
gene	O
expression	O
was	O
suppressed	O
by	O
ADR	O
treatment	O
,	O
mainly	O
after	O
8	O
weeks	O
in	O
both	O
heart	O
and	O
liver	O
.	O

Knowing	O
that	O
heart	O
mitochondria	O
represent	O
almost	O
40	O
%	O
of	O
heart	O
muscle	O
by	O
weight	O
,	O
we	O
conclude	O
that	O
the	O
deteriorating	O
effects	O
of	O
ADR	O
on	O
cardiovascular	O
function	O
involve	O
mitochondrial	B-Disease
structural	I-Disease
and	I-Disease
functional	I-Disease
impairment	I-Disease
.	O

